<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-440223285707902670</id><updated>2026-01-31T00:19:46.749-08:00</updated><category term="diabetes mellitus"/><category term="kehamilan"/><category term="klasifikasi  tipe diabetes mellitus"/><category term="Perjalanan Penyakit Diabetes Mellitus"/><category term="definisi diabetes mellitus"/><category term="deteksi dini mata"/><category term="empat pilar diabetes mellitus"/><category term="gejala diabetes mellitus"/><category term="obat diabetes"/><category term="patofisiologi"/><category term="patogenesisi"/><category term="penyebab diabetes mellitus"/><category term="prinsip perencanaan makanan"/><category term="terapi gizi"/><category term="vitamin d"/><title type='text'>Penyakit Diabetes Mellitus</title><subtitle type='html'></subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default?redirect=false'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>14</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-3087100955212181584</id><published>2011-10-13T19:59:00.000-07:00</published><updated>2011-10-13T20:02:44.570-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="diabetes mellitus"/><category scheme="http://www.blogger.com/atom/ns#" term="prinsip perencanaan makanan"/><title type='text'>PRINSIP PERENCANAAN MAKANAN UNTUK DIABETES MELLITUS</title><content type='html'>&lt;!--[if !mso]&gt; &lt;style&gt; v\:* {behavior:url(#default#VML);} o\:* {behavior:url(#default#VML);} w\:* {behavior:url(#default#VML);} .shape {behavior:url(#default#VML);} &lt;/style&gt; &lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;o:officedocumentsettings&gt;   &lt;o:allowpng/&gt;  &lt;/o:OfficeDocumentSettings&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:worddocument&gt;   &lt;w:view&gt;Normal&lt;/w:View&gt;   &lt;w:zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:trackmoves&gt;false&lt;/w:TrackMoves&gt;   &lt;w:trackformatting/&gt;   &lt;w:punctuationkerning/&gt;   &lt;w:validateagainstschemas/&gt;   &lt;w:saveifxmlinvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:ignoremixedcontent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:alwaysshowplaceholdertext&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:donotpromoteqf/&gt;   &lt;w:lidthemeother&gt;EN-US&lt;/w:LidThemeOther&gt;   &lt;w:lidthemeasian&gt;X-NONE&lt;/w:LidThemeAsian&gt;   &lt;w:lidthemecomplexscript&gt;X-NONE&lt;/w:LidThemeComplexScript&gt;   &lt;w:compatibility&gt;    &lt;w:breakwrappedtables/&gt;    &lt;w:snaptogridincell/&gt;    &lt;w:wraptextwithpunct/&gt;    &lt;w:useasianbreakrules/&gt;    &lt;w:dontgrowautofit/&gt;    &lt;w:splitpgbreakandparamark/&gt;    &lt;w:enableopentypekerning/&gt;    &lt;w:dontflipmirrorindents/&gt;    &lt;w:overridetablestylehps/&gt;   &lt;/w:Compatibility&gt;   &lt;m:mathpr&gt;    &lt;m:mathfont val=&quot;Cambria Math&quot;&gt;    &lt;m:brkbin val=&quot;before&quot;&gt;    &lt;m:brkbinsub val=&quot;&amp;#45;-&quot;&gt;    &lt;m:smallfrac val=&quot;off&quot;&gt;    &lt;m:dispdef/&gt;    &lt;m:lmargin val=&quot;0&quot;&gt;    &lt;m:rmargin val=&quot;0&quot;&gt;    &lt;m:defjc val=&quot;centerGroup&quot;&gt;    &lt;m:wrapindent val=&quot;1440&quot;&gt;    &lt;m:intlim val=&quot;subSup&quot;&gt;    &lt;m:narylim val=&quot;undOvr&quot;&gt;   &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:latentstyles deflockedstate=&quot;false&quot; defunhidewhenused=&quot;true&quot; defsemihidden=&quot;true&quot; defqformat=&quot;false&quot; defpriority=&quot;99&quot; latentstylecount=&quot;267&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;0&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Normal&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;heading 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 7&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 8&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 9&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 7&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 8&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 9&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;35&quot; qformat=&quot;true&quot; name=&quot;caption&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;10&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Title&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;1&quot; name=&quot;Default Paragraph Font&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;11&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Subtitle&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;22&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Strong&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;20&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Emphasis&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;59&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Table Grid&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Placeholder Text&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;1&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;No Spacing&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Revision&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;34&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;List Paragraph&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;29&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Quote&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;30&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Intense Quote&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;19&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Subtle Emphasis&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;21&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Intense Emphasis&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;31&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Subtle Reference&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;32&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Intense Reference&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;33&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Book Title&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;37&quot; name=&quot;Bibliography&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; qformat=&quot;true&quot; name=&quot;TOC Heading&quot;&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;  /* Style Definitions */  table.MsoNormalTable  {mso-style-name:&quot;Table Normal&quot;;  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-parent:&quot;&quot;;  mso-padding-alt:0cm 5.4pt 0cm 5.4pt;  mso-para-margin-top:0cm;  mso-para-margin-right:0cm;  mso-para-margin-bottom:10.0pt;  mso-para-margin-left:0cm;  line-height:115%;  mso-pagination:widow-orphan;  font-size:11.0pt;  font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;  mso-ascii-font-family:Calibri;  mso-ascii-theme-font:minor-latin;  mso-hansi-font-family:Calibri;  mso-hansi-theme-font:minor-latin;  mso-bidi-font-family:&quot;Times New Roman&quot;;  mso-bidi-theme-font:minor-bidi;} &lt;/style&gt; &lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;o:shapedefaults ext=&quot;edit&quot; spidmax=&quot;1027&quot;&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;o:shapelayout ext=&quot;edit&quot;&gt;   &lt;o:idmap ext=&quot;edit&quot; data=&quot;1&quot;&gt;  &lt;/o:shapelayout&gt;&lt;/xml&gt;&lt;![endif]--&gt;  &lt;p class=&quot;MsoListParagraphCxSpFirst&quot; style=&quot;margin-left:14.2pt;mso-add-space: auto&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight:normal&quot;&gt;PRINSIP PERENCANAAN MAKANAN UNTUK DIABETES MELLITUS&lt;/b&gt;&lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:14.2pt;mso-add-space: auto&quot;&gt;&lt;b style=&quot;mso-bidi-font-weight:normal&quot;&gt; &lt;/b&gt;&lt;/p&gt;    &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left: 32.2pt; text-indent: -18pt;&quot;&gt;Prinsip perencanaan makan bagi diabetes, menurut&lt;span style=&quot;mso-spacerun:yes&quot;&gt;  &lt;/span&gt;Suyono, 2004, yaitu:&lt;span style=&quot;&quot;&gt;&lt;span style=&quot;&quot;&gt;&lt;br /&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto;text-indent:-18.0pt;mso-list:l0 level1 lfo1&quot;&gt;&lt;span style=&quot;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin&quot;&gt;&lt;span style=&quot;mso-list:Ignore&quot;&gt;1)&lt;span style=&quot;font:7.0pt &amp;quot;Times New Roman&amp;quot;&quot;&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Kebutuhan Kalori Kebutuhan kalori sesuai untuk mencapai dan mempertahankan berat badan ideal. Komposisi energi adalah 60-70% dari karbohidrat, 10-15% dari protein dan 20-25% dari lemak. &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Ada beberapa cara untuk menentukan jumlah kalori yang dibutuhkan orang dengan diabetes. Diantaranya adalah dengan memperhitungkan berdasarkan kebutuhan kalori basal yang besarnya 25-30 kalori/ kg BB ideal, ditambah dan dikurangi bergantung pada beberapa faktor yaitu jenis kelamin, umur, aktifitas, kehamilan atau laktasi, adanya komplikasi dan berat badan. &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Cara yang lebih gampang lagi adalah dengan pegangan kasar, yaitu untuk pasien kurus 2300-2500 kalori, normal 1700-2100 kalori dan gemuk 1300-1500 kalori.&lt;span style=&quot;mso-spacerun:yes&quot;&gt;   &lt;/span&gt;&lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;&lt;img style=&quot;width: 458px; height: 139px;&quot; src=&quot;data:image/png;base64,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&quot; alt=&quot;&quot; /&gt;&lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt; &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Jumlah kalori disesuaikan dengan pertumbuhan, status gizi, umur, stress akut dan kegiatan jasmani untuk mencapai dan mempertahankan berat badan idaman. Untuk penentuan status gizi, dipakai Body Mass Index (BMI) = Indeks Massa Tubuh (IMT). &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Perhitungan berat badan idaman dengan rumus Brocca yang dimodifikasi adalah sebagai berikut: &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Berat badan idaman = 90% x (TB dalam cm - 100) x 1 kg. &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Bagi pria dengan tinggi badan di bawah 160 cm dan wanita di bawah 150 cm, rumus modifikasi menjadi: &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Berat badan ideal = (TB dalam cm - 100) x 1 kg. &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Berat Badan kurang&lt;span style=&quot;mso-spacerun:yes&quot;&gt;  &lt;/span&gt;=&amp;lt;90% BB idaman &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Berat Badan normal&lt;span style=&quot;mso-spacerun:yes&quot;&gt;  &lt;/span&gt;=90-110% BB idaman &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Berat Badan lebih&lt;span style=&quot;mso-spacerun:yes&quot;&gt;   &lt;/span&gt;=110-120% &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;BB idaman Gemuk&lt;span style=&quot;mso-spacerun:yes&quot;&gt;    &lt;/span&gt;=&amp;gt;120% &lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;BB idaman Sedangkan menurut Indeks Massa Tubuh (IMT) yaitu&lt;span style=&quot;mso-spacerun:yes&quot;&gt;   &lt;/span&gt;&lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:14.2pt;mso-add-space: auto&quot;&gt;&lt;img style=&quot;width: 150px; height: 70px;&quot; src=&quot;data:image/png;base64,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&quot; alt=&quot;&quot; /&gt;&lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:14.2pt;mso-add-space: auto&quot;&gt; &lt;img style=&quot;width: 439px; height: 196px;&quot; src=&quot;data:image/png;base64,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&quot; alt=&quot;&quot; /&gt;&lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:14.2pt;mso-add-space: auto&quot;&gt; &lt;/p&gt;&lt;span style=&quot;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin&quot;&gt;&lt;span style=&quot;mso-list:Ignore&quot;&gt;2)&lt;span style=&quot;font:7.0pt &amp;quot;Times New Roman&amp;quot;&quot;&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Gula   &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:32.2pt;mso-add-space: auto&quot;&gt;Gula dan produk-produk lain dari gula dikurangi, kecuali pada keadaan tertentu, misalnya pasien dengan diet rendah protein dan yang mendapat makanan cair, gula boleh diberikan untuk mencukupi kebutuhan kalori, dalam jumlah terbatas. Penggunaan gula sedikit dalam bumbu diperbolehkan sehingga memungkinkan pasien dapat makan makanan keluarga. Anjuran penggunaan gula untuk orang dengan DM sama dengan untuk orang normal yaitu tidak lebih dari 5% kebutuhan kalori total. &lt;/p&gt;&lt;span style=&quot;mso-bidi-font-family: Calibri;mso-bidi-theme-font:minor-latin&quot;&gt;&lt;span style=&quot;mso-list:Ignore&quot;&gt;3)&lt;span style=&quot;font:7.0pt &amp;quot;Times New Roman&amp;quot;&quot;&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style=&quot;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin&quot;&gt;Standar diet diabetes melitus &lt;/span&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:32.2pt;margin-bottom:.0001pt;mso-add-space:auto; line-height:normal;mso-layout-grid-align:none;text-autospace:none&quot;&gt;&lt;span style=&quot;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin&quot;&gt;Untuk perencanaan pola makan sehari, pasien diberi petunjuk berapa kebutuhan bahan makanan setiap kali makan dalam sehari dalam bentuk penukar (P). Daftar bahan makanan penukar adalah suatu daftar nama bahan makanan dengan ukuran tertentu dan dikelompokkan berdasarkan kandungan kalori, protein, lemak dan hidrat arang. Setiap &lt;/span&gt;&lt;span style=&quot;font-size:10.5pt;mso-bidi-font-family:Calibri; mso-bidi-theme-font:minor-latin&quot;&gt;kelompok bahan makanan dianggap mempunyai nilai gizi yang kurang lebih sama.&lt;/span&gt;&lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:32.2pt;margin-bottom:.0001pt;mso-add-space:auto; line-height:normal;mso-layout-grid-align:none;text-autospace:none&quot;&gt;&lt;span style=&quot;font-size:10.5pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin&quot;&gt; &lt;/span&gt;&lt;/p&gt;  &lt;p class=&quot;MsoListParagraphCxSpLast&quot; style=&quot;margin-top:0cm;margin-right:0cm; margin-bottom:0cm;margin-left:32.2pt;margin-bottom:.0001pt;mso-add-space:auto; line-height:normal;mso-layout-grid-align:none;text-autospace:none&quot;&gt;&lt;span style=&quot;font-size:10.5pt;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin&quot;&gt; &lt;/span&gt;&lt;/p&gt;</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/3087100955212181584/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/prinsip-perencanaan-makanan-untuk.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/3087100955212181584'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/3087100955212181584'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/prinsip-perencanaan-makanan-untuk.html' title='PRINSIP PERENCANAAN MAKANAN UNTUK DIABETES MELLITUS'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-4964991776805929290</id><published>2011-10-13T19:55:00.000-07:00</published><updated>2011-10-13T19:57:42.110-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="diabetes mellitus"/><category scheme="http://www.blogger.com/atom/ns#" term="terapi gizi"/><title type='text'>TERAPI GIZI UNTUK DIABETES MELITUS</title><content type='html'>&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;o:officedocumentsettings&gt;   &lt;o:allowpng/&gt;  &lt;/o:OfficeDocumentSettings&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:worddocument&gt;   &lt;w:view&gt;Normal&lt;/w:View&gt;   &lt;w:zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:trackmoves/&gt;   &lt;w:trackformatting/&gt;   &lt;w:punctuationkerning/&gt;   &lt;w:validateagainstschemas/&gt;   &lt;w:saveifxmlinvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:ignoremixedcontent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:alwaysshowplaceholdertext&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:donotpromoteqf/&gt;   &lt;w:lidthemeother&gt;EN-US&lt;/w:LidThemeOther&gt;   &lt;w:lidthemeasian&gt;X-NONE&lt;/w:LidThemeAsian&gt;   &lt;w:lidthemecomplexscript&gt;X-NONE&lt;/w:LidThemeComplexScript&gt;   &lt;w:compatibility&gt;    &lt;w:breakwrappedtables/&gt;    &lt;w:snaptogridincell/&gt;    &lt;w:wraptextwithpunct/&gt;    &lt;w:useasianbreakrules/&gt;    &lt;w:dontgrowautofit/&gt;    &lt;w:splitpgbreakandparamark/&gt;    &lt;w:enableopentypekerning/&gt;    &lt;w:dontflipmirrorindents/&gt;    &lt;w:overridetablestylehps/&gt;   &lt;/w:Compatibility&gt;   &lt;m:mathpr&gt;    &lt;m:mathfont val=&quot;Cambria Math&quot;&gt;    &lt;m:brkbin val=&quot;before&quot;&gt;    &lt;m:brkbinsub val=&quot;&amp;#45;-&quot;&gt;    &lt;m:smallfrac val=&quot;off&quot;&gt;    &lt;m:dispdef/&gt;    &lt;m:lmargin val=&quot;0&quot;&gt;    &lt;m:rmargin val=&quot;0&quot;&gt;    &lt;m:defjc val=&quot;centerGroup&quot;&gt;    &lt;m:wrapindent val=&quot;1440&quot;&gt;    &lt;m:intlim val=&quot;subSup&quot;&gt;    &lt;m:narylim val=&quot;undOvr&quot;&gt;   &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:latentstyles deflockedstate=&quot;false&quot; defunhidewhenused=&quot;true&quot; defsemihidden=&quot;true&quot; defqformat=&quot;false&quot; defpriority=&quot;99&quot; latentstylecount=&quot;267&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;0&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Normal&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;heading 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 7&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 8&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 9&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 7&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 8&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 9&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;35&quot; qformat=&quot;true&quot; name=&quot;caption&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;10&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Title&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;1&quot; name=&quot;Default Paragraph Font&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;11&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Subtitle&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;22&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Strong&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;20&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Emphasis&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;59&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Table Grid&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Placeholder Text&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;1&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;No Spacing&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Revision&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;34&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;List Paragraph&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;29&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Quote&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;30&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Intense Quote&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;19&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Subtle Emphasis&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;21&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Intense Emphasis&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;31&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Subtle Reference&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;32&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Intense Reference&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;33&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Book Title&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;37&quot; name=&quot;Bibliography&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; qformat=&quot;true&quot; name=&quot;TOC Heading&quot;&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;  /* Style Definitions */  table.MsoNormalTable  {mso-style-name:&quot;Table Normal&quot;;  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-parent:&quot;&quot;;  mso-padding-alt:0cm 5.4pt 0cm 5.4pt;  mso-para-margin-top:0cm;  mso-para-margin-right:0cm;  mso-para-margin-bottom:10.0pt;  mso-para-margin-left:0cm;  line-height:115%;  mso-pagination:widow-orphan;  font-size:11.0pt;  font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;  mso-ascii-font-family:Calibri;  mso-ascii-theme-font:minor-latin;  mso-hansi-font-family:Calibri;  mso-hansi-theme-font:minor-latin;  mso-bidi-font-family:&quot;Times New Roman&quot;;  mso-bidi-theme-font:minor-bidi;} &lt;/style&gt; &lt;![endif]--&gt;  &lt;p style=&quot;font-weight: bold;&quot; class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;TERAPI GIZI UNTUK DIABETES MELITUS&lt;/span&gt;&lt;/p&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;  &lt;/span&gt;&lt;p class=&quot;MsoNormal&quot;&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;Menurut Suyono, 2004 terapi gizi bertujuan membantu orang dengan DM memperbaiki kebiasaan gizi dan olahraga untuk mendapatkan kontrol metabolik yang lebih baik. Terapi gizinya, yaitu:&lt;/span&gt;&lt;/p&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;  &lt;/span&gt;&lt;p class=&quot;MsoListParagraphCxSpFirst&quot; style=&quot;margin-left:14.2pt;mso-add-space: auto;text-indent:-14.2pt;mso-list:l0 level1 lfo1&quot;&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;&lt;span style=&quot;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin&quot;&gt;&lt;span style=&quot;mso-list:Ignore&quot;&gt;1)&lt;span style=&quot;font:7.0pt &amp;quot;Times New Roman&amp;quot;&quot;&gt;    &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Terapi gizi pada DM tipe 1 &lt;/span&gt;&lt;/p&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;  &lt;/span&gt;&lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:14.2pt;mso-add-space: auto&quot;&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;Perlu ditetapkan perencanaan makan yang berdasarkan asupan makan sehari-hari individu dan digunakan sebagai dasar untuk mengintegrasikan terapi insulin dengan pola makan dan latihan jasmani yang biasanya dilakukan. Individu yang menggunakan terapi insulin dianjurkan makan pada waktu yang konsisten dan sinkron dengan waktu kerja insulin yang digunakan. Selanjutnya individu perlu memantau kadar glukosa darah sesuai dengan dosis insulin dan jumlah makanan yang biasa dimakan. &lt;/span&gt;&lt;/p&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;  &lt;/span&gt;&lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:14.2pt;mso-add-space: auto&quot;&gt;&lt;span style=&quot;font-size:130%;&quot;&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;  &lt;/span&gt;&lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:14.2pt;mso-add-space: auto;text-indent:-18.0pt;mso-list:l0 level1 lfo1&quot;&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;&lt;span style=&quot;mso-bidi-font-family:Calibri;mso-bidi-theme-font:minor-latin&quot;&gt;&lt;span style=&quot;mso-list:Ignore&quot;&gt;2)&lt;span style=&quot;font:7.0pt &amp;quot;Times New Roman&amp;quot;&quot;&gt;      &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;Terapi gizi pada DM tipe 2 &lt;/span&gt;&lt;/p&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;  &lt;/span&gt;&lt;p class=&quot;MsoListParagraphCxSpMiddle&quot; style=&quot;margin-left:14.2pt;mso-add-space: auto&quot;&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;Penekanan tujuan terapi gizi medis pada diabetes tipe 2 hendaknya pada pengendalian glukosa, lipid, dan hipertensi. Penurunan berat badan dan diet hipokalori (pada pasien yang gemuk) biasanya memperbaiki kadar glikemik jangka pendek dan mempunyai potensi meningkatkan kontrol metabolik jangka lama. Diet dengan kalori sangat rendah, pada umumnya tidak efektif untuk mencapai penurunan berat jangka lama, dalam hai ini perlu ditekankan bahwa tujuan diet adalah pada pengendalian glukosa dan lipid. Namun demikian pada sebagian individu penurunan berat badan dapat juga dicapai dan dipertahankan.&lt;span style=&quot;mso-spacerun:yes&quot;&gt;  &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;  &lt;/span&gt;&lt;p class=&quot;MsoListParagraphCxSpLast&quot; style=&quot;margin-left:14.2pt;mso-add-space:auto&quot;&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;Perencanaan makan hendaknya dengan kandungan zat gizi yang cukup dan disertai pengurangan total lemak terutama lemak jenuh. Pengaturan porsi makanan sedemikian rupa sehingga asupan zat gizi terbesar sepanjang hari. Penurunan berat badan ringan atau sedang (5-10 kg), sudah terbukti dapat meningkatkan kontrol diabetes, walaupun berat badan idaman tidak tercapai. Penurunan berat badan dapat diusahakan dicapai dengan baik dengan penurunan asupan energi dan peningkatan pengeluaran energi. Dianjurkan pembatasan kalori sedang yaitu 250-500 kkal lebih rendah dari asupan rata-rata sehari. &lt;/span&gt;&lt;/p&gt;  &lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;o:officedocumentsettings&gt;   &lt;o:allowpng/&gt;  &lt;/o:OfficeDocumentSettings&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:worddocument&gt;   &lt;w:view&gt;Normal&lt;/w:View&gt;   &lt;w:zoom&gt;0&lt;/w:Zoom&gt;   &lt;w:trackmoves/&gt;   &lt;w:trackformatting/&gt;   &lt;w:punctuationkerning/&gt;   &lt;w:validateagainstschemas/&gt;   &lt;w:saveifxmlinvalid&gt;false&lt;/w:SaveIfXMLInvalid&gt;   &lt;w:ignoremixedcontent&gt;false&lt;/w:IgnoreMixedContent&gt;   &lt;w:alwaysshowplaceholdertext&gt;false&lt;/w:AlwaysShowPlaceholderText&gt;   &lt;w:donotpromoteqf/&gt;   &lt;w:lidthemeother&gt;EN-US&lt;/w:LidThemeOther&gt;   &lt;w:lidthemeasian&gt;X-NONE&lt;/w:LidThemeAsian&gt;   &lt;w:lidthemecomplexscript&gt;X-NONE&lt;/w:LidThemeComplexScript&gt;   &lt;w:compatibility&gt;    &lt;w:breakwrappedtables/&gt;    &lt;w:snaptogridincell/&gt;    &lt;w:wraptextwithpunct/&gt;    &lt;w:useasianbreakrules/&gt;    &lt;w:dontgrowautofit/&gt;    &lt;w:splitpgbreakandparamark/&gt;    &lt;w:enableopentypekerning/&gt;    &lt;w:dontflipmirrorindents/&gt;    &lt;w:overridetablestylehps/&gt;   &lt;/w:Compatibility&gt;   &lt;m:mathpr&gt;    &lt;m:mathfont val=&quot;Cambria Math&quot;&gt;    &lt;m:brkbin val=&quot;before&quot;&gt;    &lt;m:brkbinsub val=&quot;&amp;#45;-&quot;&gt;    &lt;m:smallfrac val=&quot;off&quot;&gt;    &lt;m:dispdef/&gt;    &lt;m:lmargin val=&quot;0&quot;&gt;    &lt;m:rmargin val=&quot;0&quot;&gt;    &lt;m:defjc val=&quot;centerGroup&quot;&gt;    &lt;m:wrapindent val=&quot;1440&quot;&gt;    &lt;m:intlim val=&quot;subSup&quot;&gt;    &lt;m:narylim val=&quot;undOvr&quot;&gt;   &lt;/m:mathPr&gt;&lt;/w:WordDocument&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 9]&gt;&lt;xml&gt;  &lt;w:latentstyles deflockedstate=&quot;false&quot; defunhidewhenused=&quot;true&quot; defsemihidden=&quot;true&quot; defqformat=&quot;false&quot; defpriority=&quot;99&quot; latentstylecount=&quot;267&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;0&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Normal&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;heading 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 7&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 8&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;9&quot; qformat=&quot;true&quot; name=&quot;heading 9&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 7&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 8&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; name=&quot;toc 9&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;35&quot; qformat=&quot;true&quot; name=&quot;caption&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;10&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Title&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;1&quot; name=&quot;Default Paragraph Font&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;11&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Subtitle&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;22&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Strong&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;20&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Emphasis&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;59&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Table Grid&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Placeholder Text&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;1&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;No Spacing&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Revision&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;34&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;List Paragraph&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;29&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Quote&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;30&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Intense Quote&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 1&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 2&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 3&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 4&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 5&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;60&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Shading Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;61&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light List Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;62&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Light Grid Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;63&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 1 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;64&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Shading 2 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;65&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 1 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;66&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium List 2 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;67&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 1 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;68&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 2 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;69&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Medium Grid 3 Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;70&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Dark List Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;71&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Shading Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;72&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful List Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;73&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; name=&quot;Colorful Grid Accent 6&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;19&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Subtle Emphasis&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;21&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Intense Emphasis&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;31&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Subtle Reference&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;32&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Intense Reference&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;33&quot; semihidden=&quot;false&quot; unhidewhenused=&quot;false&quot; qformat=&quot;true&quot; name=&quot;Book Title&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;37&quot; name=&quot;Bibliography&quot;&gt;   &lt;w:lsdexception locked=&quot;false&quot; priority=&quot;39&quot; qformat=&quot;true&quot; name=&quot;TOC Heading&quot;&gt;  &lt;/w:LatentStyles&gt; &lt;/xml&gt;&lt;![endif]--&gt;&lt;!--[if gte mso 10]&gt; &lt;style&gt;  /* Style Definitions */  table.MsoNormalTable  {mso-style-name:&quot;Table Normal&quot;;  mso-tstyle-rowband-size:0;  mso-tstyle-colband-size:0;  mso-style-noshow:yes;  mso-style-priority:99;  mso-style-parent:&quot;&quot;;  mso-padding-alt:0cm 5.4pt 0cm 5.4pt;  mso-para-margin-top:0cm;  mso-para-margin-right:0cm;  mso-para-margin-bottom:10.0pt;  mso-para-margin-left:0cm;  line-height:115%;  mso-pagination:widow-orphan;  font-size:11.0pt;  font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;  mso-ascii-font-family:Calibri;  mso-ascii-theme-font:minor-latin;  mso-hansi-font-family:Calibri;  mso-hansi-theme-font:minor-latin;  mso-bidi-font-family:&quot;Times New Roman&quot;;  mso-bidi-theme-font:minor-bidi;} &lt;/style&gt; &lt;![endif]--&gt;</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/4964991776805929290/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/terapi-gizi-untuk-diabetes-melitus.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/4964991776805929290'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/4964991776805929290'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/terapi-gizi-untuk-diabetes-melitus.html' title='TERAPI GIZI UNTUK DIABETES MELITUS'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-1506768545036606605</id><published>2011-10-12T21:11:00.000-07:00</published><updated>2011-10-12T21:32:20.931-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="empat pilar diabetes mellitus"/><title type='text'>Empat pilar diabetes mellitus</title><content type='html'>&lt;span style=&quot;font-size:130%;&quot;&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Empat pilar diabetes mellitus &lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Empat pilar diabetes mellitus antara lain:&lt;br /&gt;a. Perencanaan makan.&lt;br /&gt;b. Latihan jasmani.&lt;br /&gt;c. Pengobatan atau obat berkhasiat hipoglikemik.&lt;br /&gt;d. Penyuluhan.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;a. Perencanaan Makan &lt;/span&gt;&lt;br /&gt;Pada dasarnya perencanaan makan pada diabetes tidak berbeda dengan perencanaan makan pada orang normal. Untuk mendapatkan kepatuhan terhadap pengaturan makan yang baik, adanya pengetahuan mengenai bahan penukar akan sangat membantu pasien. Menurut Suyono (2004), selain perencanaan makan, ada juga terapi gizi dengan tujuan membantu orang dengan DM memperbaiki kebiasaan gizi dan olahraga untuk mendapatkan kontrol metabolik yang lebih baik.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;b. Latihan Jasmani &lt;/span&gt;&lt;br /&gt;Manfaat latihan jasmani Manfaat latihan jasmani bagi penyandang DM antara lain meningkatkan penurunan kadar glukosa darah, mencegah kegemukan, ikut berperan dalam mengatasi kemungkinan terjadi komplikasi aterogenik, gangguan lipid darah, peningkatan tekanan darah, hiperkoagulasi darah.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;c. Pengobatan atau Farmakologi&lt;/span&gt;&lt;br /&gt;Terapi ini berupa tambahan pemberian obat-obatan jika sebelumnya sasaran  gula darah belum tercapai dengan diet dan latihan jasmani.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;d. Penyuluhan  &lt;/span&gt;&lt;br /&gt;DM merupakan sakit kronis yang memerlukan perilaku penanganan mandiri yang khusus seumur hidup. Karena diet, aktifitas fisik dan stres fisik serta emosional dapat mempengaruhi pengendalian diabetes, maka penderita harus belajar untuk mengatur keseimbangan berbagai faktor. Penderita bukan hanya harus belajar keterampilan untuk merawat diri sendiri setiap hari guna menghindari penurunan atau kenaikan kadar glukosa darah yang mendadak, tetapi juga harus memiliki perilaku preventif dalam gaya hidup untuk menghindari komplikasi diabetik jangka panjang. Penghargaan penderita tentang pentingnya pengetahuan dan keterampilan yang harus dimiliki oleh penderita diabetes dapat membantu perawat dalam melakukan pendidikan dan penyuluhan (Smeltzer and Bare, 2002).  Menurut Suyono (2004), penyuluhan kesehatan merupakan suatu proses yang berlangsung secara terus menerus, yang kemajuannya harus terus diamati terutama oleh mereka yang memberikan penyuluhan.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/1506768545036606605/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/empat-pilar-diabetes-mellitus.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/1506768545036606605'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/1506768545036606605'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/empat-pilar-diabetes-mellitus.html' title='Empat pilar diabetes mellitus'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-7602197086179515625</id><published>2011-10-11T21:45:00.000-07:00</published><updated>2011-10-11T21:48:11.153-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="diabetes mellitus"/><category scheme="http://www.blogger.com/atom/ns#" term="kehamilan"/><category scheme="http://www.blogger.com/atom/ns#" term="patofisiologi"/><title type='text'>Patofisiologi Diabetes Melitus dalam Kehamilan</title><content type='html'>&lt;span style=&quot;font-size:130%;&quot;&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Patofisiologi Diabetes Melitus dalam Kehamilan &lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Pada Diabetes Melitus Gestasional, selain terjadi perubahan-perubahan fisiologis hormonal dan metabolic yang normal pada kehamilan, didapatkan keadaan jumlah/fungsi insulin ibu yang tidak optimal. Serta terjadi juga perubahan kinetika insulin dan resistensi terhadap efek insulin. Akibatnya adalah komposisi sumber energi dalam plasma ibu berubah (kadar gula darah tinggi, sementara itu kadar insulin tetap tinggi).&lt;br /&gt;&lt;br /&gt;Melalui difusi terfasilitasi dalam membrane plasenta, pada sirkulasi janin juga ikut terjadi komposisi sumber energy yang abnormal yang dapat menyebabkan kemungkinan terjadi berbagai komplikasi. Selain itu terjadi juga hiperinsulinemia, hipokolosemia, hiperbilirubinemia, dan sebagainya). Dalam hal ini terjadi berbagai kelainan yang menyebabkan pelbagai komplikasi pada ibu dan janin. Pada intinya, Diabetes Melitus pada kehamilan dapat terjadi karena proses kehamilan itu sendiri, Namun juga dapat terjadi karena Diabetes Melitus tipe 1 atau 2 yang baru diketahui pada saat hamil. Bila Diabetes Melitus terjadi karena proses kehamilan itu sendiri, setelah melahirkan kadar gula darahnya akan kembali menjadi normal dan dalam beberapa tahun kemudian kemungkinan baru akan benar-benar menetap menjadi Diabetes Melitus.&lt;br /&gt;&lt;br /&gt;Diabetes Melitus pada kehamilan dapat terjadi karena perubahan metabolik fisiologik yang terjadi pada saat kehamilan. Perubahan tersebut mengarah pada terjadinya resistensi insulin. Bila sel beta pankreas tidak dapat mengimbangi perubahan tersebut, maka akan terjadi Diabetes Melitus pada kehamilan. Setelah melahirkan, karena perubahan fisiologis pada saat hamil telah hilang, maka ibu akan menjadi normal kembali. Namun sebaliknya, bila ibu sebelumnya sudah menyandang Diabetes Melitus dan baru diketahui Diabetes Melitus pada saat hamil, maka setelah melahirkan ibu tetap akan menderita Diabetes Melitus.&lt;br /&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/7602197086179515625/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/patofisiologi-diabetes-melitus-dalam.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/7602197086179515625'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/7602197086179515625'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/patofisiologi-diabetes-melitus-dalam.html' title='Patofisiologi Diabetes Melitus dalam Kehamilan'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-3132499161308766974</id><published>2011-10-11T21:20:00.000-07:00</published><updated>2011-10-11T21:45:35.444-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="kehamilan"/><category scheme="http://www.blogger.com/atom/ns#" term="klasifikasi  tipe diabetes mellitus"/><title type='text'>Tipe Diabetes Pada Kehamilan</title><content type='html'>&lt;span style=&quot;font-size:130%;&quot;&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Tipe Diabetes Pada Kehamilan&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Pembagian Diabetes Melitus pada Kehamilan terbagi menjadi :&lt;br /&gt;1) Diabetes Melitus yang memang sudah diketahui sebelumnya dan kemudian menjadi hamil (Diabetes Melitus Hamil=DMH=Diabetes Melitus Gestasional). Sebagian besar termasuk golongan Insulin Dependent Diabetes Melitus/IDDM (Diabetes Melitus yang tergantung pada insulin).&lt;br /&gt;&lt;br /&gt;2) Diabetes Melitus baru saja ditemukan pada saat kehamilan (Diabetes Melitus Gestasional=DMG). Umumnya termasuk golongan Non Insulin Dependent Diabetes Melitus/NIDDM (Diabetes Melitus yang tidak tergantung pada insulin).&lt;br /&gt;&lt;br /&gt;Sedangkan Diabetes Melitus Gestasional sendiri dibagi menjadi dua sub kelompok:&lt;br /&gt;a) Sebenarnya sudah mengidap Diabetes Melitus sebelumnya, tapi baru diketahui saat hamil (sama dengan Diabetes Melitus Hamil).&lt;br /&gt;&lt;br /&gt;b) Sebelumnya belum mengidap diabetes mellitus, baru mengidap diabetes mellitus dalam masa kehamilan (Pregnancy-Induced Diabetes Melitus, DMG sesungguhnya) sesuai dengan definisi lama WHO 1980.&lt;br /&gt;&lt;br /&gt;Kedua sub kelompok ini baru dapat dibedakan setelah dilakukan Tes Toleransi Glukosa Oral (TTGO) ulangan pasca persalinan. Untuk sub kelompok Diabetes Melitus Hamil, hasil Test Toleransi Glukosa Oral (TTGO) pasca persalinan masih akan tetap abnormal, sementara untuk Diabetes Melitus Gestasional hasil kembali normal (Maryunani, 2008).  &lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/3132499161308766974/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/tipe-diabetes-pada-kehamilan.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/3132499161308766974'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/3132499161308766974'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/tipe-diabetes-pada-kehamilan.html' title='Tipe Diabetes Pada Kehamilan'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-3461688766040560405</id><published>2011-10-11T19:38:00.000-07:00</published><updated>2011-10-11T19:47:01.282-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="gejala diabetes mellitus"/><title type='text'>Gejala Diabetes Mellitus</title><content type='html'>&lt;span style=&quot;font-weight: bold;&quot;&gt;Gejala Diabetes Mellitus &lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-size:130%;&quot;&gt;Gejala diabetes bisa muncul secara mendadak, bisa juga ketika seseorang melakukan pemeriksaan untuk penyakit selain Diabetes. Gejala yang sangat umum adalah :&lt;br /&gt;a.  sering kencing pada malam hari (poliuria) &lt;br /&gt;b.  selalu merasa haus (polidipsia) &lt;br /&gt;c.  selalu merasa lapar (polifagia) &lt;br /&gt;Gejala umum lain yang menyebabkan seseorang ingin segera pergi ke dokter adalah kelainan kulit seperti gatal dan bisul,kelainan ginekologi seperti keputihan,serta kesemutan yang disertai mati rasa. Kadang-kadang tubuh menjadi lemah dan terasa lelah. Biasanya akan muncul luka atau bisul yang tak kunjung sembuh atau terjadi infeksi di saluran kemih. Bisa juga terjadi impotensi, katarak, atau seorang perempuan melahirkan bayi dengan berat badan lebih dari 4 kilogram.&lt;br /&gt;Gejala – gejala awal Dahaga/haus&lt;br /&gt;a.  Berat badan turun &lt;br /&gt;b. Luka lambat sembuh &lt;br /&gt;c. Penglihatan menjadi kabur&lt;br /&gt;&lt;br /&gt;Komplikasi :&lt;br /&gt;a. Koma &lt;br /&gt;b. Darah tinggi &lt;br /&gt;c. Buta &lt;br /&gt;d. Kerusakan buah pinggang &lt;br /&gt;e. Penyakit jantung &lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/3461688766040560405/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/gejala-diabetes-mellitus.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/3461688766040560405'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/3461688766040560405'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/gejala-diabetes-mellitus.html' title='Gejala Diabetes Mellitus'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-1197520174299066542</id><published>2011-10-11T19:29:00.000-07:00</published><updated>2011-10-11T19:38:06.537-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="patogenesisi"/><category scheme="http://www.blogger.com/atom/ns#" term="Perjalanan Penyakit Diabetes Mellitus"/><title type='text'>Patogenesis (Perjalanan Penyakit) Diabetes Mellitus</title><content type='html'>&lt;span style=&quot;font-size:130%;&quot;&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Patogenesis (Perjalanan Penyakit) Diabetes Mellitus&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Perkembangan penyakit dapat dibagi menjadi 4 tahap, yaitu:&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;a. Normal atau Sehat &lt;/span&gt;&lt;br /&gt;1) Kadar gula darah normal&lt;br /&gt;2) Perlu waktu bertahun-tahun untuk berkembang menjadi Diabetes Mellitus.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;b. Pre Diabetes &lt;/span&gt;&lt;br /&gt;1) Mulai terjadi peningkatan kadar glukosda darah secara bertahap.&lt;br /&gt;2) Kadar glukosa darah tidak cukup tinggi untuk menimbulkan gejala tetapi cukup&lt;br /&gt;     mampu menyebabkan kerusakan dan gangguan fungsi berbagai jaringan tubuh.&lt;br /&gt;3) Beresiko mengalami komplikasi&lt;br /&gt;4) Sering disertai faktor resiko lain seperti hipertensi,dislipidemia dan kegemukan&lt;br /&gt;     atau obesitas. 5) Dapat dilakukan upaya untuk mencegah terjadinya komplikasi&lt;br /&gt;    dan perkembangan menjadi diabetes.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;c. Diabetes Sering ditemukan komplikasi pada saat diagnosis &lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;d. Komplikasi &lt;/span&gt;&lt;br /&gt;1) Terutama penyakit jantung koroner dan stroke&lt;br /&gt;2) Dapat menyebabkan kerusakan berbagai organ misalnya mata, ginjal, dan syaraf&lt;br /&gt;3) Dapat berakibat fatal.&lt;br /&gt;&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/1197520174299066542/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/patogenesis-perjalanan-penyakit.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/1197520174299066542'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/1197520174299066542'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/patogenesis-perjalanan-penyakit.html' title='Patogenesis (Perjalanan Penyakit) Diabetes Mellitus'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-9198910999948697791</id><published>2011-10-11T19:19:00.000-07:00</published><updated>2011-10-11T19:25:57.279-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="penyebab diabetes mellitus"/><title type='text'>Penyebab Diabetes Mellitus</title><content type='html'>&lt;span style=&quot;font-size:130%;&quot;&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Penyebab Diabetes Mellitus &lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Diabetes mellitus disebabkan berkurangnya produksi dan ketersediaan insulin dalam tubuh atau terjadinya gangguan fungsi insulin yang sebenarnya berjumlah cukup. Kekurangan insulin disebabkan adanya kerusakan sebagian kecil atau sebagian besar sel-sel beta pulau langerhans dalam kelenjar pankreas yang berfungsi menghasilkan insulin. Namun, jika dirunut lebih lanjut, beberapa faktor yang menyebabkan DM sebagai berikut :&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;a. Genetik atau Faktor Keturunan&lt;/span&gt;&lt;br /&gt;Diabetes mellitus cenderung diturunkan atau diawariskan, bukan ditularkan. Anggota keluarga penderita DM (diabetisi) memiliki kemungkinan lebih besar terserang penyakit ini dibandingkan dengan anggota keluarga yang tidak menderita DM. Para ahli kesehatan juga menyebutkan DM merupakan penyakit yang terpaut kromosom seks atau kelamin. Biasanya kaum laki-laki menjadi penderita sesungguhnya, sedangkan kaum perempuan sebagai pihak yang membawa gen untuk diwariskan kepada anak-anaknya. &lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;b. Virus dan Bakteri &lt;/span&gt;&lt;br /&gt;Virus penyebab DM adalah rubela,mumps,dan human coxsackievirus  B4. Melalui mekanisme infeksi sitolitik dalam sel beta, virus ini mengakibatkan destruksi atau perusakan sel. Bisa juga, virus ini menyerang melalui reaksi otoimunitas yang menyebabkan hilangnya otoimun dalam sel beta. Diabetes mellitus akibat bakteri masih belum bisa dideteksi. Namun, para ahli kesehatan menduga bakteri cukup berperan menyebabkan DM. &lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;c. Bahan Toksik atau Beracun&lt;/span&gt;&lt;br /&gt;Bahan beracun yang mampu merusak sel beta secara langsung adalah alloxan, pyrinuron&lt;br /&gt;(rodentisida), dan streptozoctin (produk dari sejenis jamur). Bahan lain adalah sianida yang berasal dari singkong. &lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;d. Nutrisi &lt;/span&gt;&lt;br /&gt;Nutrisi yang berlebihan (overnutrition) merupakan faktor resiko pertama yang diketahui menyebabkan DM. Semakin berat badan berlebih atau obesitas akibat nutrisi yang berlebihan, semakin besar kemungkinan seseorang terjangkit DM (Depkes RI, 2003).&lt;br /&gt;&lt;br /&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/9198910999948697791/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/penyebab-diabetes-mellitus.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/9198910999948697791'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/9198910999948697791'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/penyebab-diabetes-mellitus.html' title='Penyebab Diabetes Mellitus'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-5864179513871435103</id><published>2011-10-11T19:13:00.000-07:00</published><updated>2011-10-11T19:27:25.761-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="klasifikasi  tipe diabetes mellitus"/><title type='text'>Klasifikasi Diabetes Melitus</title><content type='html'>&lt;span style=&quot;font-weight: bold;&quot;&gt;Klasifikasi atau Tipe Diabetes Melitus &lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;a. Diabetes Tipe 1&lt;/span&gt;,  DM tipe 1 atau yang dulu dikenal dengan nama Insulin Dependent Diabetes Mellitus (IDDM), terjadi karena kerusakan sel b pankreas (reaksi autoimun). Bila kerusakan sel beta telah mencapai 80--90% maka gejala DM mulai muncul. Perusakan sel beta ini lebih cepat terjadi pada anak-anak daripada dewasa. Sebagian besar penderita DM tipe 1 mempunyai antibodi yang menunjukkan adanya proses autoimun, dan sebagian kecil tidak terjadi proses autoimun. Kondisi ini digolongkan sebagai tipe 1 idiopatik. Sebagian besar (75%) kasus terjadi sebelum usia 30 tahun, tetapi usia tidak termasuk kriteria untuk klasifikasi. &lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;b. Diabetes Tipe 2&lt;/span&gt;,  DM tipe 2 merupakan 90% dari kasus DM yang dulu dikenal sebagai non insulin dependent Diabetes Mellitus (NIDDM). Pada diabetes ini terjadi penurunan kemampuan insulin bekerja di jaringan perifer (insulin resistance) dan disfungsi sel beta. Akibatnya, pankreas tidak mampu memproduksi insulin yang cukup untuk mengkompensasi insulin resistan. Kedua hal ini menyebabkan terjadinya defisiensi insulin relatif. Gejala minimal dan kegemukan sering berhubungan dengan kondisi ini,yang umumnya terjadi pada usia &amp;gt; 40 tahun. Kadar insulin bisa normal, rendah, maupun tinggi, sehingga penderita tidak tergantung pada pemberian insulin.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;c. DM Dalam Kehamilan,&lt;/span&gt;  DM dan kehamilan (Gestational Diabetes Mellitus - GDM) adalah kehamilan normal yang disertai dengan peningkatan insulin resistan (ibu hamil gagal mempertahankan euglycemia). Faktor risiko GDM: riwayat keluarga DM, kegemukan, dan glikosuria. GDM ini meningkatkan morbiditas neonatus, misalnya hipoglikemia, ikterus, polisitemia, dan makrosomia. Hal ini terjadi karena bayi dari ibu GDM mensekresi insulin lebih besar sehingga merangsang pertumbuhan bayi dan makrosomia. Frekuensi GDM kira-kira 3--5% dan para ibu tersebut meningkat risikonya untuk menjadi DM di masa mendatang. &lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;d. Diabetes Tipe Lain&lt;/span&gt;,  Subkelas DM di mana individu mengalami hiperglikemia akibat kelainan spesifik (kelainan genetik fungsi sel beta), endokrinopati (penyakit&lt;br /&gt;Cushing’s , akromegali), penggunaan obat yang mengganggu fungsi sel beta (dilantin), penggunaan obat yang mengganggu kerja insulin (b-adrenergik), dan infeksi/sindroma genetik&lt;br /&gt;(Down’s, Klinefelter’s).</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/5864179513871435103/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/klasifikasi-diabetes-melitus.html#comment-form' title='2 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/5864179513871435103'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/5864179513871435103'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/klasifikasi-diabetes-melitus.html' title='Klasifikasi Diabetes Melitus'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>2</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-5977566677468267610</id><published>2011-10-11T19:07:00.000-07:00</published><updated>2011-10-11T19:13:00.974-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="definisi diabetes mellitus"/><title type='text'>Definisi Diabetes Mellitus</title><content type='html'>&lt;span style=&quot;font-size:130%;&quot;&gt;&lt;span&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Definisi Diabetes Melitus &lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span&gt;&lt;span&gt;Diabetes mellitus&lt;/span&gt;&lt;/span&gt; adalah keadaan hiperglikema kronik disertai berbagai kelainan metabolik akibat gangguan hormonal yang menimbulkan berbagai komplikasi kronik pada mata, ginjal, syaraf dan pembuluh darah disertai lesi pada membran basalis dalam pemeriksaan dengan mikroskop elektron (Mansjoer, 2000).  &lt;br /&gt;&lt;br /&gt;Diabetes mellitus adalah suatu penyakit kronis yang menimbulkan gangguan multi sistem dan mempunyai karakteristik hyperglikemia yang disebabkan defisiensi insulin atau kerja insulin yang tidak adekuat (Brunner dan Sudartha, 2001).&lt;br /&gt;&lt;br /&gt;Diabetes mellitus adalah penyakit yang mengenai semua organ tubuh dan menimbulkan berbagai macam keluhan dengan gejala yang sangat bervariasi (Waspadji, 2002). Dari pengertian-pengertian diatas dapat di ambil kesimpulan bahwa diabetes mellitus merupakan suatu sindrom gangguan metabolik secara genetis dan klinis ditandai oleh hiperglikemia yang meliputi kelainan metabolisme karbohidrat, lemak dan protein yang dapat mengenai semua organ tubuh dengan gejala yang sangat bervariasi.&lt;/span&gt;&lt;/span&gt;</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/5977566677468267610/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/definisi-diabetes-mellitus.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/5977566677468267610'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/5977566677468267610'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/definisi-diabetes-mellitus.html' title='Definisi Diabetes Mellitus'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-6923103355477580047</id><published>2011-10-10T19:03:00.000-07:00</published><updated>2011-10-10T19:13:02.116-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="obat diabetes"/><title type='text'>Obat Diabetes</title><content type='html'>&lt;span style=&quot;font-weight:bold;&quot;&gt;Obat Diabetes&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Pengobatan diabetes secara menyeluruh mencakup diet yang&lt;br /&gt;benar, olahraga yang teratur, kemudian dilanjutkan dengan&lt;br /&gt;obat-obatan yang diminum, atau suntikan insulin.&lt;br /&gt;Pada diabetes tipe 1, mutlak memerlukan suntikan insulin&lt;br /&gt;setiap hari; sedangkan pada diabetes tipe 2, kadang dengan&lt;br /&gt;diet dan olahraga saja glukosa darah bisa menjadi normal,&lt;br /&gt;namun umumnya perlu minum obat anti diabetes secara oral&lt;br /&gt;atau tablet, pada keadaan tertentu diabetes tipe 2 memerlukan&lt;br /&gt;suntikan insulin, atau bahkan perlu kombinasi suntikan insulin dan tablet. Di&lt;br /&gt;negara yang sudah maju, telah dipikirkan upaya cangkok&lt;br /&gt;pankreas untuk mengganti pankreas yang sudah rusak, hanya&lt;br /&gt;saja hasilnya sampai saat ini belum ada yang memuaskan.&lt;br /&gt;&lt;br /&gt;Kemajuan teknologi dewasa ini telah menemukan banyak obat&lt;br /&gt;tablet jenis baru dengan hasil yang cukup menggembirakan,&lt;br /&gt;demikian pula bermacam-macam insulin baru telah dipasarkan.&lt;br /&gt;Sehingga disamping angka kejadian diabetes yang terus&lt;br /&gt;meningkat, kemajuan dalam pengobatan diabetes juga terus&lt;br /&gt;berpacu untuk mengantisipasinya.&lt;br /&gt;&lt;br /&gt;Dalam Bab ini akan dibicarakan tentang bermacam-macam&lt;br /&gt;tablet oral untuk menurunkan glukosa darah. Obat tablet ini&lt;br /&gt;disebut sebagai Oral Anti Diabetes (OAD) atau Oral&lt;br /&gt;Hypoglycemic Agents (OHA). Hingga kini dikenal ada lima&lt;br /&gt;macam OAD yang dipasarkan, tiap macam OAD mempunyai&lt;br /&gt;susunan kimia yang berbeda dan cara menurunkan glukosa&lt;br /&gt;yang berlainan. Ada yang merangsang pankreas untuk&lt;br /&gt;memproduksi insulin lebih banyak, yang lain bekerja&lt;br /&gt;mengurangi resistensi terhadap insulin, sedangkan yang&lt;br /&gt;lainnya menghambat penyerapan karbohidrat dari usus.&lt;br /&gt;Pasien diabetes tipe 2, pada permulaan pengobatan biasanya&lt;br /&gt;memakai satu jenis OAD, namun untuk lebih efektif&lt;br /&gt;menurunkan glukosa darah, kadang diperlukan lebih dari satu&lt;br /&gt;macam OAD.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;SULFONYLUREA&lt;/span&gt;&lt;br /&gt;Sulfonylurea adalah tablet OAD yang paling banyak&lt;br /&gt;dikenal dalam puluhan tahun terakhir ini. Untuk&lt;br /&gt;menurunkan glukosa darah, obat ini merangsang sel&lt;br /&gt;beta dari pankreas untuk memproduksi lebih banyak&lt;br /&gt;insulin. Jadi syarat pemakaian obat ini adalah apabila&lt;br /&gt;pankreas masih baik untuk membentuk insulin, sehingga&lt;br /&gt;obat ini hanya bisa dipakai pada diabetes tipe 2.&lt;br /&gt;&lt;br /&gt;Kebanyakan pasien diabetes mengenal obat golongan&lt;br /&gt;sulfonylurea ini, yaitu antara lain :&lt;br /&gt;* Chlorpropamide&lt;br /&gt;* Glibenclamide atau Glyburide&lt;br /&gt;Saat ini yang paling banyak dipakai adalah glimepiride,&lt;br /&gt;glibenclamide, dan glipizide. Pemberian obat&lt;br /&gt;sulfonylurea biasanya 15 sampai 30 menit sebelum&lt;br /&gt;makan.&lt;br /&gt;Glibenclamide adalah OAD yang cukup kuat menurunkan&lt;br /&gt;glukosa darah, pada dosis yang tinggi bisa menyebabkan&lt;br /&gt;hipoglikemia. Obat ini di pasaran dikenal dengan nama&lt;br /&gt;dagang Daonil atau Euglucon, masih ada lagi buatan&lt;br /&gt;lokal, seperti Glimel, Renabetic, Prodiamel, atau yang&lt;br /&gt;generik Glibenclamide buatan Indo Farma.&lt;br /&gt;Glimepiride diberikan satu kali sehari, yang ada di&lt;br /&gt;pasaran bisa 1 mg, 2 mg, 3 mg, atau 4 mg. Obat ini&lt;br /&gt;aman bagi penderita dengan komplikasi ginjal, karena&lt;br /&gt;tidak mengganggu absorpsi maupun kerja obat. Obat&lt;br /&gt;orisinal adalah Amaryl, yang buatan lokal antara lain&lt;br /&gt;Metrix, Gluvas, Amadiab, atau Glamarol.&lt;br /&gt;Glipizide relatif lebih ringan dan lebih jarang&lt;br /&gt;menimbulkan hipoglikemia, tinggal dalam peredaran&lt;br /&gt;darah hanya beberapa jam, kecuali yang tipe XL, beredar&lt;br /&gt;dalam darah sampai 24 jam. Contoh yang orisinal adalah&lt;br /&gt;Minidiab atau Glucotrol dan Glucotrol XL, ada sediaan 5&lt;br /&gt;mg atau 10 mg.&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Efek Samping&lt;/span&gt;&lt;br /&gt;Sulfonylurea bisa menyebabkan hipoglikemia, terutama&lt;br /&gt;bila dipakai dalam 3 – 4 bulan pertama pengobatan&lt;br /&gt;akibat perubahan diet dan pasien mulai sadar&lt;br /&gt;berolahraga serta minum obat. Apabila ada gangguan&lt;br /&gt;fungsi ginjal atau hati, dosis perlu diperhatikan karena&lt;br /&gt;lebih mudah timbul hipoglikemia. Namun secara umum&lt;br /&gt;obat ini baik untuk menurunkan glukosa darah.&lt;br /&gt;Yang Harus Diperhatikan&lt;br /&gt;Semua usaha menurunkan glukosa darah diluar obat&lt;br /&gt;seperti olahraga lebih dari biasanya, tidak makan atau&lt;br /&gt;makan terlalu sedikit, apabila dilakukan bersamaan&lt;br /&gt;dengan minum sulfonylurea, mudah menyebabkan&lt;br /&gt;hipoglikemia.&lt;br /&gt;Demikian bila menggunakan beberapa obat pilek&lt;br /&gt;decongestan, atau alkohol, bisa menurunkan glukosa.&lt;br /&gt;Sebaliknya pada pemakaian steroid, penyekat beta,&lt;br /&gt;niacin, atau obat jerawat retin-A, dapat mengurangi efek&lt;br /&gt;obat sehingga glukosa tidak mau turun.&lt;br /&gt;Anda dianjurkan membuat pencatatan semua data obat&lt;br /&gt;yang dipakai, semua copy resep dari semua dokter anda,&lt;br /&gt;serta catatan bila terjadi kemungkinan efek samping&lt;br /&gt;obat.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;BIGUANIDES&lt;/span&gt;&lt;br /&gt;Obat biguanides memperbaiki kerja insulin dalam tubuh,&lt;br /&gt;dengan cara mengurangi resistensi insulin.&lt;br /&gt;Pada diabetes tipe 2, terjadi pembentukan glukosa oleh&lt;br /&gt;hati yang melebihi normal. Biguanides menghambat&lt;br /&gt;proses ini, sehingga kebutuhan insulin untuk mengangkut&lt;br /&gt;glukosa dari darah masuk ke sel berkurang, dan glukosa&lt;br /&gt;darah menjadi turun.&lt;br /&gt;Karena cara kerja yang demikian, obat ini jarang sekali&lt;br /&gt;menyebabkan hipoglikemia.&lt;br /&gt;Satu-satunya biguanides yang beredar di pasaran adalah&lt;br /&gt;Metformin, contohnya Glucophage, masih ada lagi&lt;br /&gt;produk lokal misalnya Diabex, Glumin, Glucotika,&lt;br /&gt;Formell, Eraphage, Gludepatic, dan Zumamet.&lt;br /&gt;Ada satu keuntungan obat ini adalah tidak menaikkan&lt;br /&gt;berat badan, jadi sering diresepkan pada diabetes tipe 2&lt;br /&gt;yang gemuk. Obat ini juga sedikit menurunkan kolesterol&lt;br /&gt;dan trigliserida.&lt;br /&gt;Obat ini biasanya diminum dua sampai tiga kali sehari&lt;br /&gt;sesudah makan. Ada kemasan Glucophage XR yang&lt;br /&gt;bekerja 24 jam, diminum sekali sehari.&lt;br /&gt;* Gliquidone&lt;br /&gt;* Gliclazide&lt;br /&gt;* Glipizide&lt;br /&gt;* Glimepiride.&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Efek Samping&lt;/span&gt;&lt;br /&gt;Metformin biasanya jarang memberikan efek samping.&lt;br /&gt;Tetapi pada beberapa orang bisa timbul keluhan&lt;br /&gt;terutama pada saluran cerna, misalnya :&lt;br /&gt;* Gangguan pengecapan&lt;br /&gt;* Nafsu makan menurun&lt;br /&gt;* Mual, muntah&lt;br /&gt;* Kembung, sebah, atau nyeri perut&lt;br /&gt;* Banyak gas di perut, atau diare&lt;br /&gt;* Pada beberapa penderita, dilaporkan bisa&lt;br /&gt;menimbulkan ruam atau bintik-bintik di kulit.&lt;br /&gt;Efek samping di atas biasanya timbul pada beberapa&lt;br /&gt;minggu pertama penggunaan obat, yang akan berangsur&lt;br /&gt;berkurang. Untuk menghindari efek samping ini,&lt;br /&gt;dianjurkan minum obat bersama atau sesudah makan,&lt;br /&gt;dan dimulai dari dosis kecil yang kemudian dosis&lt;br /&gt;ditingkatkan.&lt;br /&gt;Bila dikombinasikan dengan obat lain, misalnya&lt;br /&gt;sulfonylurea, meglitinide, atau insulin, obat metformin&lt;br /&gt;bisa menimbulkan hipoglikemia.&lt;br /&gt;Yang Harus Diperhatikan&lt;br /&gt;Hati-hati jangan minum alkohol, bila alkohol dan&lt;br /&gt;metformin diminum bersama, bisa terjadi penimbunan&lt;br /&gt;obat dalam tubuh dan timbul lactic acidosis, keadaan ini&lt;br /&gt;bisa berbahaya, dengan keluhan sebagai berikut:&lt;br /&gt;* Rasa capai&lt;br /&gt;* Nyeri otot&lt;br /&gt;* Sukar bernafas&lt;br /&gt;* Nyeri perut&lt;br /&gt;* Pusing, mengantuk, sampai gangguan kesadaran.&lt;br /&gt;Keluhan perut akibat obat metformin bisa diatasi dengan&lt;br /&gt;obat simetidin atau obat perut lain untuk mengatasi&lt;br /&gt;keluhan mual, muntah, kembung, dan diare.&lt;br /&gt;Bila terjadi lactic acidosis (meskipun jarang), harus&lt;br /&gt;menghentikan obat metformin, dan dokter perlu memberi&lt;br /&gt;suntikan iv dye (obat kontras yang biasanya digunakan&lt;br /&gt;untuk pemeriksaan radiologi).&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;ALPHA-GLUCOSIDASE INHIBITORS&lt;/span&gt;&lt;br /&gt;Obat golongan ini bekerja di usus, menghambat enzim di&lt;br /&gt;saluran cerna, sehingga pemecahan karbohidrat menjadi&lt;br /&gt;glukosa atau pencernaan karbohidrat di usus menjadi&lt;br /&gt;berkurang. Hasil akhir dari pemakaian obat ini adalah&lt;br /&gt;penyerapan glukosa ke darah menjadi lambat, dan&lt;br /&gt;glukosa darah sesudah makan tidak cepat naik.&lt;br /&gt;Termasuk obat golongan ini kita kenal dengan Acarbose&lt;br /&gt;dan Miglitol. Acarbose ada di pasaran dengan nama&lt;br /&gt;Glucobay, dalam kemasan 50 mg dan 100 mg, yang&lt;br /&gt;diminum bersamaan dengan makanan, ditujukan&lt;br /&gt;terutama untuk mengatasi kenaikan glukosa darah&lt;br /&gt;sesudah makan.&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Efek Samping&lt;/span&gt;&lt;br /&gt;Obat ini umumnya aman dan efektif, namun ada efek&lt;br /&gt;samping yang kadang mengganggu, yaitu perut&lt;br /&gt;kembung, terasa banyak gas, banyak kentut, bahkan&lt;br /&gt;diare. Keluhan ini biasanya timbul pada awal pemakaian&lt;br /&gt;obat, yang kemudian berangsur bisa berkurang.&lt;br /&gt;Bila diminum bersama dengan suntikan insulin atau&lt;br /&gt;tablet sulfonylurea, kadang bisa menyebabkan&lt;br /&gt;hipoglikemia. Apabila efek samping ini terjadi, maka&lt;br /&gt;dianjurkan minum susu atau suntik glukosa, karena&lt;br /&gt;makanan gula atau buah manis akan dihambat&lt;br /&gt;penyerapannya oleh acarbose.&lt;br /&gt;Yang Harus Diperhatikan&lt;br /&gt;Karena kerap timbul keluhan perut, maka acarbose&lt;br /&gt;jangan diberikan pada keadaan sebagai berikut :&lt;br /&gt;* Irritable bowel syndrome&lt;br /&gt;* radang usus kronis, ulcerative colitis atau Crohn’s&lt;br /&gt;disease&lt;br /&gt;* gangguan penyerapan usus yang kronis, chronic&lt;br /&gt;malabsorption disorder.&lt;br /&gt;Dosis yang tinggi dari acarbose dapat menggangu fungsi&lt;br /&gt;hati, tetapi bila dosis obat diturunkan atau dihentikan&lt;br /&gt;maka hati akan pulih (reversible).&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;MEGLITINIDES&lt;/span&gt;&lt;br /&gt;Obat ini secara susunan kimiawi berbeda dengan&lt;br /&gt;sulfonylurea, namun cara kerjanya sama. Obat ini&lt;br /&gt;menyebabkan pelepasan insulin dari pankreas secara&lt;br /&gt;cepat dan dalam waktu singkat. Sehubungan dengan&lt;br /&gt;sifat cepat dan singkat ini, maka obat ini harus diminum&lt;br /&gt;bersama dengan makanan. Termasuk golongan obat ini&lt;br /&gt;adalah Repaglinide (Novonorm) dan Nateglinide (Starlix).&lt;br /&gt;Efek Samping Meskipun sama seperti sulfonylurea, efek&lt;br /&gt;samping hipoglikemia boleh dikatakan jarang terjadi, hal&lt;br /&gt;ini disebabkan oleh efek rangsangan pelepasan insulin&lt;br /&gt;hanya terjadi pada saat glukosa darah tinggi. Yang Harus&lt;br /&gt;Diperhatikan Seperti halnya dengan sulfonylurea,&lt;br /&gt;hati-hati bila minum alkohol atau efek interaksi dengan&lt;br /&gt;obat lain.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;THIAZOLIDINEDIONES&lt;/span&gt;&lt;br /&gt;Obat ini baik bagi penderita diabetes tipe 2 dengan&lt;br /&gt;resistensi insulin, karena bekerja dengan merangsang&lt;br /&gt;jaringan tubuh menjadi lebih sensitif terhadap insulin,&lt;br /&gt;sehingga insulin bisa bekerja dengan lebih baik, glukosa&lt;br /&gt;darahpun akan lebih banyak diangkut masuk ke dalam&lt;br /&gt;sel, dan kadar glukosa darah akan turun.&lt;br /&gt;Selain itu, obat thiazolidinediones juga menjaga hati agar&lt;br /&gt;tidak banyak memproduksi glukosa. Efek&lt;br /&gt;menguntungkan lainnya adalah obat ini bisa menurunkan&lt;br /&gt;trigliserida darah.&lt;br /&gt;Termasuk kelompok obat ini adalah Pioglitazone (Actos)&lt;br /&gt;dan Rosiglitazone (Avandia). Dulu ada Troglitazone&lt;br /&gt;(Rezulin), yang ditemukan pada tahun 1997, namun&lt;br /&gt;beberapa tahun yang lalu telah ditarik dan dilarang&lt;br /&gt;beredar, karena menimbulkan kerusakan hati.&lt;br /&gt;Efek Samping&lt;br /&gt;Beberapa efek merugikan yang mungkin timbul adalah&lt;br /&gt;bengkak, berat badan naik, dan rasa capai. Efek serius&lt;br /&gt;yang jarang terjadi adalah gangguan hati, sehingga pada&lt;br /&gt;pemakaian pioglitazone atau rosiglitazone, perlu&lt;br /&gt;pemeriksaan faal hati terutama pada tahun pertama&lt;br /&gt;pemakaian obat. Keluhan gangguan hati yang mungkin&lt;br /&gt;terjadi antara lain:&lt;br /&gt;* Mual dan muntah&lt;br /&gt;* Nyeri perut&lt;br /&gt;* Rasa capai&lt;br /&gt;* Nefsu makan turun&lt;br /&gt;* Warna urin kuning tua&lt;br /&gt;* Warna kulit kuning&lt;br /&gt;Yang Harus Diperhatikan&lt;br /&gt;Obat ini baik sekali diserap bila diminum bersama&lt;br /&gt;dengan makanan, dan tidak menyebabkan hipoglikemia.&lt;br /&gt;Akan tetapi bila dikombinasikan dengan sulfonylurea&lt;br /&gt;atau insulin, maka mungkin bisa menyebabkan&lt;br /&gt;hipoglikemia.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;KOMBINASI OBAT&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;Obat anti diabetes oral bisa dikombinasikan satu dengan&lt;br /&gt;kelompok yang lain, atau kadang perlu dikombinasikan&lt;br /&gt;dengan insulin. Tujuan kombinasi ini adalah agar efek&lt;br /&gt;obat lebih optimal dalam mengontrol glukosa darah.&lt;br /&gt;&lt;br /&gt;Apabila dua obat kombinasi masih belum berhasil baik,&lt;br /&gt;dokter bahkan boleh meresepkan tiga jenis obat&lt;br /&gt;sekaligus, karena cara kerjanya bisa bersama saling&lt;br /&gt;menguntungkan untuk menurunkan glukosa.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;Sulfonylurea dan Metformin&lt;/span&gt;&lt;br /&gt;Golongan sulfonylurea paling banyak atau paling sering&lt;br /&gt;dikombinasikan dengan obat anti diabetes kelompok lain,&lt;br /&gt;karena efek kombinasi bisa memperbaiki dan menambah&lt;br /&gt;kerja insulin.&lt;br /&gt;Kombinasi sulfonylurea dan metformin lebih baik&lt;br /&gt;daripada bila kedua obat dipakai secara terpisah sendiri.&lt;br /&gt;Metformin bahkan baik karena tidak menaikkan berat&lt;br /&gt;badan bahkan kadang menurunkannya.&lt;br /&gt;Efek samping kombinasi ini adalah gangguan perut&lt;br /&gt;seperti mual atau diare, kadang bisa menimbulkan&lt;br /&gt;hipoglikemia.&lt;br /&gt;Kini telah dipasarkan kombinasi dua kelompok obat ini,&lt;br /&gt;contohnya adalah tablet Glucovance, yang tersedia&lt;br /&gt;dalam tiga kemasan, yaitu mengandung&lt;br /&gt;metformin/glibenclamide 500 mg/5 mg, 500 mg/2.5 mg,&lt;br /&gt;dan 250 mg/1.25 mg.&lt;br /&gt;Dalam waktu dekat akan beredar pula kombinasi&lt;br /&gt;glimepiride dan metformin dalam satu tablet.&lt;br /&gt;Sulfonylurea dan Alpha-Glucosidase Inhibitor&lt;br /&gt;Pada kasus dimana glukosa darah meningkat banyak&lt;br /&gt;pada 2 jam sesudah makan, maka pemakaian&lt;br /&gt;sulfonylurea yang dikombinasikan dengan acarbose akan&lt;br /&gt;lebih berhasil baik.&lt;br /&gt;Efek samping yang bisa terjadi adalah kram perut,&lt;br /&gt;banyak gas atau diare. Kadang juga bisa timbul&lt;br /&gt;hipoglikemia.&lt;br /&gt;Sulfonylurea dan Thiazolidinediones&lt;br /&gt;Bila penggunaan sulfonylurea sudah maksimal dan&lt;br /&gt;masih belum berhasil baik, mungkin penyebabnya adalah&lt;br /&gt;resistensi insulin karena kegemukan, bisa dicoba&lt;br /&gt;kombinasi baru ini dengan menambahkan&lt;br /&gt;thiazolidinediones. Sulfonylurea akan merangsang&lt;br /&gt;produksi insulin sedangkan thiazolidinediones&lt;br /&gt;memperbaiki kerja insulin.&lt;br /&gt;Metformin dan Alpha-Glucosidase Inhibitor&lt;br /&gt;Penambahan acarbose atau miglitol pada metformin&lt;br /&gt;adalah lebih baik dalam menurunkan glukosa darah&lt;br /&gt;daripada pemakaian metformin secara tunggal.&lt;br /&gt;Efek samping adalah bisa menimbulkan keluhan pada&lt;br /&gt;perut.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;Metformin dan Thiazolidinediones&lt;/span&gt;&lt;br /&gt;Telah diakui efek menguntungkan dari kombinsai&lt;br /&gt;pioglitazone atau rosiglitazone dengan metformin.&lt;br /&gt;Sekarang sudah beredar di pasaran satu obat yang&lt;br /&gt;berisikan kombinasi dua kelompok obat tersebut di atas,&lt;br /&gt;yaitu rosiglitazone (avandia) dengan metformin dalam&lt;br /&gt;bentuk Avandamet, dan pioglitazone (actos) dengan&lt;br /&gt;metformin dalam satu tablet Actos-met.</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/6923103355477580047/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/obat-diabetes.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/6923103355477580047'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/6923103355477580047'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/10/obat-diabetes.html' title='Obat Diabetes'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-5353435677918725128</id><published>2011-08-24T20:23:00.000-07:00</published><updated>2011-08-24T20:34:32.777-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="diabetes mellitus"/><category scheme="http://www.blogger.com/atom/ns#" term="kehamilan"/><title type='text'>Diabetes Mellitus dalam Kehamilan</title><content type='html'>&lt;span style=&quot;font-style: italic;&quot;&gt;Diabetes Mellitus dalam Kehamilan&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;Eddy Suparman&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;Bagian SMF Obstetri dan Ginekologi Fakultas Kedokteran Universitas Sam Ratulangi/&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;Rumah Sakit Umum Pusat Manado&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;PENDAHULUAN&lt;/span&gt;&lt;br /&gt;Diabetes Mellitus Gestasional (DMG) didefinisikan sebagai&lt;br /&gt;gangguan toleransi glukosa berbagai tingkat yang&lt;br /&gt;diketahui pertama kali saat hamil tanpa membedakan apakah&lt;br /&gt;penderita perlu mendapat insulin atau tidak. Pada kehamilan&lt;br /&gt;trimester pertama kadar glukosa akan turun antara 55-65% dan&lt;br /&gt;hal ini merupakan respon terhadap transportasi glukosa dari&lt;br /&gt;ibu ke janin. Sebagian besar DMG asimtomatis sehingga&lt;br /&gt;diagnosis ditentukan secara kebetulan pada saat pemeriksaan&lt;br /&gt;rutin(1,2).&lt;br /&gt;&lt;br /&gt;Di Indonesia insiden DMG sekitar 1,9-3,6% dan sekitar&lt;br /&gt;40-60% wanita yang pernah mengalami DMG pada pengamatan&lt;br /&gt;lanjut pasca persalinan akan mengidap diabetes&lt;br /&gt;mellitus atau gangguan toleransi glukosa. Pemeriksaan penyaring&lt;br /&gt;dapat dilakukan dengan pemeriksaan glukosa darah&lt;br /&gt;sewaktu dan 2 jam post prandial (pp). Bila hasilnya belum&lt;br /&gt;dapat memastikan diagnosis DM, dapat diikuti dengan test&lt;br /&gt;toleransi glukosa oral. DM ditegakkan apabila kadar glukosa&lt;br /&gt;darah sewaktu melebihi 200 mg%. Jika didapatkan nilai di&lt;br /&gt;bawah 100 mg% berarti bukan DM dan bila nilainya diantara&lt;br /&gt;100-200 mg% belum pasti DM(1,3).&lt;br /&gt;Pada wanita hamil, sampai saat ini pemeriksaan yang&lt;br /&gt;terbaik adalah dengan test tantangan glukosa yaitu dengan&lt;br /&gt;pembebanan 50 gram glukosa dan kadar glikosa darah diukur&lt;br /&gt;1 jam kemudian. Jika kadar glukosa darah setelah 1 jam&lt;br /&gt;pembebanan melebihi 140 mg% maka dilanjutkan dengan&lt;br /&gt;pemeriksaan test tolesansi glukosa oral(2).&lt;br /&gt;Faktor risiko tinggi yang membutuhkan pemeriksaan&lt;br /&gt;penyaring antara lain :&lt;br /&gt;A. Riwayat kebidanan :&lt;br /&gt;1) Riwayat lahir mati&lt;br /&gt;2) Riwayat melahirkan bayi dengan berat &amp;gt; 4000 gr&lt;br /&gt;3) Adanya riwayat melahirkan prematur&lt;br /&gt;4) Adanya riwayat preeklamsia pada multipara&lt;br /&gt;5) Polihidramnion&lt;br /&gt;6) Riwayat &amp;gt;3 kali abortus spontan&lt;br /&gt;7) Hipertensi kronik&lt;br /&gt;8) Monilisasi berat yang berulang&lt;br /&gt;9) Infeksi saluran kemih yang berulang selama hamil&lt;br /&gt;B. Riwayat Ibu :&lt;br /&gt;1) Adanya riwayat DM pada keluarga&lt;br /&gt;2) Umur &amp;gt; 30 tahun&lt;br /&gt;3) Pernah menderita DMG pada kehamilan sebelumnya&lt;br /&gt;Pada penderita dengan faktor risiko tinggi seperti di atas,&lt;br /&gt;pemeriksaan penyaring dapat dilakukan lebih awal dilakukan&lt;br /&gt;dimulai pada usia kehamilan 18-22 minggu. Jika hasilnya&lt;br /&gt;negatif maka pemeriksaan dapat diulang kembali pada kehamilan&lt;br /&gt;26-30 minggu(1,2,5,6,7,9).&lt;br /&gt;Klasifikasi diagnosis DM yang dianjurkan adalah klasifikasi&lt;br /&gt;menurut WHO tahun 1985, yaitu:&lt;br /&gt;• Diabetes Mellitus&lt;br /&gt;1) DM tergantung insulin (DM TI)&lt;br /&gt;2) DM tidak tergantung insulin (DM TTI)&lt;br /&gt;− Tidak gemuk&lt;br /&gt;− Gemuk&lt;br /&gt;3) DM terkait Malnutrisi (DMTM)&lt;br /&gt;4) DM tipe lain yang berhubungan dengan keadaan sindroma&lt;br /&gt;tertentu, seperti:&lt;br /&gt;− Penyakit pankreas&lt;br /&gt;− Penyakit hormonal&lt;br /&gt;− Karena obat/ bahan kimia lain&lt;br /&gt;− Kelainan receptor insulin&lt;br /&gt;− Sindroma genetik tertentu&lt;br /&gt;− Sirosis hepatis&lt;br /&gt;• Toleransi Glukosa Terganggu&lt;br /&gt;− Tidak gemuk&lt;br /&gt;− Gemuk&lt;br /&gt;− Yang berhubungan dengan keadaan atau sindroma tertentu.&lt;br /&gt;• Diabetes Mellitus Gestasional (DMG)&lt;br /&gt;• Kelas risiko statistik&lt;br /&gt;(pasien dengan toleransi glukosa yang normal, tetapi jelas&lt;br /&gt;mempunyai risiko yang lebih besar untuk timbulnya DM)&lt;br /&gt;− Toleransi glukosa pernah abnormal&lt;br /&gt;− Toleransi glukosa potensial abnormal.&lt;br /&gt;Pembagian diabetes mellitus pada kehamilan&lt;br /&gt;1) DM yang memamg sudah diketahui sebelumnya dan&lt;br /&gt;22 Cermin Dunia Kedokteran No. 139, 2003&lt;br /&gt;kemudian menjadi hamil (DM hamil = DM progestasional).&lt;br /&gt;Sebagian besar termasuk golongan IDDM (Insulin Dependent&lt;br /&gt;DM)&lt;br /&gt;2) DM yang baru saja ditemukan pada saat kehamilan (DM&lt;br /&gt;Gestasional = DMG). Umumnya termasuk golongan IIDDM&lt;br /&gt;(Non Insulin Dependent DM)(2,5,6)&lt;br /&gt;DMG sendiri dibagi dua sub kelompok.&lt;br /&gt;1) Sebenarnya sudah mengidap DM sebelumnya, tetapi baru&lt;br /&gt;diketahui pada saat hamil (sama dengan DMH)&lt;br /&gt;2) Sebelumnya belum mengidap DM dan baru mengidap DM&lt;br /&gt;pada masa kehamilan (Pregnancy-Induced Diabetes Mellitus).&lt;br /&gt;Merupakan DMG sesungguhnya, sesuai dengan definisi lama&lt;br /&gt;WHO 1980(1,5,6,7).&lt;br /&gt;&lt;br /&gt;Ke dua sub kelompok ini baru dapat dibedakan setelah&lt;br /&gt;dilakukan tes toleransi glukosa oral (TTGO) ulangan pasca&lt;br /&gt;persalinan. Untuk sub kelompok DMH, hasil TTGO pasca&lt;br /&gt;persalinan masih tetap abnormal, sedangkan untuk DMG hasil&lt;br /&gt;akan kembali normal. Menurut O&#39;Sullivan dan Mahan, diagnosis&lt;br /&gt;DMG dibagi dalam dua tahap, yaitu : Test Tantangan&lt;br /&gt;Glukosa (Glukosa Challenge Test) dan Test Toleransi Glukosa&lt;br /&gt;Oral. Test tantangan glukosa dilakukan tanpa harus berpuasa&lt;br /&gt;yaitu pada saat ibu hamil berkunjung ke poliklinik diberikan&lt;br /&gt;50 gr glukosa yang dilarutkan dalam air 1 gelas. Contoh darah&lt;br /&gt;vena diambil setelah 1 jam pembebanan. Test ini disebut&lt;br /&gt;positif bila kadar glukosa plasma sama dengan atau lebih dari&lt;br /&gt;140 mg%. Test toleransi glukosa oral dilakukan dengan cara&lt;br /&gt;penderita makan cukup kalori minimal 3 hari sebelum&lt;br /&gt;pemeriksaan, kemudian semalam sebelum hari pemeriksaan&lt;br /&gt;harus berpuasa selama 8-12 jam. Setelah persiapan dalam&lt;br /&gt;keadaan berpuasa, contoh darah diambil pada pagi hari dan&lt;br /&gt;penderita diberi beban glukosa 75 gram dalam 200 ml air.&lt;br /&gt;Contoh darah berikutnya diperiksa dua jam setelah beban&lt;br /&gt;glukosa. Contoh darah yang diperiksa adalah plasma&lt;br /&gt;vena(1,2,3,4,6,8,10,11)&lt;br /&gt;Kriteria diagnosis WHO (1980 dan 1985) sama dengan&lt;br /&gt;kriteria diagnosis DM pada keadaan tidak hamil.&lt;br /&gt;Kriteria diagnosis modifikasi WHO-PERKENI (1997)&lt;br /&gt;adalah sebagai berikut:&lt;br /&gt;− Diperiksa hanya kadar glukosa plasma 2 jam pp.&lt;br /&gt;− Nilai &amp;gt;200 mg/dl : diabetes mellitus (jika baru diketahui&lt;br /&gt;saat hamil, DMG).&lt;br /&gt;− Nilai 140-200 mg/dl : toleransi glukosa terganggu (TGT)&lt;br /&gt;− Nilai &amp;lt;140 mg/dl : normal&lt;br /&gt;Sesuai anjuran WHO, pada temuan TGT (gala darah 2 jam pp&lt;br /&gt;140-200 mg/dl) ditangani juga sebagai kasus DMG, sehingga&lt;br /&gt;penderita dengan kadar gula yang lebih rendah (dalam kriteria&lt;br /&gt;O’Sullivan) juga termasuk dalam yang ditangani(1,3,4,6,11,12).&lt;br /&gt;METABOLISME KARBOHIDRAT PADA KEHAMILAN&lt;br /&gt;NORMAL&lt;br /&gt;Pada wanita hamil normal terjadi banyak sekali perubahan&lt;br /&gt;hormonal dan metabolik untuk pertumbuhan dan perkembangan&lt;br /&gt;fetus yang optimal. Pada kehamilan normal, kadar glukosa&lt;br /&gt;plasma ibu menjadi lebih rendah secara bermakna, karena:&lt;br /&gt;1) Ambilan glukosa sirkulasi plasenta meningkat&lt;br /&gt;2) Produksi glukosa dari hati menurun&lt;br /&gt;3) Produksi alanin (salah satu prekursor glukoneogenesis&lt;br /&gt;menurun)&lt;br /&gt;4) Efektifitas ekskresi ginjal meningkat&lt;br /&gt;5) Efek hormon-hormon gestasional (human plasental&lt;br /&gt;lactogen, hormon-hormon plasenta lainnya, hormon-hormon&lt;br /&gt;ovarium, hormon pankreas dan adrenal, growth factor, dan&lt;br /&gt;sebabagainya) (2,5,8).&lt;br /&gt;Selain itu terjadi juga perubahan metabolisme lemak dan asam&lt;br /&gt;amino.&lt;br /&gt;PATOFIOLOGI DIABETES MELLITUS PADA KEHAMILAN&lt;br /&gt;Pada DMG, selain perubahan-perubahan fisiologi tersebut,&lt;br /&gt;akan terjadi suatu keadaan di mana jumlah/fungsi insulin&lt;br /&gt;menjadi tidak optimal. Terjadi perubahan kinetika insulin dan&lt;br /&gt;resistensi terhadap efek insulin. Akibatnya, komposisi sumber&lt;br /&gt;energi dalam plasma ibu bertambah (kadar gula darah tinggi,&lt;br /&gt;kadar insulin tetap tinggi).&lt;br /&gt;Melalui difusi terfasilitasi dalam membran plasenta, di&lt;br /&gt;mana sirkulasi janin juga ikut terjadi komposisi sumber energi&lt;br /&gt;abnormal. (menyebabkan kemungkinan terjadi berbagai komplikasi).&lt;br /&gt;Selain itu terjadi juga hiperinsulinemia sehingga janin&lt;br /&gt;juga mengalami gangguan metabolik (hipoglikemia, hipomagnesemia,&lt;br /&gt;hipokalsemia, hiperbilirubinemia, dan sebagainya(&lt;br /&gt;3,5,8).&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;MORBIDITAS DAN MORTALITAS IBU DAN JANIN&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;PADA DMG&lt;/span&gt;&lt;br /&gt;Komplikasi maternal meliputi infeksi saluran kemih,&lt;br /&gt;hidramnion dan hipertensi (kronik/preeklampsia/eklampsia),&lt;br /&gt;sedangkan komplikasi fetal intrauterin adalah risiko abortus&lt;br /&gt;spontan, kelainan kongenital (terutama pertumbuhan sistim&lt;br /&gt;syaraf pusat), insufisiensi plasenta (mengakibatkan hipoksemia&lt;br /&gt;kronik), kematian intra uterin, makrosomia dan organomegali(&lt;br /&gt;11,12,13).&lt;br /&gt;Komplikasi neonatus pasca persalinan meliputi prematuritas,&lt;br /&gt;kematian perinatall neonatal, trauma lahir, gangguan&lt;br /&gt;metabolik (hipoglikemia, hipomagnesemia, hipokalsemia dan&lt;br /&gt;hiperbilirubinemia), sindrom gawat napas neonatus, polisitemia,&lt;br /&gt;trombosis vena renalis. Komplikasi pada usia anak atau&lt;br /&gt;dewasa adalah gangguan tumbuh kembang intelektual,&lt;br /&gt;obesitas sampai diabetes mellitus itu sendiri(1,3,7,9,14).&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;PENGELOLAAN DIABETES MELLITUS PADA KEHAMILAN&lt;/span&gt;&lt;br /&gt;1. PENGELOLAAN MEDIS&lt;br /&gt;Sesuai dengan pengelolaan medis DM pada umumnya,&lt;br /&gt;pengelolaan DMG juga terutama didasari atas pengelolaan&lt;br /&gt;gizi/diet dan pengendalian berat badan ibu.&lt;br /&gt;A. Prinsip penanganan&lt;br /&gt;• Kontrol secara ketat gula darah, sebab bila kontrol kurang&lt;br /&gt;baik upayakan lahir lebih dini, pertimbangkan kematangan&lt;br /&gt;paru janin. Dapat terjadi kematian janin memdadak. Berikan&lt;br /&gt;insulin yang bekerja cepat, bila mungkin diberikan melalui&lt;br /&gt;drips.&lt;br /&gt;• Hindari adanya infeksi saluran kemih atau infeksi lainnya.&lt;br /&gt;Lakukan upaya pencegahan infeksi dengan baik.&lt;br /&gt;Cermin Dunia Kedokteran No. 139, 2003 23&lt;br /&gt;• Pada bayi baru lahir dapat cepat terjadi hipoglikemia&lt;br /&gt;sehingga perlu diberikan infus glukosa(4,6,9).&lt;br /&gt;B. Diet&lt;br /&gt;• Penanganan DMG yang terutama adalah diet, dianjurkan&lt;br /&gt;diberikan 25 kalori/kgBB ideal, kecuali pada penderita yang&lt;br /&gt;gemuk dipertimbangkan kalori yang lebih mudah.&lt;br /&gt;• Cara yang dianjurkan adalah cara Broca yaitu BB ideal =&lt;br /&gt;(TB-100)-10% BB.&lt;br /&gt;• Kebutuhan kalori adalah jumlah keseluruhan kalori yang&lt;br /&gt;diperhitungkan dari:&lt;br /&gt;− Kalori basal 25 kal/kgBB ideal&lt;br /&gt;− Kalori kegiatan jasmani 10-30%&lt;br /&gt;− Kalori untuk kehamilan 300 kalor&lt;br /&gt;− Perlu diingat kebutuhan protein ibu hamil 1-1.5 gr/kgBB.&lt;br /&gt;Jika dengan terapi diet selama 2 minggu kadar glukosa&lt;br /&gt;darah belum mencapai normal atau normoglikemia, yaitu&lt;br /&gt;kadar glukosa darah puasa di bawah 105 mg/dl dan 2 jam pp di&lt;br /&gt;bawah 120 mg/dl, maka terapi insulin harus segera dimulai.&lt;br /&gt;Pemantauan dapat dikerjakan dengan menggunakan alat&lt;br /&gt;pengukur glukosa darah kapiler. Perhitungan menu seimbang&lt;br /&gt;sama dengan perhitungan pada kasus DM umumnya, dengan&lt;br /&gt;ditambahkan sejumlah 300-500 kalori per hari untuk tumbuh&lt;br /&gt;kembang janin selama masa kehamilan sampai dengan masa&lt;br /&gt;menyusui selesai(10,13).&lt;br /&gt;selesai&lt;br /&gt;Pengelolaan DM dalam kehamilan bertujuan untuk :&lt;br /&gt;− Mempertahankan kadar glukosa darah puasa &amp;lt; 105 mg/dl&lt;br /&gt;− Mempertahankan kadar glukosa darah 2 jam pp &amp;lt; 120&lt;br /&gt;mg/dl&lt;br /&gt;− Mempertahankan kadar Hb glikosilat (Hb Alc) &amp;lt; 6%&lt;br /&gt;− Mencegah episode hipoglikemia&lt;br /&gt;− Mencegah ketonuria/ketoasidosis deiabetik&lt;br /&gt;− Mengusahakan tumbuh kembang janin yang optimal dan&lt;br /&gt;normal.&lt;br /&gt;Dianjurkan pemantauan gula darah teratur minimal 2 kali&lt;br /&gt;seminggu (ideal setiap hari, jika mungkin dengan alat pemeriksaan&lt;br /&gt;sendiri di rumah).&lt;br /&gt;Dianjurkan kontrol sesuai jadwal pemeriksaan antenatal,&lt;br /&gt;semakin dekat dengan perkiraan persalinan maka kontrol&lt;br /&gt;semakin sering. Hb glikosilat diperiksa secara ideal setiap 6-8&lt;br /&gt;minggu sekali(4,5,7,9).&lt;br /&gt;sekali&lt;br /&gt;Tabel 1. Kisaran kenaikan berat badan selama kehamilan normal (g).&lt;br /&gt;&lt;img src=&quot;data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAYIAAACYCAIAAABmonmXAAAgAElEQVR4nO19bYgcR5pmQHNgDAsCge8SDLd3Cf7h64Vb+oduGpZNuN38ca3DZrheuAane4u56R/9Y7gZlJC7aGmwhpadTQ2+06E73aSvsTC2pYtB7Nzo1D3O+TCekUvOHXSr8ZSSEZ6mnaQkGk1RJJ6mSIK4HxGRGfnRrfrIyoxqxfNLqsrOeuqNzKcyIt7nfQGWkJCQaBSgaQISEhLPOqQMSUhINAwpQxISEg1DypCEhETDGEGGgISEhMQomIoMDX+wRLMQf7AEZyg4PSw8w5HoSRk6mRB/sARnKDg9LDxDKUMSMzBYgjMUnB4WnuGzK0MxTCelr+/H6Rv7ryevw/jovz9BePpgBVtn5gAAAJxe3aExCW6uvjQH5k6dObfzaOpheirD+O7FxVNzAJw+c+7mI/LSox+sqs9lXmmOHsbR3Xf+Sp0DYE595Z27McaiBZDi0TtnT/3x6k4PY9ECyB08pfM2hkRxXv+cvdSDiTQ1yaxWDDVY8c3V03NMhuJHV185dXp1J76/deaPTq/enPZt9BSG8S/OvfQc++14cXWnh/He1bPK6dWbcbB1Zu5Fel81RQ/j+O4P3r8b4UfvnD1FYihYACki79yfzAkZwMzBUzpvY9j/JsiJTvqMJGUoi4wM3d868zw4vboT93ZWX+QekZphGP/ke39zM8B47+rZFwB4/szWfRxsnZmbO716M45vrp7+J9O+z4e82uO7FxdPPf/SuV/EggWQ0bv8ivoc1XEhA0gPntJ5G0MqQwDAHsY4hmc5GYofpv8F4MN9jKPP0hnbh3/4bJmbvhUPnhmMLEPpv3s7qy+yBxCMMY53Vk8DAOb+9ep3/uwUmDt15i/OnJoDAIBTr1x9FOP47juvqHNJlIa+/Ya7nOJga3FubnEriOOd1dMguYvmuA8ihMHcwmvfWTwNwOkzZxdOAQDA3Kmz7zxKpk6ZB6tK6MXB1uIcAACcXtzyYgEDGN99//1rF888T8iIF0Du4BEOnRkZOvcGU44Y96B69sMPExmiE7TbX7xOX4k/BACA1z+PP3sdgMvv0xdvvw5UGBcObvrLDY8KZYg+KM29tHrz1zurLwLwnLp6zdtanAPPn9n6PNhanAMvru7s7ay+COYWt4Jhf2KHlqG/ePncL2J6M5feRXSda079xs3g71dPz4G5l1Zv/mTrzPNgbnHrs7fII8Dhzupp8lRVKb1HO+fOnJoDc39y7tNrggUwfvSTn9yN7289XYYaDCA7eIRDZ0aGPjxk8zD4xXnwzc/ZtIzqSPyZraaPPOxpaBk+xDimT0Nn4UM6RNmDG/xio2EKMrS4FRzsrL5Ipkjsmv77Pf4uGvqncmiGO+e+vkWWf59+F53ZCshbKdUXV997g7uL5oafiQx/tcfk/rz4tlgBfHTtb7Y+pVPFIWWooQDikypDcfxh8hD5zf2Yk6H4IXn6+fkypyzJ5OuNhxjjh5C8Zz/8Q9nBs4GRZei4pY1j7qKbcTKnmFPPXtwZfv9lCIbBztalnUcxxnvvb10LjlnaOOYu2gnYnOI59ex3h9/AGuFqpyu+HZECmEwYubne70QN4ImVoezuWCpDTJ6W32UPOH+AAKjw4WG6pw/36Xbb+/8lf/BJlqFko4ftp6THHXsXPXrnlbPfC6pnGD+6+sopGnjyI8yI8TvQBMfdRfeuvvJXw890hqZ3f+vMH5GN+dg79/LL57xYtAByH53bKRMigNmDp3TeRsDlDb2+T6TE/ozLJeJwVqPH/fL7KlimTztv/N/3VfV1+p9zn8Vf2LmDP4ua/orD4qmDRddNKchlWp72wo6cO/3at147PQcAmDuz9p0zzwMAwNzXzp//WvqrO/fS6s1hb6jjGcbeuZfS87IlifK0F7rCCsCLr537+mly/HfWSFbU3J/++z9Nz/OcuvqDIR83nhbA6O6WdoqcM31GECiADLwMCRXA7MEjHCq8DEkkqG+w6JXN7qMzW0PeRnUxJNKQ8Bt2DVgGkKGOAEoZOpmoa7DiYOvPXmATkHjnGy9PZwlzfARbZ15gyzTxzdWXv1FpPsHkkAHEWMrQSUVtg8US5AAY0cRQE0M+K+fU4rmdaqc8FUAGEMt6QxISEtPDVGRo+IMlmoX4gyU4Q8HpYeEZjkRPytDJhPiDJThDwelh4RlKGcI49tLcZwrN9mZmu31yVDZYfddUAAAAKJbbR9WcE2M8HsPonmPMAwAUY7sbIe6VecO5F2WO4V6pgR4KPWgb87aXLOzk44ai7rahAKC0nG6fHNF1Wgr/XabHsBg3jPquRQmabh8X41YkPDV6J1aGMMZ4HxoLBiT+DRR5205RhlDXsW6EtTOrARUN1qHvnHf8wypOlcfoDHuec8UNByjctbRF0z3A+MA1FzW7E0Ud+8hXaqDHbmk1kaFC3PquqSzZ3pPIa2uK5fbjvmspWtuLnnj2EhWCaTEsxg1j1HXWtv1U/QpxyxMeWSilDBHwMlSKQQDXFQMeLUOD0N+b0SeoagaL/KQrhr3rVx6HCRjuQ8Nw/EPcd01l2fEPMY5DuKaYbr/4Sl30Ys9WExnKxw31XUvRHR8R8prp3nfNRd3pIoxxCI3p3+cY4zRuTDcVo73r9xlhPm4/DvKERxZ0KUMEqQwhH257EcaDsHPJUAAA84bz/x6RZ04AwB8bS/SnbB8aKgCa7T0J3Q0NAKAsLl351exYOFJUN1h9f7dtKJPOcYoYl2HfhxdM516UvfPJvzuf5l/xxh28iWSI8EzjFnm2xt6MPFtT37x6UWWrBLFnq+OsGIzIMI0bReTv2oaitJxuvxDJ7169mCU8eiClDBEQTUkXhlAAW+o6DA4jr62BZcePQrgGDBiSHwcS6b5rKpp95x8cfR2GMQrgenvsK7lJVDpYaOwn82MwFsPIszUAAABLttcTW4YwF7d+0zKUiRv3eo9MCZ9IGZoakqchsjDUC+Eat2KtGvB3TIa4a4heE4FnLymGfd2tfjJSDyoeLNQlulzhKcdmiMJP2sZ82c0jmgwlces1LUMYc3HjJ6rId3QD7ksZmhpya0NxCNcAne5yr5TLUITxgGx+KC0YVPkQUBOql6Gl8wI8DRHwK0FrMIwxPvSd5fJX6qJ3pAwtnacL0mQVEnUdfdF077umxlYMHL2mtaGS9TLkO0slcftxkCcs14bGRH6JGvmODnQTdiOMUXBr+6cPMzKkrMMgCt0NDWi214XmphsOkO/oE/yiNohKB6vfddZ0uyPG2hDGKHCtFZF2yjAulyEubk3ulDGkcWOI7jnGiu315E7ZdMDlDXHXxoAuPANFM6EfxZHX1gBQWjDok6QJ3bp1fVMFQP3b7125ctmYB0y2Zg5VDBbqu5ayqGmKbm53wqofCUe/i7qOrgCQ2bkjEw0+S6j4Sg300stNtb24NG5seyRJw0Fhp23UkTdUErcD11xc1BYVzdz2KMFC3AqEp0SPHDyl80o0C/EHS3CGgtPDwjOUMiQxA4MlOEPB6WHhGUoZkpiBwRKcoeD0sPAMpQxJzMBgCc5QcHpYeIbPmgzF2YQgRTOh37tjq5nV6WcNEw1W1IWmDgAAmgVJsv/ERseKGJIsildZls2h7yxzQ78Gw7gZa2sGKPLaLNOG+lcrdLROzJBmotBwPd3jWge9EyBDmMsAIneLotmd3mTZaylm0/46wWAd+tubTreP0R5szdNMq4m3b6thSG3rLNkP+fBtl+30kAydx01t2KcgcVNtL0aR927bDRAKXEtXTLdP7vnJ9uknY0g2i7ktvKd6XGuhd8JkCGN84JoLIJsYWgL02H8wzDXwVPuroKhksJDv6GANhoOCM3P8qzPBmAyPyDnm0vCasbYyDAK4uWl/K3vtxSFc150uwgeTO1onYYgC2FJ4P8dTPa41BfAEyZC24YaHkQ9NTeEz/VlCBADKOgwGGAWupQMAFM244kXJu4qx/euP31QBACubjqXn7a+qfefL7HnERjWDRW+VgiWqiqfMSmXo0HfWTPeg6DKrzcxB0XctK+MywRhFPrTMd7sRypAf18MxAcND31kGyqK2qGQS4o7zuNYUwBMkQ/zaUIRYEJmoo66jzxtwn5hoQjwI4Eb7zuewpbXgHoo6tqbqzt2us0zkjJldk+es/Hma/spPQVXpi6rp9osGcdFkiHlNmpahntfehMEgT4NclnYnaliG9qExr1m7IRoEcF3JPIsd5XGVMjQC+EkZeykNIor8n163DQWoBtzHUcfWFgz7A9fv4xAa3AonMK7dzbvM+DNnzyM2KhgstAct2w0HWHgZYj8tJaU/apQhFHmXLbiHih9NEqYVy31yp0kZ4j+RVJLgPv0Ij6uUoRFwjAyhyGtrmum4t5zEYkZKdirzre//99fAMlclr2h25Ra/i+cRGBMPVs9rb7DNHVRwZgq1NnToOyt0waU5aytXTCO7c0dAp7ePJ3e0TsBwHxrzNFCxZ6v8lX+Ux1WuDY2AI2SIrmvobOV/3oD7OLxhWrshOvSdZfWt/31FV8kkDqO9G9s/+QdnOVuBKDlzlD+P2JhssPrd7be3iQZFDzy/L8pOGS6VoaSoIG7Q2prnmHmOGITuht78TtkggOuKtuGGUehuaHy1iWM8rrXQOwEyxC0MJWOfzLaM678l/lXj0nX7VaBtuHdvOlfahkKTYlC4a2kKyZG5Bt9QAQBANewL+T9vXffvZM8TCr1KPcFgsVQXCvKbOanRsRqGqYWUU6K+ay6ld1Qj1tYSmqrtxUla07xh3/JJltDEjtaJGLJPZxlhw3hc66B3AmRIogTiD5bgDAWnh4VnKGVIYgYGS3CGgtPDwjOUMiQxA4MlOEPB6WHhGUoZkpiBwRKcoeD0sPAMT4wMJR48ABSjfXt3e7vYqycO4VpDDtZ9aCwJ2wl20p2yvCFTDGtrSffRA9dcAAAAsEC3dRq0tiZ1Dun+BgxxsX1ro9ZWFsDjrLbS2soBRV5bS1LOyQr/DHq7msIEg1U0ZApibS3pPor87TWSCEPR5IY98m+87dL+CTQNJ9++tdkN+0PfWVaM7W70xLOXgO74qMhHbtjzQF1HVzW+DDvag+0fSRkaElUMVmLILDYdbS59EWMuUYg8CnHb4c1bWwmox63QvrVZa2uaAc9SCgp89neltTUF8h0dlKW6J4kPYL4Fv/i9aykAqLZ3SBJKtBVDU8Br3/9ReszegLyVGla5R83M2X5zx9YAUFfsS5amAKXldD5mT6edj3NvdR+45gLLXkHET0snC70O+TzbsbQqnr3Hw8SDxRkyhTJz5LuPosi/ZRvzJM5Ne8oYMv2UuPatDXvKUN+1FKXldPc8e6UF91CBzwXblGaOFLFnq6UyRH9DvvJpunNyVxCTfduLUOGYQz9vWD3qbPvQUBVjuxs9ds2FzJ8Muo6uatZuiA5cc0G1vTgZwqhja6/aXo9MqhXT/b3v6EC33AAVnDu1YcLByhgyBZKhI7qPshmEIDLEZmTpC3Qy+6TTqAxhYmEFSZ6vlKHjcaQMYYwj371uGwookaFk8ShzTFlbxPKzJa3NIs/Wsn+SeYuXId5DSzVrHxrETzTxpTY2KhisxJApVKGP8u6jh75jGHBfDBmiZLKku46+DvdvNyxD0T3H3HAcUwPlT2dShrLou6aiZNaGcM/b/qHf79jakunccp3WkTIU5Y45WobyR44rQ2ySTw8+GTKEk6fFYtPRZteGissW/FpMU9ZWBtR19BXeNUpfpMUhG7S2HrBPZ09nRT77u9LaymMQwHUlqVaJwk77fNvrxZ6tsoV9YMAQH7jmgkK3JJZT4cgck7yFcpOy/JGo6+iq7nRRKkNkOm25vd+wMkNsUtZ3TWWBXfpkyann2a9qdqdPixbGxXIKtaGKwUoMmYLslDHku4+iqLtt6G0vQkJYW0NoZHqUY659a7M7ZQeuuaC0YIDQ0c1j5U5ZHmRtj+RcsL2GqGNrClBaV65v6mDxLzVaG3HZWCaeR9X24swx+rfNlRcAyBpWk7kbf+S//eu1r5EMFMNYyp0WLPwr8pe2nalQBMAaDL+itk9ajb9D7ZfGBdtQ2TF1JzZNNqcoGDJFsLYWu4/2XVNZ0LR5zXzXY07jpq2tqO+eX6I5BGXtWxu1tnKVSI02YVTgI62tEpVB/MESnKHg9LDwDKUMSczAYAnOUHB6WHiGUoYkZmCwBGcoOD0sPEMpQxIzMFiCMxScHhaeoZQhiRkYLMEZCk4PC8/wWZYhriw52Q5LyoY+Y42kxxss0itgPh+qnmcvsfgJYRBnn973oaUBkO261XDzaNpvgbZvKVYmaDaAtC24YlzqhANxum+fMBnCJeXxY89eY6l3M9gGejyMNVi0aEZOsVEAWwp5sdm0l7zDHvnvWc69iKaYLTOza5N5QyjctTQ1TSDI51sV83TGxzgBtF/V7E6U1E4Qpvv2syNDE7SBHrbTtEAYd7AKXg20B60Ltrmo2l7cdO9jBr4VByHJelg267BHe7C1wKX+FysT3G8ygKjr6DpJpkVJhm3yZqPdt58RGbrmc22gO/tpw2hmiNcM488BeJk+C5DGHqrtDTKdphv8VqOiIhlCfXfTcr/I+VcwbsqZiQsOewJafqRZTxnyHR2omrbAWgcXvHhvXr3YcLtEVhwulRuChrtvPyMyxDnL0F62YXQXhdCgjm1m1GC2jzu/4TpNP4MyFHXa1o0A5W10GDclQ0c47PuuqVpNN48mNR423HCAAthSFkx3TywZQnuwNZ+aOfinoaa7bz97MpRvGE1eIUNSqAvV4zpNzxSqkCHakb3o5sW4waehosN+EMAL590g17W5dhniQ0d+zz7+VCgZSgtjaYahAc741nj37RMqQ7y3sO9altvPyFCmbS4+RoZirtM03GugfNm4qECG0t6EiWT/r+tNGsQT8MsWKPIup3O0Jh32/IUXebauO5/38pUJ7jfqsGdIJgT0/8133z55MkR2dugOLgo72+ZyC+6hdFLWdTINoz/5fbpcF3m2prRgEAeupQPV9r7kOk3P1I5/ZUvUmReb3SljSB32KOp+YG8TDer73oOo2VrUAWwpuuUGcbhraSuOfyjYThnG9I5Y0qzdMBXA5rtvn0AZSu3gJKOEmpvJfBgoLbgfpA2j4ee7XGIRy/LQNm7BDRUA9fx/u8J1mm76e42AyVZecnv2nDY1aBDPO+zZYFEo5Pe8UYd9cuEleUyFygRNOuz3oaFydwSDAN23T6QMSczAYAnOUHB6WHiGUoYkZmCwBGcoOD0sPEMpQxIzMFiCMxScHhaeoZQhiRkYLMEZCk4PC8/w2ZEhsuSWgPM3joM4hGuF1dlZRRWDxTtai02QJ8WYa8AetI1XWbpNukrdbO9jhmLTbYzzZtdGra0EUcfWdBbDIp9CP+7p05tpGcI47aVBoplNrh0ZlXW/aRyTDxbnaMU43wS5AozDkEohy/pDXUdfMJx7UZIQ3+SGfVnT7bzZVYSMB+IEpp0+i3wK/bjroHdiZIhco2q+P9RokDLEkHG04kIT5AowJsPyTG42cEI0j06abhfNrs17g1Fww9rcNGncinwe5/tx10LvBMjQvGbthoiUnlkw3SBJGlJaH3SurQFAfz9JVvA/W3gRAM32etwUjCW5K68aK/Oq7Q3SBgbrcO8T5n3VAFi7fvfn6VvBoOmvfyQmG6yso5W+yDVBbpBhxgNx4JoLirHdDW/b+rdgMBCgXSLfdLtgdu3dadoNc+Bam2nz2HJNz/TjrofeCZChZHmIrA1RszUrZfBVANdpsQXUdda2/V7SO4wZWaOOrS1ZboCijq0pqn17n/yQJuUjUu8r+41N3hIVEw1WztGavoGa71OWu3tJiyc2TWtchrJNtwtm192Pmu1hH3mXLb51/TEmQZlFPQq4SVmKvu9+YBvzrJocDSjy3zvPjwF7kj9Mr9fUtRD5P72eLCumpjOMc2+JigkGq+Bo5d8kTZCraLtWhQyhqPuuaV12TJ2sCjcuQxgf1XT7wDUXGra20l8X7qOP8yqXtcCeGr2TJ0M9z35VMx3XvcK0g5j0ftjZvuL2UXFBoSBDnZ7X1jTTcW855OSpDKEo95aoGH+wShytXLkCVhGiMYb83ZL6MHt0hVWE5tE4WWcZFMyuv/yoOWtrYWBVA9492mrL+nHXQu/EyVDs2SozE7JHGLLpQy/K2LPV+Rbci8NdS1NU2xsEsEWWPOikzL1t62y3Zd6A+yjjfc281dTXfiqqGKzi01DSBLkCVCRDpPJBr9nex1mkTbcLZtevBNgpyywDHcGH78ddB72ZlqF0YYi7W3qevQTAvHHlXVtXmZP4wDWX2EVJtvYVzboONzUANNt7ErobGgBAWzeNeQBe0IwVDQDFuHTdfhUsJD8ethczfyx5S9twQ0FXqSuVobImyBNjHIbpDzq5i1IPM6vx3qC19dim20lSW6PNoyl4Kc/xKevHXQO9mZah4XHgWpuVTCVmBeIPluAMBaeHhWcoZSgPFMA1a6IH4JmD+IMlOEPB6WHhGUoZ4kDy7gSePU0J4g+W4AwFp4eFZyhlSGIGBktwhoLTw8IzPDkyVNhiVDTTGa06PT3FWiHVpWy1iBx8Itwc4w1WoWurYE1HMWbuVpYUVuTTiLU1H7iix7X6SI7CsGAJprXxFVoNGeOCo7VIeHr0xJYhjHEmZ8e/ZRvzI7soMsmHDLROfh4T5ryJg7EGq9C1VbhSyoPQ3dC4wr4FPo1s2KO+aylp4Mo8rlOI5AgMC5bgbevdboRQAFsKK56bc7TmCY8slCdVhjDGNKCjDVuJDBHPVMk1erwMofDBg8keAWrDuIPF5woJ1nSUpuHwRRQKzszgo6asrWVXTuJxnUokR2NYnrR96DvLwIAh/QVKUg2KhEcW9BMtQ6RsO9d59enu0xAaYMV2LC19AD5wrU23e80AAKjfvnI5fTZOLibEu1sD0jddAUDVli53PrVVAMDKpmPpAMwbzsed9On6kDPWwqA5yapChgr/brjN1qHvLANlUVtUaBpOwYvw5tULTZk5Ch/He1ynEskqZCjbail1tBb6zY4eyGdBhi7AD4Z2n4bQALrlBiipAsFmZLFnq2DJ9nqkKIzudAf0YsqdxKf+GrQH1y+Rd4HScrq9vmsp6ck12+tmjbWNze5Oogwl1RQGAVxXFMt9kjesiyNDWY+rsDLEp/VijBNHa6HfrJShEhnSHR8N7T5N3qIj0U9mZNylU/SX8Sf5XeS1NcWwr//UjxDfGDb2bDVz8ihvrG0IJ1CG8jYOze58LKwMYXyUx1UgGULBDev8bjYtnjhau1KGssjKEFlU0+xfPhzefZqXoS+SPbKjZajEwkpLeSrrMPjqaBkKCsbaZlDZ2pBATUf3oTFP11Niz1aXHT/I8wk+asraWq56dN0nnkYkJ5WhqNNmdZE4EEfr4wJhuTaU2ynTNtzwiTe0+zR9i/yE3nbb5+nVGXu2SvYj2cZK7Nkq/fniT/JFCDcsN0Co6+i67R34zjJxTqcy1HdNWlAmb6xtBFXIkGg7ZYMArivahhtGobuh6Y6PBNkpw7hchlKPa8M7ZbhYTujetv1BN0IYo8i/y/bsOUer3ClLUMgbmjdsSGr6Ziymx7hP//yba/8cAACAccFOCqQ5D9Pz0yXPeaP9SRhAgxxgXPMzFlbLefvylcstBSiaCX/z8Zu0z6thEC8jWDbYuf/6rfP/rmCsbQBjDVaxa6tQTUfTT0+b6Bb4NGJtTS9U1fbiYz2u1UVyBIY5SzBNrWLQHb9XdLQWCE+PnuAyNG2cmCyhIsQfLMEZCk4PC89QytCwYFOw2UgFGgniD5bgDAWnh4VnKGVoOITJFIyrLnhSIP5gCc5QcHpYeIZShiRmYLAEZyg4PSw8w9pliHWlBAAoxqXb7nvbpUkQITQqW4iJQ7hWdrJ9aCwVUzCOtqz2fWgt1bc6NHlj2MizW8M0p63oGp3U33gMJmLIFlkrd7RWQ6+knWz1kRyJYdG0TH1wgFijqu9/W7MM9Tx7Kdm5QOEnbWNx5CLNqOtYN6Y5MypNwep3nTXdhH6EkP+uVVNh6Yk7MkZdaC4/9cqoRoYm3rU9BhMw7HnOFTckDhuyK1/ZPn0V9MrayU4hkqMwLJiWSbOshMUU+t/WKkPId/Rsy2YU/LB9Y6RbehDAdWWoBZpB6O+V3H7osf/g+F+Ykpsf+Y6utb0IYbQHW6NL55ioojFs1LG1leNbOVchQxX4G49BFQz3oWEQd05VjtZq6OW7v3SeTCGSIzIsJKYCoBjtXZL3MIX+t3XK0KHvLA81xyClBlT79u2cL/TuQ/Y0yBtWFWO72+twhtX/9P3rf6cBAJTFpSveE9dSaJJQ4Fo6AEDRjCveF665QDMjkgQTQDo3FG/+Q99Z0Z0uSkrDAKDat7/kjKl7nRzVX/lkSmVeupw8rOY/KEFSC5080+Ybw8aZA37h2hoA6op9ydIUoLSczsfOcR+RkB9psEbFUcaOajAxw74PL5jOvajSLokV0cu1k30yjUhOIEPkBX/XNhQ6Say+/22dMkT97sNQZF/m0HeWgbbhhod911KYjxQYMER7sKW14B5KngwTwyrr0ocCuN72YhbTge/oBgzxIIAbbb79G02i/4rVMSiOPf+jlHQZynV8jQpUI8/WgNb2osPQ3dDAsvPRu9kPokABbKnrMDiMvLYGlh3vp9nGsN4gd4DvQ0NVjO1u9Ng1FzIf+iUsfERqahtlsEaFyDKUZFou2V5PPBnKtZOdSiQnlSGM0/5uecIVKLvgMpT1hfKvJDvoyT566uToefaSYtjXXT9in8v6Pi8Y9gdu/tkS48h3r9uGAsplKJPbzjc7442phwWq3HmSM2Q+iJ6dLEUzqMvGcta8dns/e4ABf844RJ6tZT8UFz/iqVfGSZchjFnCtGK6T4SToVw72UBUGcKI/pBX3/+2Thkik8zM2hCOvG3oF+cLw8nQcmbJI6JytJIAAAs1SURBVONrpdU/lRbMtFen+3TzLb4xdNSxtSXTueU6rVGehnIdX4eQIXc3+0H0u3LtOvnvjjMyxB3AcSjIUK9T+AjOdDrCYI2KorVVtLUhtmxRXbPWaujl28nu7k8hklXJ0FImgJX1v613pwztwdY80MxtL0TkB8q8XNbsEfVdS8lMLlBhUtZ1dJUWx0V7N7Y/+X1qWN2H5qYbDpDv6KrtxQeuuaCYbj+8YVq7ITr0nWW2rrZAHarMN5jIUDaU/PIKk4B8x9eoQDXybE0xtrtRTLY8bu1uZj+IfVvf0VmHPBTccpy3s41hvUH2gO2PfuboZIcikSEasd2fvVn4iHrWhoTdKWNAgWutiLhTVmwn2/BOGS6XoeieY6zYXm8a/W9rzxsia10kByFZe8/VCcpNuIBq2BfyPtIW3A9IkUMANAt+vkv9eKrtxfs/dK5cNuYB0E3469/SGY1qvPVfnSttQyFex39kTVzXoP+JrSlAaV25vqmDxb/UFDb3SbfD0p0y1ui1Bf/xDtfxdaGEqgNtTdG0RfJVOyFZ62EfpFtuUnBxQDvB0qrjh9nGsKoBf8sd4Djm1wAAACwYxlI6jyMfunLxfO4jatopw5P7G4/B+AxR19Fpiou969Mi7xU5Wiugh3FZO9nqIzkKw5xp+cA1Fxe1RYU9PUyj/23tMjSrSPOGhv6T6pdIRkadeUPThOAMBaeHhWcoZWh4jJpFXZzc1Yyas6inCMEZCk4PC89QytCUkOx/qXXlOo4P8QdLcIaC08PCM5QyJDEDgyU4Q8HpYeEZShmSmIHBEpyh4PSw8AxFkKF9tml1fG7jUUb5SUA2BSZpGkHICzHzGrud9VjXaGKzTjdHCs7s+ptHl3Y6LtLI9T6u0yBeEjf6utdmOxqJZyg5ps7m0YVm1sUSBXnCuCSk06I3xaehfWg0VGF14t41JHFwYhk69B174qr4dbRnST7KabshGoTuBsttyTmziyXox8ewDEs6HZfQyPc+rjPtpSRuhPkebM2T2CHf0ZWW0+0x785XNZbELzazLpYoyBPGJSGdEj2MpQwdfYZJZQgFsKVM3pyjRhlKEEIjzfDmCRSaNdfaIIjvdJyj8Tjb+xhP7rkfJ4CZuA0CuLlpf4vcA2kafdKlqubm0RhzzawTsBIFBcI43056ZAgmQ1mD+ID0CNBWDE0B+tf/KQC0Oxjgvez3Ii6fCgAAgLYJf8R1c37i5SzpfEpYKkPDutj72VbRqQyF0ODnRLTDQdKK2ul0nCQnLdNv2v8Va36g2d6TAg1FM1Y08C+WjH+T+xa5ptUNyFDUhdZ5Lp5lNjpcgdaPdRetKabbL6fB9z5GNVuiMC7Ere9aFmd267umMm84d0OvrbdgMKggkiMy5JtZU4pJiYISwvRP0pBOld70ZShvdo9DuAZo+nJyiRds94eerS6Y7gHrIPYw3xKaOD+s3RAduOZCqW01b3M/0sX+5q1r2ZNTGXoQdhx7O7uyEEKDCGXfNRWFI9D5sqRp9RqpClCgMa/ZnQjjwrconKRmGUo6ydABwiLJEOt0fAwNvt9cnTKUj1vPa29my2XQvlUg80xUnwxlm1njXImCMsIMM2PmKAc3KcsYxPkiFcklXvC7DljRj9QKmG0JnfWClslQLxzBxZ49OW1gpi0V58aZHrBqlkBp0+rDo2ngsm+R+5r1T8rII2SyKimKDKWdjo+jQXof7zfwNJTG7XHkXbbgHsp8dL/rnLecy6amsFpaNT8N8c2sEXuBlCjYDUoIJ6AhnSq9qcrQggH3C2b34WQoTnYfyP5IXOjmPJwMDeVif+vjT7Mnjz1bVTRjRSs6gI6UoTu98qbVh0fTyFMqOUkja0OZ8gO5taGGmkdnOh0fQ4P0Pj7A9RrEGUjcvkgMXAyt/+F8mzrs6cPF53U3jybIr0ORee4PdvOE+TVNFtJp0puCDJGJhv2eYyzTklQZg/ghV76LGeXTF5mXfUDrnLGT5ltC43TaUjopW2DVy4ZxsX/n8hvZk/ddU1EN+IB1Kx6kX853dFKNJJUh8i3+z89yDJNJWQmNeSpD+W/x8ae5k4xrH5lEhlC4a+nn2cVaKB5af/PofKfjozovc72P6zWI04/PxA1j7je171oKWeyjfB7X3Twa40wza8o4KVGQI5wewYV0ivSmIUOkMOu80f4kRKyqGzOIf9tceYFMTuzOl8wb8dpbf6uSCUviZf+PG2+10v62Sutat8N3c143jZcBAAAYtm2wyU7yfMF89uFXw7rYl1a/lp78P2/8h39JJvo2dAzaugBjzC0BpH+6ZBgkt0JdeevvOIYb7m+Jy38dBlEZDc32HrGfzfRbZE9iOW+tZL9d1YPFj5vv6CTaSZmEYjvp+ptHFzsdowKNfrH3cX0G8bK4UaR3NbdRQ++L+ppHF5pZl5UoyBMuC+l06GEsbhY12rvx9o9Y1YxKEnCeLdQ6WGNBcIaC08PCMzwBMoT6rqXydU+s90rqOUocDcGvUSw8Q8HpYeEZTlGGJCQkJIbHVGRo+IMlmoX4gyU4Q8HpYeEZjkRPytDJhPiDJThDwelh4RlKGZKYgcESnKHg9LDwDKUM4UKnMIJRtr3HLrEhBsYeLNpvKYkVabcLAKBpb/UX+mCIOrams2zjAo18WQ+W/jpuCfpR6CWpthyffNyKfOoo9JGt01JaMuWpBVLGjKSUIYxxHMILttfLmCS8S2aZDCH/Xavs9aoa7zWC8QYLhbuWpnKpIoe+c55rAdJQ+iLGGA8CuK7QMlJFGoVkxYkb8oxAD3UdfYF1fyL5sbm4FVstHZWBWS3DbJ2WkpIpQxRIGTeSUoYwxih68CBEOJMEjB77DwrDjfZga7H0KemZkyG0B1sLzPqIMWY/6WmSW2OFPlBww9rcNKn3qkAj+Chb1uPHgWsp1EDDG1OmQy81hbGLLR831M/zuV9XoY9SMxBfMuX4AinjR1LKEI/cMCTPpeRhuMdq4gH1rVu/5AqSHGHzmxmMMVjId3SgatpCrs6hv9s2SK/HxqytB6616T5hdtACjTevXsgaWb979eKkzZpHo2cuKMZ2N7xt69+CAXmQ5OJWbMP95tWLNVlbS78+X4Pp+AIp40dSyhCPbOyijq29ans9MgFWTLefmEvzBUmeNRkiBVg23HCAAthS+LqfiD6QP7nThAwhalhPPlE4GWKOpXzpYRa3fl8wGWIlUzL8SwukSBmqBpnY8fVfWD9ozu+eKUjyrMlQzkmfdQujrqOvw/1PG5ChqNO2bgR8fQ/hZAhF3XdN67Jj6vl1XBK3sCeUDKUlU1IcVSBFylA1KMgQm4eziB9VkORZk6GYK0gSebaeqRaKus7Sebf/uP5CH4mbmNvuvJunEXyULevx48C1aGGNtF7VVOhhjLmiIr38ejONW9zP87lfV6GPgnZkSqYkOKpAyviRlDLEIzsMtBbnvQj3PPtVze5EbFJWKEiS0ayZwzhrQwFsKbrlBnG4a2kr3EZPv+us6XYnanKnLFPvVaydsr5rKmQ9MSdDSdya2inDhUWJXMkUEpZjC6TInbKJkfYpYhWOkurUySpsz7OXAJhvvXfjTa4giXX9f76W+cMZw1iDlQSHVEdCfddSFjVN0c3tDn2Gr7/QRwJ+8lKgUSjrwb5LHXlDad10xbjUIZWFc3Er8qmj0Ee2TkuxZMrvhymQMmYkpQxJzMBgCc5QcHpYeIZShiRmYLAEZyg4PSw8QylDEjMwWIIzFJweFp6hlCGJGRgswRkKTg8Lz3CKMiQhISExJKYiQxISEhLTgJQhCQmJhiFlSEJComFIGZKQkGgYUoYkJCQahpQhCQmJhvH/AcSDAvSHE+b3AAAAAElFTkSuQmCC&quot; alt=&quot;&quot; /&gt;&lt;br /&gt;Kenaikan berat badan ibu dianjurkan sekitar 1-2.5 kg pada&lt;br /&gt;trimester pertama dan selanjutnya rata-rata 0.5 kg setiap&lt;br /&gt;minggu. Sampai akhir kehamilan, kenaikan berat badan yang&lt;br /&gt;dianjurkan tergantung status gizi awal ibu (ibu BB kurang&lt;br /&gt;14-20 kg, ibu BB normal 12.5-17.5 kg dan ibu BB&lt;br /&gt;lebih/obesitas 7.5-12.5 kg).&lt;br /&gt;GDP =&lt;br /&gt;gula darah puasa GDP &amp;lt; 130 mg/dl GDP &amp;gt; 130 mg/dl&lt;br /&gt;GD 2jpp =&lt;br /&gt;gula darah 2 jam postprandial&lt;br /&gt;Perencanaan makan (diet)&lt;br /&gt;1-2 minggu&lt;br /&gt;GDP &amp;gt; 105 mg/dl atau&lt;br /&gt;GD 2jpp &amp;gt; 120 mg/dl&lt;br /&gt;GDP &amp;lt; 105 mg/dl atau&lt;br /&gt;GD 2jpp &amp;lt; 120 mg/dl&lt;br /&gt;Teruskan diet Teruskan diet&lt;br /&gt;+ INSULIN&lt;br /&gt;Algoritma Penatalaksanaan Medik Kehamilan dengan DM&lt;br /&gt;Gambar 1. Penatalaksanaan Medik Kehamilan Dengan DM.&lt;br /&gt;Jika pengelolaan diet saja tidak berhasil, maka insulin&lt;br /&gt;langsung digunakan. Insulin yang digunakan harus preparat&lt;br /&gt;insulin manusia (human insulin), karena insulin yang bukan&lt;br /&gt;berasal dari manusia (non-human insulin) dapat menyebabkan&lt;br /&gt;terbentuknya antibodi terhadap insulin endogen dan antibodi&lt;br /&gt;ini dapat menembus sawar darah plasenta (placental blood&lt;br /&gt;barrier) sehingga dapat mempengaruhi janin(4,6,8).&lt;br /&gt;Pada DMG, insulin yang digunakan adalah insulin dosis&lt;br /&gt;rendah dengan lama kerja intermediate dan diberikan 1-2 kali&lt;br /&gt;sehari. Pada DMH, pemberian insulin mungkin harus lebih&lt;br /&gt;sering, dapat dikombinasikan antara insulin kerja pendek dan&lt;br /&gt;intermediate, untuk mencapai kadar glukosa yang diharapkan(&lt;br /&gt;4,6,9).&lt;br /&gt;Obat hipoglikemik oral tidak digunakan dalam DMG&lt;br /&gt;karena efek teratogenitasnya yang tinggi dan dapat diekskresikan&lt;br /&gt;dalam jumlah besar melalui ASI(3,4,9,10).&lt;br /&gt;C. Insulin&lt;br /&gt;− Pada umumnya pemberian insulin dimulai dari dosis kecil&lt;br /&gt;dan bertambah secara bertahap sesuai dengan usia kehamilan&lt;br /&gt;yang semakin meningkat.&lt;br /&gt;− Insulin yang dipakai sebaiknya human insulin dengan&lt;br /&gt;dosis 0.5-1.5 U/kgBB.&lt;br /&gt;− Selain itu, pemantauan glukosa darah juga dapat melalui&lt;br /&gt;pemeriksaan HBA1C berkala tiap 6-8 minggu dengan kadar&lt;br /&gt;HBA1C yang diharapkan sebesar 6%. Obat anti diabetik oral&lt;br /&gt;tidak dapat digunakan karena dapat melewati sawar plasenta,&lt;br /&gt;disamping bersifat teratogenik. Beberapa preparat insulin yang&lt;br /&gt;bekerja cepat adalah Humulin R (40 IU, 100 IU) dan Actrapid&lt;br /&gt;Human 40, 100(2,6,9).&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;2. PENGELOLAAN OBSTETRIK&lt;/span&gt;&lt;br /&gt;− Pada pemeriksaan antenatal dilakukan pemantauan keadaan&lt;br /&gt;klinis ibu dan janin, terutama tekanan darah, pembesaran/&lt;br /&gt;24 Cermin Dunia Kedokteran No. 139, 2003&lt;br /&gt;tinggi fundus uteri, denyut jantung janin, kadar gula darah ibu,&lt;br /&gt;pemeriksaan USG dan kardiotokografi (jika memungkinkan).&lt;br /&gt;− Pada tingkat Polindes dilakukan pemantauan ibu dan janin&lt;br /&gt;dengan pengukuran tinggi fundus uteri dan mendengarkan&lt;br /&gt;denyut jantung janin.&lt;br /&gt;− Pada tingkat Puskesmas dilakukan pemantauan ibu dan&lt;br /&gt;janin dengan pengukuran tinggi fundus uteri dan mendengarkan&lt;br /&gt;denyut jantung janin.&lt;br /&gt;− Pada tingkat rumah sakit, pemantauan ibu dan janin&lt;br /&gt;dilakukan dengan cara :&lt;br /&gt;• Pengukuran tinggi fundus uteri&lt;br /&gt;• NST - USG serial&lt;br /&gt;• Penilaian menyeluruh janin dengan skor dinamik janin&lt;br /&gt;plasenta (FDJP), nilai FDJP &amp;lt; 5 merupakan tanda gawat janin.&lt;br /&gt;Penilaian ini dilakukan setiap minggu sejak usia kehamilan 36&lt;br /&gt;minggu. Adanya makrosomia, pertumbuhan janin terhambat&lt;br /&gt;(PJT) dan gawat janin merupakan indikasi untuk melakukan&lt;br /&gt;persalinan secara seksio sesarea.&lt;br /&gt;• Pada janin yang sehat, dengan nilai FDJP &amp;gt; 6, dapat&lt;br /&gt;dilahirkan pada usia kehamilan cukup waktu (40-42 mg)&lt;br /&gt;dengan persalinan biasa. Pemantauan pergerakan janin (normal&lt;br /&gt;&amp;gt;l0x/12 jam).&lt;br /&gt;• Bayi yang dilahirkan dari ibu DMG memerlukan perawatan&lt;br /&gt;khusus.&lt;br /&gt;• Bila akan melakukan terminasi kehamilan harus dilakukan&lt;br /&gt;amniosentesis terlebih dahulu untuk memastikan kematangan&lt;br /&gt;janin (bila usia kehamilan &amp;lt; 38 mg).&lt;br /&gt;• Kehamilan DMG dengan komplikasi (hipertensi, preeklamsia,&lt;br /&gt;kelainan vaskuler dan infeksi seperti glomerulonefritis,&lt;br /&gt;sistitis dan monilisasis) harus dirawat sejak usia&lt;br /&gt;kehamilan 34 minggu. Penderita DMG dengan komplikasi&lt;br /&gt;biasanya memerlukan insulin(3,4,5,7).&lt;br /&gt;• Penilaian paling ideal adalah penilaian janin dengan skor&lt;br /&gt;fungsi dinamik janin-plasenta (FDJP).&lt;br /&gt;&lt;br /&gt;&lt;img src=&quot;data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAY4AAAFTCAIAAAChxnzaAAAgAElEQVR4nO2934vkSJ7gaflP9Kw99W3r8fwtKNiOh21bltFLLGRyd8ExsXu2rFM7/hAsBcmVDh1XQ8DkELtlh0MSCUnnrcAnuYLYirUhuZqCrLgycqYINturjaoecqod0bm10Z5qdecFMYEQlYEjDLsHk+SS3D3SI9Ij3OX+/bxUpYd+mEymj75msh9IAwAALDxo3gkAAAB4O6AqAABqAKgKAIAaAKoCAKAGgKoAAKgBoCoAAGrAtKq6BQAAcCO8q6qm3BIAAODKgKoAAKgBoCoAAGoAqAoAgBoAqgIAoAaAqgAAqAGgKgAAagCoCgCAGgCqAgCgBoCqAACoAaAqAABqAKgKAIAaAKoCAKAGgKoAAKgBoCoAAGoAqAoAgBoAqgIAoAaAqgAAqAGgqhUCbhZQX0BVKwTcLKC+gKpWCLhZQH0BVa0QcLOA+gKqWiHgZgH1BVS1QsDNAuoLqGqFgJsF1BdQ1QoBNwuoL6CqFQJuFlBfQFUrBNwsoL6AqlYIuFlAfQFVrRBws4D6AqpaIeBmAfUFVLVCwM0C6ssqquoWAExm3sUTGM+kW7PMqgIAoHaAqgAAqAGgKgAAagCoCgCAGgCqAgCgBoCqgDkSS0ZQCdvxhB+rRDILIYQ2Pf+8sL2KhIsRQqjFw2TkaH1ON5iMC/+0ECKFX7TWWoecTjpC+qcylIfjE5+EvHXhBheQ7msxWUmEuXCLyUQnIW+NbrCyzE1VWVnMwcTxhB9lf8C211PFHSLhYISQRXnfHCAtKCXyv45iCu4FG1zAhEJfKFYjzwkwJUnIW9nTHvmHbYoRbvJAGXFUisGJcNaqllE9z30yXhaJZNbIXUvv21hVPXFYNzYbmNsad5kz4eBap6q9iqrSfceZaNLvq85co6qQ07TEqNh/ymgD4W0eDFI12J4/LKTmdVoUTRLye0yeFW6tiuUD5wITJZJZV1PVhYUeitU7UVSVzm70miNOdMibhKxjV0RpOVB+p0m3SMkyg4Bv40myuKyq4mM/HOjSbR2E/vHk9w+o6uZYEFVprdO4CTsi0n3etMn6uiNO0j+pnteklDQKolHxy5eh0qVbq177L6OJpwNVLSIVVaUisZhMQt7a/WS/aWfF4EwyxxOPC2VGxb0OxSae3nn4v65lkW/kc5cghLfoFiZMxio8atMGQsi8CzNVnYe8NSZYHrmt+e6YdnpnXzMLIUQoJQg1P/7oZ4jy0LxcLSaTQdh9QDFCqEG9F2emhrC167m2+SXWKva5QzDCd+hWw2JyUE5bVp6/PhUuHldDXFkWSVXmHWUxmfR5a/dgf9tyRKS11iqW95ve5wd0bZxoKm+hYlnpfsUIQpjQLYIs+ulfp6oKOTWFQIXdNsUIIdz0XhyaYsU8l5hCGauRQn+aHTytpGRl2lRMxhR64G1cqCrWPRUuNvF1JNwWD4JKmSnsnr5Ooli2CdkR4Xks2wQRJs9C3sKOiFTPsxuU91NVBf3u/XanN+bdVlKVOuZN0uTHKu4yYtleT4Wcoo08okeUB+HRfbbfi5UKeNPa5oE59abnn/neJiI7IjyPhIstJs+6jGy4IlBxlxFsse6rctoK5RnCqxILq6r78lQ42LSqngjX5cFLPoWqRsrKbzhtENaNdR5VvQy7Huu8iPUg4NtWkwfqTLINZHu9nmcj2xWBioSDxxb67zgljjhRvmejFg+TYZmeEHYBb2OsqrAxQovJJO4ysuX5UcBdV5yMlJlRVf1hWB6GN0XF/rMDRk0bQiKZhdYIoeU2e11KQl6kKm3tlIfDNMSSEbROyIZprKi0n1qU/7c8eeaY3V/kRy40XBTSBqqaxOKpyvZ81eet+zI5k+yO7fWSgLdcEen+FKoaLSu/GO6VSGbhdUI20pZa01ie0+K/3E/Tkxbx348r9JEv9hltIFDVbKioahDwbWxiFqMqfe57m/ju7m7zvozVlVRlXjmOJ556dC1TFaGUZLHzSJqqqip/iKyoimxRska9F7FJTKmNNXmbqr4+K6cNVDWJBVKVCngTY8K6sTaq0sr3bLzNdu8yeaanV1WprPQrqiJ0i+Cm14u07nPaKH1gytMzUVV9ye4QxxPiEQVVzYbRL4CYuIeh0pmq0oKR3qkLVBUJB6854ncB38a46fXOslj4D5LZhHXjuMtIg/LjSLgYtXjwkjfX0nNV0lSqAPY82yIO92Ol1fGTztFZFlOnXyQpDwLexLYrgsT3bGQ7vBdrrYKnnWeB720iykPzucBiX/+WN3GDei/itAL41S9KaUtVhR0R6RPhrOG0DQRYFFVlXwDJjggHOlOVVse82cjUM42qtKqUFfFfsiYAU5Qtyl8GfBuTHRFGvreJiMv9SOtB8GT/y+7P0yKYVgBPq4X+uWDWBpOnsWyTXFXmE1X6nJyMJA+4gJF+VZgyLkM17MtiMZnoE+HuiijvbFXsFaVi2SYI4ebP/6//xUr/FPxWuDZCmNy9SzFC6E8/efp/EoQwfXDA7qD1//mP05j7Ht9vIVS5a8XAPD2LCg9dghFCiLj813+Tpew/PP003dJi+/vUQtgV0Xkodkja+Yb/+qv/YJnont1La5H0P/3KbEC2HdpAyNr6+M+GaSN/dvAf/y1CCKGfbH74L9/W/2a1WJx+VQ3KuAwH5UKqIrHripPC1pU7V6jEpW/mQaGsfMLv/QwhhBBhspdtSRj3KELYEZEKhGsjhBCynf1Hjvk7vcdoXuiPy4X+n1FKEGrQR4+ZbZE//ml26j//ON9lTNdEAADeFeitDgBADQBVAQBQA0BVAADUAFAVAAA1YOVU9erVq7/8y7+cdyqAhaZ2pXoVWDlVcc5rl2bghoESsoCAqgCgCpSQBQRUBQBVoIQsIKAqAKgCJWQBAVUBQBUoIQsIqAoAqkAJWUBAVQBQBUrIAgKqAoAqUEIWEFAVAFSBErKAgKoAoAqUkAUEVAUAVaCELCCgKgCoAiVkAQFVAUAVKCELCKgKAKpACVlAQFUAUAVKyAICqgKAKlBCFhBQFQBUgRKygICqAKAKlJAFBFQFAFWghCwgoCoAqAIlZAEBVQEAUANAVQAA1ABQFXBZVOxzh2CEGrR9KDr7Mhndps/pBpPxyI8WQhbl/ermiWQWMljseZ+38n+UDx5LRsYfYSqSkLcsJs8ls0aP/RZU3OtQjBBqUO9FXPxdtsmYY0U9r4kRQrjp9aLsx0EoOaMNhFo8nObkY7NxRQFVAZdE9Tx7zTyuKjx0N9qXeOITyaxJoulzupb+SR3z5hpxuB+riza7OrFk4/Ry4R5eW4RqEIodgl0RZQlTx7zZGNGeiuXjtgiUCoRrY0dEWms9CMUOQbbT6YajlwW8DVAVcEki4eA1R5xorbU+9x+PjaomMI2q4hceJeXIZdxm78TlVZUTcmp7fuqaQcB3d9kH1sRjJSHftr2e0loFvIk3mDy7eqpXG1AVcFnOJNtAmLJDP7eJCo/atIEQwrTTiyPJCEKEyTj/HeFtHgyGqgo5rVbB+pw2iHPPsZvtUtgxCLsPCjWvPqdrW+yBS7CpW5VPcWpqiMMNul95tIFQg3p/9zvh4vSkuarygyPc5MHA1EO3mOeS9FrK8U/c4+5HwwpdJFxXnEo2QVUq9rnrPO7FSutz39tEeJ2sY4Rsh/eyrIsnJ/irv3bWECJM/qG6TS/SKuy2TcKzmvKg/EtegQ45HVOVrh+gKuDyqFB2HIIQIk5Hhkod8yZp8mMVdxmxbK+nEskswuRZyFvYEZHqeXaD8n6mqpdh12OdStzU57RB7t6luNQYpALetLZ5cB7LNkGbnu9z2iDuYahOhLNuey+Cyil0n1ML004vfi2cNUR2RHgeCRdbTCa5ofL/6XNKHHGifM9GLR4myvdsZLsiUJFwMCm1E+UNaqQtY6X1mWzv8mCQTFBVtjkmrBubq3MPQzUI+DYuViEvSPC5ycZYq55nW9lVr6V/wa6Ikli2TYU0qf7y2myZaJVd/rWUhRsDVAVcERV2O46N8DbvfkKLr3LKwyR7xrSK/WcHjGLTFp5IZuF1Qja83khzjanZHceyTYZN10mYN7EjhJBF+d9mFcBcN+VTDGuIsWQEUR6m9c6xqtJaR77YHzZ1h5ya/xleQhETha054nUsH7r8WA0PPiGP2hRjV5x2h0erSnBygnNVlbexmBykBh8o37OxKyKlqr9E+TVelML6AKoC3gETy3z85xRtev758Pf0OY9i2SbE8cRTzzxpiWQWJnSLlL6LGfKnMW1+dkWgjKqGbUN65KHtnlVOcTlVnUl2hzieEI/oVKoyCSCO+F4yUq5s/QtK18Z8tww5xa6I/hunDdNopRPJrGJ2XUVVSf6FcVidrPwSg6qm2n9hAVW9K4lkd4w7zPf7Ta/3jWdb6Qc7dfykcxSlz/nvJbMJ68Zxl5EG5X0dCQdblL8M+DYmOyIcFI5bbC83LTi20+kGPc/OnkYVPO18+TdZRc9UhcTzyilUz7Mt2+up4ZOvIuHirE6EHRHpWDKCHRElklkbTJ7Gsk2GFcAWD5OR2CdFhYeu/VGh+naxCAah2LEdEelBdslxKHZIUb4XJDj4Mv2CMazephXAge/ZlIfFhFV/iSUjuMmDJBCuDW1VoKrVI/nGc+82bbJeeKWr8NAlGCGEiMv9qBRVIYTpgwN2B5E/zuIQwrhHEcq+4lf6VWUtwWl18pNfih1iGn0cz3N+an5lzGzyI0K3Cqf43x9+9E8RQgitUbphjrdJN9NjE7vS6Ez5ryTbQKhBHz1mtkXu3qU/Moe/x6jZKe0ApXzP7Ixp+9AvxYPjVHXue5sIIYQalD1Nu1zkDeEmi1LiLDobl2DrjxBCCDU//uhn5au2/mT3z5vDJvRGkx8nAS//8n1kOoKRnad85/L9yBYOUBVwDUysPQGzQQWf339ynEZmque5T4KRX8LJu9cRUBVwDSSSNYofuYDZciIcm7aPQqW1HoTdh27nbw6rv4x+uKg3oCpgpqRVuWLXIWDm5GObEEq7v4/+Mu80zhpQFQBUefPmzbyTAFQBVQFAiS+++OIv/uIv5p0KoAqoCgBKcM4//PDDeacCqAKqAoASnPPbt2/POxVAFVAVAJSAErKYgKoAoMTR0RGUkAUEVAUAJXzfhxKygICqAKAEqGoxAVUBQAmjKt/3550QoASoCgBKnJ6egqoWEFAVAFQBVS0goCoA0FrrL7744sOMWwXee++9eScN0BpUBQCGb7/99tY4OOfzThqgNagKAHIq8ZTh9PR03ukCtAZVAUDOq1evKp7a29ubd6KAlJVQ1enpKc8wb878n99+++28UwcsEHt7e0VVQeP64rASqtJa3759e2xLBJRFoMibN2/ee+89Uzbef//9eScHGLIqqjIDuyrAXB/AKKaJ4NatW0dHR/NOCzBkVVSlxwVWEFIBY7l9+zb0UVg0VkhVlcAKQipgEr7vQx+FRWOFVKXLgRWEVABQI1ZLVXlgBSEVANSL1VKVzgIrCKmWjMLyzNkiyOX1pZTv2aiwimq+gDPdl7yVreTMw3y542wx4ok7FimvyQ5cByunqqOjIwiplpOQU7NuuwqEayO8zYNB9rdz3/uAUtv28oU8VSRcjM26qmeSbRQWSj8RTsvzz8fvGD5xWDcurv8ed5mzbEsZLyA3rqr09YcLhUZrrXUkHIwQsijvv/0gIafDgnVpXr16da3Hv96jAZPIVZWWskIopHpey+seutj2/LzYRcLBm0ZJyvdsnC0HrXpeq5NuNrpjfOyHA11UlR6E/jGsz3rdzCWq6nNqoWKhMa+4KT1V4tz3mCmd747yH7uXTgCwMGSqUmG349iItGWcljDld1peTxXcpLXW+kQ46+krMxIOXnPEyXDji3bUuqQq4CaYk6qaNllfNyVDa61Vz2tSShqXVZUKeBO3LqmqCe9Adcyb65d3JbAw5K1ImLKDz2VYqv0xGZfcpLXWSchbpplJ+Z6NEHZEpJOQs2Ltb9yOWoOqbpw5qaq1e7C/bTki0lprFcv7Te/zA7pGeV9rFfvcIRghhGmnd9ZlFkJoi3kuMb8Ehw5GyGLy7IVHGwghhAiT0bi9CKUEodxlg1DsEIQQXt949E2iB2H3AcUIoQb1vvraa2KEEELWXecDc/wk3wDhJg8CThFC1t1HD5vYnCV7aaeV2q1dz7XN0bpets3vvjSp7f6iss2LWGsVHrXTSzAtuUf97IwFCJNnIW8VmnqBcaRR1YlkW01+XAjZe55dyNNCOJ/V+37wPXeXbWOLyeREfPQwzeXJO2pQ1Y0zL1Xdl6d5UH0iXJcHL7lRVdxl5A6TZzp+4dEGdsQ/+J6NbFcEKhIOJkzGw1KSN0+M7BWFnKINJs+Gp1U9z97mYaICvt2Wg4A3rW0enMeyTdCm5/tpAoalsM8pccSJ8j0btXiYJJJZaIPJMxUeusSqvp9x0+udRcLF41N77nubiOyI8DwSLraYTGLJCHZEpM8k28COiBLJrDVHnOi4y8i6I050dhCtT4SzBo/GRRQLg/1B3qaufG8jfSmW2qe0NkVi3Tl85rU6/plw8KbX/cx1040v2hFUdePMT1XJmWR3bK+XBLzlikj3jSkKJUClj3Q/K4KJZNZ4VV2015AzyTYwZQfCj41chliU/+2IqrTWkS/2GW2g6lliyUihoA6rEolk1vjUlrexmEwGAd+2mjxQ5763iR0RqWPeJE1+rMwjJE7yg4ycERhh2KyuIuFatH3oR1qfSfZB4Y11JtkdwrpZC8C5721iYlOvp/SJcNbXyR03bZe4eEdQ1U0zR1WZ8Hub7d5l8kwXVZV9i0lLw5SqmrRXiUEoOaMN3Nzvftoqh/T9EVWdSXaHOJ4Qj0aEOBNVaRMDIoQQcbkfaa3iXodihBAmDvdjBaqakkK/KsJkrNUxbzYKb6I044abZT2hEsksZMIl823H/H+1d1V5x+J77rJNpcAVmaeq0vKU+iIzRSQcbJpy0vdYlNW/stpQNOwRk79IL9ireF5nV4QD5Xu2xbrfeTayHd6LtVbB084zmakq63Fz2mXWBpOnsWyToRCbXi8aVtBSzn1v01zIUFXpR6XXWWp/8L1NRHmYx33Jue/RUkN+VkUd/pJIZjWa/DgJD12CQVXAyjKvflXmfaUiseum1Zy8IvZfs8ZsTBzupw3kCNF7jJY6JCPKw7jLCEZ4mwfx+L1KD3f/M+/RQ9pAqaGyVvY0hDmVbAOhRvPjnT9Jj/+Qsw2EGvTRY2ZbxD3sd5mF18k6RqhB20d5b+jhNVG6afbdpFlibWL+u0F/bDZh97J+0v/pG749bLbF27zvF2MB3OSBinpeEyNM3AO+S1CxrxAArBIr11v9XZh188QgeOI9Gbb+PnY/ffbk/udBasBZdhkDgLoDqroExRaxGRAJx8qGqqmw295hbNuiD7rhQJt+DO4n/oxOBQB1B1Q1NcMBrrMamxr53E2rh8TpyFDFPe7YKK2TPi50YgSAVQdUBdwEWXNeZXiK+eg29Xe06x1NmYS8NbvDz/ZoAKgKuDFCTqvD1E+Es3aV7/2q57mzmswA2gTrQT1UpULJWTrEhTgHXf74Sf95eYIihIjjCX/c57Gsj0xedyt+hTxL61yYPnguPumY72uF8yHi8u4T78mEsYHFlJkjcG/SfEZjrmKlnpCQNwlZLzT2Kb/TpFvk0qoaBHwbX7Yarl77L6MxP19lGCkwB+qgqrjLiJW13ZgRgluef17stKlj/5BRjBqlwV9Dht0vsx8ka/HQdFY2o/lUINwmk3E6e5FpPNJaxz3ubFSnrEkxW5rem2ZA3zr9eHf8fEYTr2JlCHlr95P9pu0Mu4M7nnic9dTNW+4a1HtxVh1W+SI20wRZu+JFJ32LWEwm4/YiW5Tg4e0201chhAl9JGOtwm7bdGtpel9/lQ0j/eldp5kO/dTFsZ/73U9bCCHLefCQNvLBm1rr7BVobbEHLsEIN72uOVqDen/3O+FihCz21S8q2/QiXTi+eRmyrp8mqUg6tMuCHiqGxVfVue9totJ3NxWJdlvGJVVpndYmxn+hm6SqE+GsYScf88U7Mla+Z6O1QvdOrSPxUXtMo4PyPbs8zFAFn7U7z8bNZ9STE69iZQh5i3VPRTb3UyTclhkE3uLhIJZtQtoyTuJeh+I1R/RHhkzqkX7/amSv34e8VZz+RZvbRHmoBwHfacvTbDDTmWQbyPb8IB/VkI8HqIz9PJOMINKW8Xkodkipua3PqYVppxe/Fs7a6ABPi8lE9TzbIu5hqLJRnCMjPbMvy0ks2wS7IkrySy4MAl11Fl5VqufZOLdJmYqqRiZUGzJJVSqWbYIalD3108I9asZJnPve5gVzHZQ6YV10FStDyFtMJnGXkS3PjwLuuuIkG29wVhg2ZB7p5/2RcUgjqoov2GtI3GVkjbJ94UfpXGlDWvyX+yOq0uWxn4W0Dcc5GfISGEtGyqktim+4jcVkMjLSU6Uj5wf5DH/DwlM94+qy8KoKOS32OR/ObE2Y/O6dVaW1HoTysUMwQrbT6Yaqz6lVON+wZI9IKZaMTKuqi65iZUqhUZWpdN/d3W3el7EqqipTuXmkp1XVpL1KpM2EjSZ/9iltlKrz4WhUVRn7OWtVjY701GZMAsrGUWhQ1SgLr6pEMguV4pHhzRsbVVVnazR/mawqrbXWKpQdh6BGk7/oMlKOqiaNE76Mqi66ipUhVZVpyc4+BaamGETCxcPxlXeY/P3IkMl8NvRBXgGcvFfxvE8c9zBU5763abGvvvM2s+bFQfBk/1nv00xVWWtAIstjP88kI5h2enFeQcvnu+p5tpkLKFdVnsjX6dFUz7PNnJFZBXBkpGdWRR2SSGaZ4WJih6zU+2wyC6+qtAWqMKX/JFWZwc/ldoqMJOTleRQikU9LlHHue5uIftoTbrl5fpKqTJ+g8pRYsezw9CTlUTgXXMVKUBr6qU+Eu5tWc/KKWPAqa1q2Hd5LG8iLQyaHn1M/9WWbmDGSSThur/IbJDz0HrUpzqavyFrZ0xAmHUba/Hh3y+xK+a9kaeznAd8lmJB1VFkIJ/+yvEbphtl3k26mV0TMKf7xBv0nJtGM0fT4B88rIz37fd4cNqo3mvxYpVNu2O7Tg10L5lTUug6qMi9hNPzQFvAmHlFV+gXQdkUwtpFJBbyJs3kUwm7H2WzyY6VjyT5Io7D4hUfXbK+n0vlD0o2NAccXlVSO6bdCFR61nYeyODVoYbfJVwEsOLOefkcdV0Z6ftp9cv9J9mqcZZexpaIGqtLlfk4I2Y4nhnMn5G8nyrjpXhByinBxFjStdfkLsWmW0lrH0ttxmhtkHRcaDirnw8TxhB+NP2yqSJMAM5eb1hPmMxpzFWMCQGDRKLaIvTtm2r/iSM9/z+7a2UQdg7D70O2M7Rmz6tRDVZdG9TrtZ7P/3HZNhwUWl/ytc4XllCZQHel5ni8LUHiJAlWWUVWxf9h+8CSY9VjfazosAABTsIyqApaFdxpQVZqvsa9LTfvdszSQadD2oejsp2u+Tz3yqbClOcJjvt9CVdLzrvqAqhkBqgIWlRkMqBrtznK/xfta9Tx7LVvf7NDdaKfjn6Yc+ZRuaVo2TRvov/7444+YPCt1npIPnHQFptUeUDUjQFXAYjKTAVUTVFVYS1nrc//xfrr02VQjn8wiacU+MYOAP+w866UfavLPheq1//L11IcF3gKoClhIZjOgaoKqzDhzTNlhVnOcfuST6nn2BetxlHs2wICq2QGqAhaS2QyomqSqfHxCNv/q9COfEsmsC7pkllUFA6pmR81U9d57790CLsP7779/kzdoZsxmQNVkVWmt087ANsLb/Pho2pFPl1IVDKiaHbfqpapbt2598cUXPjAdX3zxxQ3foNkxkwFVfV4anJwt5lYkHaMnpx75dCKctfLpVCwPeCrKStf2VR9QNUPqpyrf92/yjLXG9/3aqmomA6oGAd/G2eDkUD527A94MNCJZHfMgFAzycGm559PP/LJDLfOPuoNwu5Dp52PYaiOwoEBVbMCVLXM1FpVeiYDqvI5P/NmKa118o3n3m3aZN0c1gz2HD/yaRDyFqoMStcq9p+ydPrQ4mRnhcmwCjMlwICqmQCqWmbqrqpLcz0jn5S/365UG4EbB1S1zKyWqq5l5JOK/aft9ufj5+sAbhBQ1TKzWqoClhpQ1TIDqgKWBlDVMgOqApYGUNUyA6qaHsioBQdUtcyAqqYHMmrBAVUtM6Cq6YGMWnBAVcsMqGp6IKMWHFDVMgOqmh7IqAUHVLXMgKqmBzJqwamBqniBW7du7e3t5f+87lPXkdPT0zx/9vb2bt26lf/z6Oho3qlbXEBVC04NVGWet1H29vau+9Q15fbt22NzDFR1AaCqBacGqjo9PR374J2enl73qWvK0dHRaHbdvn173ulaaEBVC04NVKXHBVYQUl3MaGAFIdXFgKoWnHqoajSwgpDqYiqBFYRUbwVUteDUQ1W6HFhBSDUNxcAKQqq3AqpacGqjqmJgBSHVNOSBFYRU0wCqWnBqoyqdBVYQUk2PCawgpJoGUNWCUydVmcAKQqrpOTo6gpBqSkBVC06dVKW1hq7qlwVybEpAVQtOzVQFANcElOQFB1Q1dwah5NlKTbbDn3Hvafj2vaYnCXlr8mrAV9sSAG6a61ZVEvJWugDaVA9Bn9ONqy7oGEtGELKKC38vPCqWbYJsp9MNldY68rlLbLOa5lWP6D9265QDFc59b3O6ojKWdyk/VwDkfnPcQFSVhLz1DoXvUpSXCB/HYj3JqufZGDuisHTdifjo4dXzSh3z5nqtZF1G9bwmpWTLS9dVn2tK3CczDW+Bd6KmqhqE/vG4V+fbVLVgT7LyPRutOWOWwxyE3QdmQV7c3O9+2jJh6fPnZmnhFg/PJCMItT795bO2qTzibR78fz2vicshbCKZlf6zeEz+26+ZhRDa2vVcG6EG9X4VCBcjZDF5Lit/ej/cr58AAB1fSURBVHFjUYryOy3v2aGzbnu961h5T4UvX061svEg4Nu4sELydMeZVCyBGXCjqlLh0fC5+q157LaY5xKEMO304tfCWUOIsO5XI3/Ki8UgFDsEIYTXNx59U3j8zBPV53Rtiz1wCUa46fWi0hmDk9Enea6Y2jHJKizFyvIm3SSOOFG+Z6MWD2Pf2zTBVyKZhV0RJZHYdcXvQ97CjohUz7MblPfHyTqWjFhMJrrPafWYiOyI8DwSLraYTPItz0f+dDMZcu57H3n+D5FwcVoLTiv1w3va/cqjDYQa1Ot+VflT72VafmSstYp97hCMsvKjwkOXYIQssvGwWBQx7bwQuxVr/77XoVlB6faHW5aPs3f4NJV7Ui2WwOy5SVUlledK+Z6NbFcEKhIOJkzGOpHMIkzGY/5kUD3P3uZhogK+3ZaDgDetbR6cx7JN0Kbn/4bTBnEPQ3UinHXb+/vg7U/yPEkks8pRVSKZlaoh8sU+ow2EWjxMlO/Z2BXRD763idCaI/q+x3iYaK1i/9kBozhtpLtAVZVjnoe8hSgPhyfNt0xG/nQj2aF63p22TLSOhIM3szpgn1Nr+CYrCnTQ82wru91rFpNJVn503GXkDpNnOn7h0QZ2Put6lPK+Vsd8+4EcHPMmafJjFXcZsWzvm15VzVkOqNEtC8fJc6xcLEFV18ENVwDLz1XIKWrxMMkNNfyf0T+lnEm2gSk7EH5cDEMQQsii/BfZg5o/dW99kudKJByMcJPn64xnajiT7A5xPCEelfKh2+20Pzlw1qzdRw9bHV+pWLYJcTzx1Euv6wJVVY65cKpSvmcP7ybO6oD94j0tp6pfvd1ZaSkkW0XCxdaueN4mmLKDZ36sdMhpodwguv/L6vVmOVDd8lNfFo5Tytu8WALXwk2pivJQjzxXV1GVzr/u4+an3/znFip9L6uU3a/P3v4kz5dBwLcxwsThfqzSf6bNRRtMnsayTUw+6BPhrBO6zcTrSLh4nWy0ZaJjyWzCunHcZeRtFcCkcszY9zbNfclCiRPhrGFHRKYCWPrTDWTFue+1sgBTFeqAV1UVdkWkdMG2KpScUYy3efcTijYLLfejai6qarPSxj88TnBaiFjzYjl88QAz5FpVZZo8drnXIqwbjzxXWaNJovNaXiQcvFZoTyn8KaXPnV0RDpTv2Rb7+teejWyH92KtVfC0I/5LVtEzNYKvfvH2J3nuFPtVIUQcT/ixPpNsA6EGffSYpXUcFQkXm8cvy6WsrwPC9MEBu4PIjghfmx2b/Dh7Xkpv/vyYP/s3//bHJhRl90qBA7I26aZV+dPkBuaZEXcZvS/zRsm8Bqd6nm3ZXk8NVZVlxdmvy7dbJnnORMLBpvnyTLI7hB35fMcVgVI9z7ZZ92vPttLXgzp+0jnsVtWcVwB75S2f9YrHkd9nci8VS6gBXgfXqqq0rRHTB91wUH2ufvanrR+bx+AeoxZCCKF/+eH/9BOEEEL/A63+yUQWWuv+Z96jh7SBUkNlzZkIE+cTfu9nZjfGzCNmbX38Z297kpeeYlvVomK+Uw4/d5jW9CJrlG6UTYrQ2n9fvt05LR7+kH1vMRHrIPys8+hhMw9gs9ZxhIi7790dUfOnvimrTd4Phlty/7RwnP0vvaZJEuV/Wy6WwOyB3upLTyzZ5rj+EABQJ0BVS4yJTfKGMACoMaAqAABqAKhqXmTNMdURfyfCWRtpyc66ZdxA8zaMawMWElDVHDECKn8Lj4SDxypp+KkeAFYQUNUcSUL+ASFrheHK5773AaVjlXQVVU095A0AFh1Q1RxJQv7R7oHXtNLOijrusuYjcWB69ITdthmIZrpW5Krqc2ohy2H3CEKY0C2CLMq/87lLEMpHF5eHvFUGxEWTB9b93e+yQctJNQEAME9AVXMkCflHTH4v0okEVCTutfjLIO8nnQ/6ozzMVBWER/fZfi9WWvc5bRDWjdNhAG0ZJ3GvQ7EZIVgYqnZWGRAnogsG1uXDa6oJAIB5AqqaI0ZVUSzbxPb85Ji37olokA/y0LEvDhhNm65iyQhaJ2Qjb4YfGVaiddZvu3tWGKo2MiCuOiRlwkjASgKWH875h8AE5r7uEahqjhhVxVr1PHv9Lttpsm6cj0eLu4xsON5T4TWHqiJblKxlE0iVdJM1eA1Fkw9V2z/YGRkQN4WqqglYfswzyYERTM7M9+6AquZIpqp00LL5FJiqqi+ZRdoyPpVsA1Eemk4MlAcBb2I7G4ZmRsCZMXFNrxdlQ+dOwuJQtcO/Kg+I68YXDKyLXptxbafVBCw/xlPzTsUiYmw13zTUQFVv3rz59ttvr/ssN04+zC0dp+26IiqOfdv69x8RjHDz0cGujf743+38q3QwMdvfpxbCTefuT4e7D5vAzRi0pDzk7bw8IC7KzjJuYB2x03Ft3idsmADbFcs/XwCoahKgqqngnEPsBtwAoKpJgKqmAlQF3AygqkmAqqYCVAXcDKCqSYCqpgJUBdwMoKpJgKqmAlSlq7PIo2xGt74eTkuXLZ0yslZzP9sgBdO2WSAVKAOqmgSoaipAVYZCT87qtMuJvN/i/YvWas7nqleBcG2Et3kwmNuVLCqgqkmAqqYCVGV4u6ouWKs5V1UahZEbXC29NoCqJgGqmgpQleGtqpq8VvNQVSrsdhwbkbaEGRdGAFVNAlQ1FaAqw9tU9f3ktZqZ7Gfr2WHKDj6XIdT+xgCqmgSoaipAVYa3RlUXrdWcRlUnkm3BjC5FTk9P/Yz3339/b28v/+ebN2/mnbp5UsyZvb29999/P//n6enpzacHVFUbyqpqZIsPa61VJHbddPG7sWs1F9qq4i6zP4A29Zyjo6NbE5jLA7k4nJ6eTsoZ3/dvPj2gqtpQUNUg4NuYuNyPtB6E8rGT2mfCWs2lZnUVCdei7UM/eusZV4Tbt2+PPo17e3vzTtf82dvbG82ZedUEQVW1oNivyvQ5yMcnI0Scjsz7SY1Zq/ls2K/KjG0+5s3GTS0qUQPGBlYrHlIZxgZWcwmpNKgKAPRIYAUhVU4lsJpj4zqoCgCqgRWEVDmVwGpeIZVeWFW9efMmnynVvPHyf8LnZOA6yAMrCKkq5IHVfPsrLKiq9IQmvfl6HVhi8sAKQqoKeWA130dvcVU1tklv7v3QgCXm9u3bEFKNZW9vb+6P3uKqSo8LrCCkAq6Pb7/9FkKqsZjuoPNNw0KrqhJYzd3rAADMi4VWlS4HVnP3OgAA82LRVZUHVhBSAcAqs+iq0llgBSHVBUC/M2DpqYGqTk9PIaS6GFAVsPTUQFXAW1m6u9DntDgdvFmHdVmZ0cWGnGYT7I/HTMJ/wQaLDahqGVjGu5DPyRX1vCZGG0yeXfMZz32PmTmdb5zZXGxh7o0rbjAzVM9zn8x2MDyoahlYxrtQmD4wEg62ilMJXgcq4E3cmreq3uliF0ZVg4Bv41nP2wGqWgaW8S70OW0Q9zBUkc9dgtac//fvs3lvGk1+PDAz25AtSn6ErD9CiDB5ZqbKGT6M6bpjW8xzCUKYet2uRzFCuOn1IhUetc1sOXib+9946cw5hH39m8KJfv01IwhZW+yBS7DZUetB2H2QTcGD0AzW1Lj4Yk0aMKFbBP2YkB+Pv1hzuXjLuWujbM6y/Box7fRilarqVV5VNHVPwrpfXZBR5bzc9VwboQb1vup6TZwe+TzPENw88H/dSTPHYl+/KmTyb5+Xz9Lpxao0ndGFFVhQ1TKwjHeh2IJjO7wXh5xiV0Q/+N4mojw0c3iZ9Swi4WDjixPhrJVKe8gpalDvRRwJB2PiHobKbPO8z1vYEZHqeXaD8v5w9sHKiVTPs63CjjJJJLPWHHGi4y4j6+PX3ZjxxfY5bRDWjbW+4GITyazUwocusez/KP5zkzT5sYq7jFi21xukUZWKhJvOuZgfbWJG5cdPQt5CuOn1ziLhYmS7IlDp7t9xShxxonzPRi0enoe8ld+jYiYr37NLO8aJZBZ2RZTEsk2wK6KJk2mDqpaBZbwL1fnjtdY69sUBoxgNVWVqGYlklnl6Y8nIiKpaPExM5YfyfmEbFfvPDhjFZvHXwvpj5RPlKcl2VMfcKED1PHtWqrr4YgsbTL7YQv0uloxYH338r4pL1VLezzYYbpkf7aKMSg+fZ3gimTXc2CQm8sU+ow1UUpXWkzI521EFvGlt82CgfM8GVS09y3gXRp7euMvIhuM9FV5zFqrqnsk2IY4nnnrmRMXp50snGlGVVnHP1HHyuaGv+2KvrKpNzz/XIxvMWlV9ye4QxxPiES2pSsWTMrnguJ7XxFN8+gRVLQPLeBdGV+VhFmnL+FSyDUR5qM+zypH5W6PJj5Pw0CW4+PQq37PN4zp8Ak+Es4advzpkNmHdOO4yUqoAVk+U1xDzCpfqefb2TBvg33axwzRcdLGJZBbe5sFAhYcuucO+/tqzrVSm6vhJ5+g0rW2pbMs4FDsEESbjyRmVr4B77nubyPZ8VVBVJBy85jz9jFkbTJ7Gsk1KqoplOZOzGmKSVzyV79nTNcDfuKriLiN21gyZCjVtYJuKPqcbsDJwhaVT1bDtZvgoxl1GMMLNRwe7NrL/t4f/x0+GG5iChIl7wHfJsJ07yWaVtzbppvm/DUrXEEII/YjQLYIQpg8O2B1EdsRvjhjBCG9z/6hwon/+b1o/NdUnxsxSihY9eJ5OTo9MQ/JwiaDrudg8DcUwZORitdbatMojhGm7GyqtVXjoEowQQsTlR/83zWqCYfzCow2EbPfpwa6F0E8++OAnkzIq/Rw5zEtKN81xNmmW8H9GKUGoQR89ZrZF3Ke/+bpNTBO7+R+TyT/709aPTQLusXTP1sE3nzaHjeqNC1Z+u2FVmSVVTOaqSLg4e3WUly8HLsfSqWqxUcdP7n+e6WmOvbGWARV8fv9JpqcLe2PdqKpU8MTd3XWs/PvFerqYXfq9A1bSvCKgqhvErE72oBsOtNYqPGq7n/hQcq/IiXBs2j4KldZ6EHYfup3eIkRVJ8LdFafdtDlt2K6mS/+vY1npydL9yqMN05Xjr501hAiTf6hu04vGdNAYlH/JY+y3DkGoG6CqGyXuccc2lT/iPJYhrP96ZVTsc8dUUZHtdLrhZOnfmKpULB+6/FjlVpqoKm1q75h2evFr4awhsiPC87QnyHm25Uhvl/ORDhojXTZeZ/1ECv1KlgJQFbD03JSq4m7bfRKogpXeoqrh5+Hh99GiqkY+IQ9GOmiMdNmI8o+vNzcY6kYAVQFLzw2pKv98kNfDKJfCIebjwkjvr6uoKhnTQaPySwyqAoCacuOdFYYB1OQvgKrn2Zbt9dRQVSoSLsauCL508JojTvRIb5fBSAeNkS4bsWQEN3mQBMK1oa0KqPDq1StYBmJhmaOqdN4QXu5XZZrVEUJrlG5UOnsg648QQgg1P/7oZ5XeLn+y++eVDhpJwMu/fB+ZTsZk5ynfqfPUPVVAVTMBFsRdZJant/poB41g6i4bdWdx7kKtAVUtMkujqtEOGn9zOHWXjbqzMHeh3oCqFpmlUdVoB41LdNmoOwtzF+oNqGosC1K6lkZVKw3chZkAqhrLgpSueqjq1atX77333g2cqKYsSGGqO6CqsSxI6aqHqnzfX5D8Wkwgc2YCqGosC1K6QFXLAGTOTABVjWVBSheoahmAzJkJoKqxLEjpAlUtA5A5MwFUNZYFKV2gqmUAMmcmgKrGsiClC1S1DEDmzARQ1VgWpHSBqpYByJyZAKoay4KULlDVMgCZMxNAVWNZkNIFqloGIHNmAqhqLAtSukBVywBkzkwAVY1lQUoXqGoZgMyZCaCqsSxI6QJVLQOQOTMBVDWWBSldoKplADJnJoCqxrIgpQtUtQxA5swEUNUis9Cq8jO++OKLW7du5f989erV9Z20joCqZgKoapFZaFV9+OGHt8YB5akCqGomgKoWmYVWlan3VXjvvffevHlzfSetI6CqmbAyqsrn8m7Q9qHo7F994aaQ0+K6TyGn6LpWglpoVelxgdVqFKbLAaqaCauiKtXz7DXqvYi1VuGhu9GWycyWdLq+xYAXXVWVwApCqrGAqmbCqqgqEum6v1prfe4/3pfJIODbuLzi79VYXVXpcmC1EiXp8oCqZsKqqEqfSbaBMGWHvlk6ODZL+Zq62yBdSBjhpvfikFkIIUIpQajFf/P33LGR+VMv0pFwcFbdi3vcsRFqbNE7eGVVlQdWEFJNAlQ1E1ZGVVqrUHYcghAiTkeGSichbyHKQz0I+LbV5IE6k2wD2Z4fcIo2mDzT+kyyO4R1Yx31vCbGrohUFkOdSXaHuIeh2WtlVaWzwGpVitHlAVXNhBVSldZaaxV2O46N8DYPfshU1efUQkNa/Jf7FLV4mOhEMoswGWttqpCEyThV1fnwTytdAdRa+74PIdUFgKpmwqqpSmvTxN6g/PuCqhq2V1iHPOQFVWUtXJm2QFVj8H3/Zk5UR0BVM2FVVJVIdsfzlc5aqTY9P85Ude57m4i43I+0HgRP9r/s/tw2qtInwlnDtNOLk1i2CWnLOImEi7Er/uF73mxg2unFp6teAQQuBu7CTFgZVX3juXebNllHCCHb4b1Yq1i2CUK4yYMkEK6NzJ/2HzlW1tyeaBUetWkDIZS6zPSiQghRHoSHLsEI2XedLYwQmsXHxAqgqmUA7sJMWBVV1ZObUVWlrc6IfFYkIW+NdJFNQt66njh0EQFVzQRQ1SJzY1FVn9M1yvvafOlMP39ORPmPXd6fMg1ax5KR1RHTKKCqmQCqWmRuXlXmS6dFLzCROubN9Qs3eO2/jAr/vqyqBqF/PLuwbv6Aqq7M6elpPmPH+++/v7e3l/8TvjgvFDepqgZxD0MV+dwlaM05/FXaKRY1mvx4IE232C1K/hFa/+d/hBBC6L+j/2Nas8uHQQ7SNj9M6COZ2yaWjGB69y7BCNkO/y4QbtaNdhB2H5jT4CYP1CAUOwQhhNc3Hn2TqLCYBnVR+hcaUNWVGTskHvobT2KOJe0mVWWV2qpCTrEroh98bxNRHpomJ9KWsSqEYCfCWTMfHyLhYot1v/PstE/tTruqqk4vPg/FDkGbnn+SxVl9TokjTpTv2ajFgxeevc3DRAV8uy2TahrqCqjqXRg71xDUBMeyIqpaq9bpYl8cMIrRUFWpL/KNhzW7tGvZWZeRNcr2hT+hAph2Tvt9oUoY+WKf0QZCLR6eSLaBKTsQfjwmDXUFVPUujAZWEFJNYiVVFXcZ2XC8p8JrXkJVidYqlJxRXKyyXaCqM8nuEMcT4lHa6VYPQskZbeAmD6JKGuoKqOodqQRWEFJNYhVVlUhmkbY03VvzbrLjVDXslmYx2X/iuIehOve9zUI7eraZaYoibRm/Fs4adkSUSGZtMHkayzZBLR5+z51dEQ6U79kWe/68koa6Aqp6R4qBFYRUF7D0qho2VA39EncZwQg3Hx3s2si+62z9aLjBmWQbCDWa/PvITE9Bdp7yHQshi959+KhNcdZfNiedgwJh+qAb/mB6WiFkUf4rcyj66DGzLeLu3f/5o4e0kbaXldPgiqCmLeugqncnD6wgpLqApVcVcL3AXXh3TGAFIdXFgKqAdwLuwkyALqBvBVQFvBPLcRe+/fbb+c6f8erVKwipLgZUBbwTy3EXOOe3bt368MMPpxBWZVRpNg9ceLWxVX1ON5i8/PiFynot02H6x1/6XIsBqAp4J5bjLhhVGd4mrD53HshYFaamPJPs3lVVdUOcnp7u7e3VuuUeVAW8E8txF4qqepuwopf+a6V1cRZdFb58Gd/IJ9zqENS3k0uq7h8ZQVXAO2Ge6rpz+/bt0QEu5tJOT0/HX3lxwm+ttSqsttILJCMIYUK3CPrHG/SfIGRtsQcuwQg3ve5XHm0g1KDeV3/trCGUdhsubdOLhpPJ4W0eDLQqDEE9/Kvhei2TqUgKVDXzU4Oq6sTR0RGvPx+OG4t3+/bto6OjiVdeUtXIaiuqz2mDsG6stWnewrTTi18LZw2RHRGem4Glw6nBVc+zLeIehsoMPn3e5y3siCidgLyv/NIQ1IvnEX/z5s2opPKLmvd74YqAqgCgWgF8i6QMJVWNrLYSfl8YI1EaAmEGJ4ysYjA6okvF/rMDRjGyKO/ruDQE9a1LHhwdHY0NFT/88MN5vxeuCKgKAIaqmkpShqqqyqutlIZzXUFV3TPZJsTxxFMvP05hCOpgutVZRoXFa1sBnCOgKmBR4JxfQlKGkqqqq608+4fvTMVNa7OKlGV7PTVUlUoXXAm+TBdGzyp62exD4jmzCevGcZeRBuV9HRaHoHZPze7RVG35RWGBqq4AqApYFCa2nU8iXzEFZZPKqsJqK/xrwQhCCCHC5B9k+v9rlG6YXTbpZjYw1czk+C8oXTMLsDBmDvwjQrcIQpg+OGB3ENkRv/x/vHwI6pc/z9drmX6guxEWqOoKgKoA4Ka5tJQBUBUAALUAVAUAQA0AVQEAUANAVQAA1ABQFQAANQBUBQBADQBVAQBQA0BVAADUAFAVAAA1AFQFAEANAFUBAFADQFUAANQAUBUAADUAVAUAQA0AVQEAUANAVQAA1ABQFQAANQBUBQBADQBVAQBQA0BVAADUAFAVAAA1AFQFAEANAFUBAFADQFUAANQAUBUAADUAVAUAQA0AVQEAUANAVQAA1ABQFQAANWBBVHUm2QZ2RDT2jyGnKIcwGc/ijNMRv/BoA6EG9V6Uz6pi+cDh/ZtLSU1IJLPQBDBlB5/LcDC/1J1Jdo+HybSbX6nglXLAYnLqswEXsxiqioSDEcLbPJhQjs0GN66qYbGrlLm4y0iDgqrGE/W8Ji7lW+Qftmn6k+2KQM0hVSqWbYJal1CVvmLBU75ng6pmzSKo6tz3Ns1r1/Z64wvx0BkLEFWpQLg2QhaoahLjFK8i4aZPPXZFdNOyUuGhSzC6rKquVvDycAxUNTsWQFWq59k4i7LbMh5XiOelqlFSeSFQ1QWMj0aH9ak1R5zcYHJU3OtkMR2oqq7MXVUqEh8Rso4vLsTjS8wglJyl4ihDeTjc5jPPsfPWEi7DzIVJyFvlXQahfOwQjPA2D34o/dViMsnfzCPnKjVqtLj/nfAckqbX6cgwCY/aeToxbXfDso8Hofz8gGVPUzmVdeRtqireRBX7IrtBtuMJP31XVe7OJ3J4r22H98rauCADB6HYIdV7NnzNqFA+Ge7ZoIyXWtMmqOote42oanwDlgplx5QT2+G9KPis/aTw8lOhfPJJXrzLhaLPaX48ix48lzxLDHG5X2nynaJ0zexc18i8VaWOeeueCJ6zTAG4yce0ZIwpMYOAb2OEENpg8kyrY95sIFSJy7JialrBxtTmCrUSeuD7z2XvcwfnRbnwtAwfufzOlaOqoq3IjggHKuBpgw1eJ+sWcQ/DqJteZqkGFPW8JsZNrxcVWnkwYd25Ro/vxNQVwOwGkbaMk1i2SakA5C0Dmd/zu4w2Pf88O9sUGTi8O8WoykRbpjwUIq9iERpT8KbYa0xUZVrKMHF45mJTgDeYPNPpO7LQ+hm/8GgD004vVoVA3mxsjjesi2D6oFssb7bnD5+gKTJnZue6XuasKuV7G46IioWyVAozRkrMSGblT0KhwStrE82+LebqGd6GwoHNK2IQ8G2cNfCPe+QmqGq4aZb+4S+YuIehKu47DB6zJtg0ScvRIjuSb4Vm9fSx0Xp4E7OcTHfLM6fwqkjD5Fgygsp3eaoMHKuq9AnMntvhA1kIoEZVNc1e41QVCRcXdZbuOPzIoIZRVfY4pNsPn47CNY2Uw9ESOFXmzOxc1818VXUmmWMudaiesQFFtcQUo6G0rpdvkmXxmNb6fJu8Y8TEb3wT//pWVWUPw5gX8ui+Ixcy/v1fM8Z3WSCOx4udFfIbVM2fkVfLqKryGzJdBo79cfh1z/w47s6O3sRp9hpRlQoPXfuD0gfu4ZFtp1NpETgRzlrhmKP5oC/UxzAAnCJzZnWua2feFUAAAIApAFUBAFADZqAqAACAG+CdVAUAADBHQFUAANQAUBUAADUAVAUAQA0AVQEAUANAVQAA1ABQFQAANQBUBQBADfj/AahuikL1aCh+AAAAAElFTkSuQmCC&quot; alt=&quot;&quot; /&gt;&lt;br /&gt;&lt;br /&gt;Gambar 2. Penatalaksanaan Obstetrik Kehamilan Dengan DM.&lt;br /&gt;&lt;br /&gt;• Seksio sesarea dipertimbangkan bila terdapat makrosomia,&lt;br /&gt;pertumbuhan janin terhambat dan gawat janin. Bila keadaan&lt;br /&gt;ibu dan janin baik dan tidak ada masalah dari aspek DM&lt;br /&gt;maupun aspek obstetri lainnya, maka dapat diharapkan penderita&lt;br /&gt;melahirkan melalui persalinan spontan pervaginam&lt;br /&gt;biasa(1,3,4,6,8,10,12,14).&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;3. PENGELOLAAN BAYI&lt;/span&gt;&lt;br /&gt;Pada bayi yang dilahirkan dari ibu yang menderita DM,&lt;br /&gt;dilakukan pemeriksaan darah tali pusat untuk mengukur kadar&lt;br /&gt;glukosa darah dan hematokrit bayi. Selain itu, persiapan&lt;br /&gt;resusitasi neonatus harus dilakukan dengan baik.&lt;br /&gt;Masalah yang mungkin timbul pada bayi adalah :&lt;br /&gt;− Perubahan morfologi/fisiologi akibat gangguan pertumbuhan&lt;br /&gt;intrauterin, makrosomia, cacat bawaan&lt;br /&gt;− Gangguan metabolik seperti hipoglikemia, hipokalsemia,&lt;br /&gt;hipomagnesemia, hiperbilirubinemia&lt;br /&gt;− Gangguan hematologik seperti polisitemia atau hiperviskositas&lt;br /&gt;darah&lt;br /&gt;− Gangguan pernafasan dan kelainan jantung bawaan&lt;br /&gt;Penanganan bayi dari ibu DMG harus dilakukan dengan&lt;br /&gt;seoptimal mungkin, yaitu dengan langkah-langkah sebagai&lt;br /&gt;berikut :&lt;br /&gt;• Pada tingkat Polindes, BIDMG harus dikelola sejak&lt;br /&gt;dilahirkan. Evaluasi dilakukan segera setelah lahir, meliputi :&lt;br /&gt;Penghitungan nilai APGAR&lt;br /&gt;− Pemeriksaan keadaan umum bayi&lt;br /&gt;− Pemeriksaan fisik untuk melihat adanya cacat bawaan&lt;br /&gt;− Pemeriksaan plasenta&lt;br /&gt;− Pemeriksaan kadar glukosa&lt;br /&gt;− Pemeriksaan hematokrit tali pusat&lt;br /&gt;− Pengawasan lanjut&lt;br /&gt;Pemeriksaan fisik diulang untuk melihat perubahan yang&lt;br /&gt;terjadi pada janin seperti gemeteran, apnea, kejang, tangis&lt;br /&gt;lemah, malas minum dan adanya tanda sindroma gawat nafas,&lt;br /&gt;kelainan jantung, kelainan ginjal, trauma lahir pada extremitas,&lt;br /&gt;kelainan metabolik dan kelainan saluran cerna. Untuk mencegah&lt;br /&gt;hipoglikemia bayi diberi minum (dosis 60-90 ml/kg BB&lt;br /&gt;hari), dibagi dalam beberapa dosis, dimulai sejak jam pertama&lt;br /&gt;selanjutnaya tiap 12 jam.(3,4,6,10,15,16,18)&lt;br /&gt;• Pada tingkat Puskesmas, BIDMG harus dikelola sejak&lt;br /&gt;lahir dan dicegah terjadinya hipoglikemia sesuai penanganan&lt;br /&gt;diatas.&lt;br /&gt;• Pada tingkat Rumah Sakit, BIDMG harus dikelola sejak&lt;br /&gt;lahir dan dicegah terjadinya hipoglikemia sesuai penanganan&lt;br /&gt;diatas ditambah dengan pemeriksaan laboratorium untuk menegakkan&lt;br /&gt;dan memantau adanya kelainan BIDMG.(4,6,8,10,15,18)&lt;br /&gt;− Kadar glukosa serum tali pusat diperiksa pada 1, 2, 4, 8,&lt;br /&gt;12, 24, 36 dan 48 jam setelah kelahiran. Apabila kadar reflectancemeter&lt;br /&gt;&amp;lt; 45 mg/dl, harus diperiksa kadar glukosa serum.&lt;br /&gt;− Kadar kalsium dan magnesium harus diperiksa pada umur&lt;br /&gt;6, 12, 24 dan 48 jam.&lt;br /&gt;− Hematokrit harus diperiksa dari tali pusat dan pemeriksaan&lt;br /&gt;selanjutnya pada umur 4 dan 24 jam.&lt;br /&gt;− Kadar serum bilirubin harus diperiksa bila bayi tampak&lt;br /&gt;kuning.&lt;br /&gt;DM Terkendali DM tidak Terkendali&lt;br /&gt;Sejak Kehamilan 34-36 minggu&lt;br /&gt;RAWAT&lt;br /&gt;Monitor setiap minggu&lt;br /&gt;GD, USG, CTG&lt;br /&gt;Monitor setiap minggu&lt;br /&gt;GD, USG, CTG&lt;br /&gt;Gawat janin&lt;br /&gt;Makrosomia&lt;br /&gt;IUGR&lt;br /&gt;anin sehat Amniosentesis&lt;br /&gt;Paru matang 40 minggu Paru belum matang&lt;br /&gt;Steroid&lt;br /&gt;Partus biasa&lt;br /&gt;Terminasi&lt;br /&gt;Algoritma Penatalaksanaan&lt;br /&gt;Cermin Dunia Kedokteran No. 139, 2003 25&lt;br /&gt;− Pemeriksaan lain dilakukan atas indikasi.&lt;br /&gt;− Mengatasi kelainan metabolik.&lt;br /&gt;1) Hipoglikemia&lt;br /&gt;− Jika kadar glukosa yang diperiksa dengan reflektometer&lt;br /&gt;meter &amp;lt; 25 mg/dl dan juga dibuktikan dengan pemeriksaan&lt;br /&gt;serum, diberikan larutan glukosa intravena sebanyak 6 mg/kg&lt;br /&gt;BB/menit dan kadar glukosa harus diperiksa setiap jam.&lt;br /&gt;− Bila kadar glukosa antara 25-45 mg/dl dan bayi tidak&lt;br /&gt;tampak sakit diberi minum larutan glukosa 5% dan kadar&lt;br /&gt;glukosa darah diperiksa setiap jam sampai stabil kemudian&lt;br /&gt;setiap 4 jam. Bila kadar glukosa tetap rendah diberi infus&lt;br /&gt;glukosa 6 mg/kgBB/&lt;br /&gt;2) Hipokalsemia dengan kejang harus diobati dengan larutan&lt;br /&gt;kalsium glukonat 10% sebanyak 1 ml/kgBB intravena, kadar&lt;br /&gt;kalsium dipantau setiap 12 jam dan selama pemantauan diperhatikan&lt;br /&gt;adanya bradikardia, aritmia jantung dan ekstravasasi&lt;br /&gt;cairan dari alat infus karena dapat menyebabkan nekrosis kulit.&lt;br /&gt;3) Hipomagnesemia&lt;br /&gt;Dapat dikoreksi dengan larutan magnesium sulfat 50%&lt;br /&gt;sebanyak 1,2 ml/kgBB/hari intramuskuler dalam dibagi dalam&lt;br /&gt;2-3 dosis.&lt;br /&gt;4) Pengobatan terhadap kelainan hematologis&lt;br /&gt;Pada keadaan hiperbilirubinemia, dilakukan pemantauan&lt;br /&gt;terhadap kadar bilirubun serum dengan seksama sejak bayi&lt;br /&gt;mulai kuning, bila perlu diberikan terapi sinar atau transfusi&lt;br /&gt;tukar. Pada polisitemia, apabila kadar hematokrit darah vena&lt;br /&gt;60-70% tanpa gejala, diberikan tambahan minum sebanyak&lt;br /&gt;20-40 ml/kgBB/hari. Kadar hematokrit diperiksa setiap 6-12&lt;br /&gt;jam, sampai nilainya dibawah 65%. Bila kadar Hematokrit &amp;gt;&lt;br /&gt;70% dan timbul gejala, harus dilakukan transfusi tukar parsial&lt;br /&gt;dengan plasma beku segar.(3,4,6,10,19,21)&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;KESIMPULAN&lt;/span&gt;&lt;br /&gt;Pengelolaan diabetes mellitus dalam kehamilan membutuhkan&lt;br /&gt;pendekatan dan kerja sama tim yang sebaik-baiknya.&lt;br /&gt;Dengan pengelolaan medis, obstetrik dan pediatrik yang baik&lt;br /&gt;maka diharapkan memperoleh hasil akhir semaksimal mungkin,&lt;br /&gt;setidak-tidaknya sama atau mendekati hasil akhir pada&lt;br /&gt;kehamilan normal.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;KEPUSTAKAAN&lt;/span&gt;&lt;br /&gt;1. Konsensus Diagnosis dan Penatalaksanaan Diabetes Mellitus Gestasional.&lt;br /&gt;Disampaikan dalam Pertemuan Tahunan Ilmu Penyakit Dalam,&lt;br /&gt;Jakarta, 1997.&lt;br /&gt;2. Konsensus diagnosis dan penatalaksanaan DMG. Jakarta: PERKENI,&lt;br /&gt;1997 : 1-12.&lt;br /&gt;3. Buku Acuan Nasional. Diabetes Mellitus Gestasional (DMG). Dalam:&lt;br /&gt;Pelayanan Kesehatan Maternal Dan Neonatal. Edisi Pertama. Jakarta :&lt;br /&gt;JNPKKR-POGI, 2000; 290-299.&lt;br /&gt;4. Suwito Tjondro Hudono. Diabetes Mellitus. Dalam: Ilmu Kebidanan.&lt;br /&gt;Edisi ke 3. Jakarta: YBPSP, 1991; 480-93.&lt;br /&gt;5. Wulur CH, Suparman E, Loho MF. Tinjauan persalinan makrosomia di&lt;br /&gt;RSUP Manado. Majalah Obstetri Ginekologi Indonesia, 1997; 21: 202-8.&lt;br /&gt;6. Carr DB, Gabbe S. Gestational diabetes : detection, management and&lt;br /&gt;implication. Clinical Diabetes, 1988: 16 : 4-11.&lt;br /&gt;7. Stepen R, Carr DB. Screening for gestational diabetes mellitus. Diabetes&lt;br /&gt;Care, 1998: 21: B14-8.&lt;br /&gt;8. Madam M, Bajaj JS. Gestational diabetes in developing country. In :&lt;br /&gt;Anne Dorhorst, david RH, eds. Diabetes and pregnancy. New York :&lt;br /&gt;John Wiley &amp;amp; Sons, 1996 : 284-9.&lt;br /&gt;9. Person B, Hanson U. Neonatal morbiditas in gestasional diabetes&lt;br /&gt;mellitus. Diabetes Care, 1998; 21: B79-83.&lt;br /&gt;10. Jovanovic L, Peterson CM. Screening for Gestational Diabetes :&lt;br /&gt;Optimum Timing and criteria for resesting. Diabetes, 1985; 34: 21.&lt;br /&gt;11. Ogata ES. Perinatal Morbiditas off spring of Diabetic Mother. Diabetes&lt;br /&gt;Rev, 1995; 65-6.&lt;br /&gt;12. Langer O, Rodriquez DA, Xenakin EMJ. Intensified Versus&lt;br /&gt;Compentional Managemant of Gestasional Diabetes Melitus. Am J&lt;br /&gt;Obstet Gynecol, 1994; 170: 1036-47.&lt;br /&gt;13. Hold M, Robinson D, Pelid Y. Gestational Diabetes Mellitus : Is it a&lt;br /&gt;clinical entity? Diabetes Rev 1995; 602-11.&lt;br /&gt;14. Petti DJ, Knowler WC, Brairt HR. Gestational diabetes: Infant and&lt;br /&gt;maternal Complication of pregnancy in relation to third trimester glucose&lt;br /&gt;tolerance in Pima Indians. Diabetes care 1980; 3: 458-64.&lt;br /&gt;15. Neiger R, Coustan MD. The role of repeat glucose tolerance test in the&lt;br /&gt;diagnosis of gestational diabetes. Am J Obstet Gynecol, 1991; 165:&lt;br /&gt;787-90.&lt;br /&gt;16. Pendegras M, Fazioni E, Defronso RA. NIDDM and gestational diabetes&lt;br /&gt;mellitus: same diseases another name. Diabetes care, 1995; 3: 566-77.&lt;br /&gt;17. Colditz GA, Willet WC, Rotnitzky A, Manson JE. Weight gain as a risk&lt;br /&gt;factor for clinical diabetes mellitus in women. Ann Intern Med, 1995;&lt;br /&gt;122: 482-6.&lt;br /&gt;18. Counstan DR, Nelson C, Carpenter MW. Maternal age and screening for&lt;br /&gt;gestational diabetes mellitus: a population base study. Obstet Gynaecol,&lt;br /&gt;1989; 73: 557-60.&lt;br /&gt;19. Jang HC, Cho NH, Jung KB. Screening for gestational diabetes mellitus&lt;br /&gt;in Korea. Int J Obstet Gynaecol, 1995; 51: 115-22.&lt;br /&gt;20. Wingjosastro GH. Penanganan diabetes mellitus gestasional. Dalam:&lt;br /&gt;Adam JMF, Sanusi H, Tendean H, Lawrence GS, Aman M eds. Konas&lt;br /&gt;IV Perkeni. Ujung Pandang: Lab ObGin FK UI Jakarta, 1997:46-8.&lt;br /&gt;21. Weiss PAM. Diabetes in pregnancy: lesson from the fetus. In: Domhorst&lt;br /&gt;A, Hadden DR eds. Diabetes in pregnancy. Chichester: John Wiley &amp;amp;&lt;br /&gt;Sons Ltd, 1996: 221-39.</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/5353435677918725128/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/08/diabetes-mellitus-dalam-kehamilan.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/5353435677918725128'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/5353435677918725128'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/08/diabetes-mellitus-dalam-kehamilan.html' title='Diabetes Mellitus dalam Kehamilan'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-2893640511381459002</id><published>2011-08-24T20:15:00.000-07:00</published><updated>2011-08-24T20:17:48.990-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="deteksi dini mata"/><title type='text'>Deteksi Dini Kebutaan akibat Diabetes Melitus di Puskesmas</title><content type='html'>&lt;span style=&quot;font-weight: bold;&quot;&gt;Deteksi Dini Kebutaan akibat&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;Diabetes Melitus&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-weight: bold;&quot;&gt;di Puskesmas&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;Dr. Dy~ri Djuwantoro&lt;/span&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;Puskesmas Sejangkung, Sambas, Kalimantan Barat&lt;/span&gt;&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;PENDAHULUAN&lt;/span&gt;&lt;br /&gt;Diabetes melitus adalah suatu sindrom kelainan&lt;br /&gt;metabolisme glukosa dan hiperglikemia yang diakibatkan oleh&lt;br /&gt;kekurangan sekresi insulin yang absolut, penurunan efektivitas&lt;br /&gt;biologis insulin atau keduanya. Sekitar 200 juta orang di&lt;br /&gt;seluruh dunia dan 20 juta orang di Amerika menderita diabetes&lt;br /&gt;melitus. Penderita diabetes melitus mempunyai kecenderungan&lt;br /&gt;25 x lebih mudah mengalami buta sebagai akibat retinopati&lt;br /&gt;diabetik daripada non-diabetes.&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;PATOGENESIS RETINOPATI DIABETIK&lt;/span&gt;&lt;br /&gt;Meskipun penelitian telah dilakukan secara intensif, namun&lt;br /&gt;patofisiologi retinopati diabetik belum diketahui hingga dewasa&lt;br /&gt;ini(2,3). Jaringan sasaran retinopati diabetik adalah kapiler&lt;br /&gt;retina. Beberapa penulis mengemukakan model hemodinamik :&lt;br /&gt;hiperperfusi retina dianggap bertanggung jawab atas timbulnya&lt;br /&gt;kerusakan, iskemi, dan retinopati kapiler(2).&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;STADIUM RETINOPATI DIABETIK&lt;/span&gt;&lt;br /&gt;Stadium-stadium komplikasi vaskuler ditetapkan berdasarkan&lt;br /&gt;gambaran oftalmologik; tiga stadium retinopati diabetik&lt;br /&gt;yaitu : non proliferatif, pra-proliferatif, dan proliferatif.&lt;br /&gt;Pada stadium non-proliferatif, kapiler retina bocor dan&lt;br /&gt;mengalami oklusi.Gambaran klinis yang dapat ditemukan adalah&lt;br /&gt;mikroaneurisma, perdarahan intraretina, dan edema makuler.&lt;br /&gt;Penderita akan mengalami penurunan ketajaman penglihatan&lt;br /&gt;hanya jika terdapat edema makuler, yang dilaporkan mengenai&lt;br /&gt;5%-20% penderita diabetes, tergantung pada tipe dan lamanya&lt;br /&gt;diabetes melitus. Di samping itu, penderita dapat asimptomatik.&lt;br /&gt;Beberapa penderita berlanjut ke stadium pra-proliferatif,&lt;br /&gt;yang secara khas ditandai oleh manik-manik venosa, kelainan&lt;br /&gt;mikrovaskuler intraretina, perdarahan retina yang luas, serta&lt;br /&gt;cotton wool spots. Terdapat kemungkinan sangat besar bahwa&lt;br /&gt;retinopati pra-proliferatif berlanjut menjadi retinopati proliferatif,&lt;br /&gt;yang bertanggung jawab atas sebagian besar penurunan&lt;br /&gt;ketajaman penglihatan yang serius dan komplikasi-komplik&#39;asi&lt;br /&gt;yang berat pada penderita diabetes.&lt;br /&gt;Pada retinopati proliferatif, sebagai akibat iskemi retina&lt;br /&gt;yang terus menerus, pembuluh darah baru (neovaskularisasi)&lt;br /&gt;terbentuk di daerah diskus optikus atau di tempat lain di lapisan&lt;br /&gt;retina. Pada stadium ini, penderita masih dapat asimptomatik&lt;br /&gt;dan penatalaksanaan laser perlu dilakukan jika retinopati dapat&lt;br /&gt;ter-diagnosis. Jikalau tidak, pembuluh-pembuluh darah ini akan&lt;br /&gt;tumbuhke dalam rongga vitreum dan berdarah akibat tarikan&lt;br /&gt;dan pergeseran korpus vitreum: Dengan adanya darah dalam&lt;br /&gt;korpus vitreum, penderita mengeluh melihat banyak &#39;apungan&#39;&lt;br /&gt;dan mengalami penurunan tajam penglihatan. Jaringan fibrous&lt;br /&gt;biasanya menyertai pembuluh darah baru dan kontraksinya&lt;br /&gt;dapat menyebabkan ablasio atau terputusnya retina.&lt;br /&gt;Segera setelah proliferasi fibrous menyebabkan terlepasnya&lt;br /&gt;(ablasio) retina, bedah laser mungkin tidak memberikan hasil&lt;br /&gt;yang efektif. Pada kasus-kasus seperti ini, tajam penglihatan&lt;br /&gt;kadang kala dapat dipulihkan dengan vitreaktomi, yaitu suatu&lt;br /&gt;operasi untuk mengangkat korpus vitreum dan menggantikannya&lt;br /&gt;dengan larutan fisiologis.&lt;br /&gt;Tipe diabetes, lamanya penyakit merupakan faktor risiko&lt;br /&gt;yang memegang peranan penting pada retinopati proliferatif, di&lt;br /&gt;samping kontrol glukosa yang kurang memadai, tekanan darah&lt;br /&gt;tinggi, proteinuri, dan kehamilan(3).&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;DETEKSI DINI&lt;/span&gt;&lt;br /&gt;Sekurang-kurangnya 50% kebutaan akibat diabetes melitus&lt;br /&gt;dapat dicegah dengan penatalaksanaan laser pada retina;&lt;br /&gt;penatalaksanaan seperti ini memberi hasil yang paling efektif&lt;br /&gt;bila dimulai sebelum penderita mengalami penurunan tajam&lt;br /&gt;penglihatan serta sebelum timbulnya perdaerahan vitreum dan&lt;br /&gt;Cermin Dunia Kedokteran No. 95, 1994 55&lt;br /&gt;ablasio retina akibat tarian. Dengan demikian, selama perawatan&lt;br /&gt;penderita diabetes, diharapkan dokter puskesmas melakukan&lt;br /&gt;pemeriksaan tajam penglihatan dan mempertimbangkan pemeriksaan&lt;br /&gt;fundoskopi pada setiap perawatan lanjutan. Perlu&lt;br /&gt;diingat bahwa retinopati diabetik stadium yang paling mudah&lt;br /&gt;diobati dapat terjadi tanpa disertai dengan gejala klimis.&lt;br /&gt;Untuk mempermudah dan menegaskan peranan doktei&lt;br /&gt;puskesmas dalam pencegahan kebutaan pada penderita diabetes&lt;br /&gt;melitus, perlu diperhatikan garis pedoman sistem rujukan yang&lt;br /&gt;dikeluarkan oleh American Academy of Ophthalmology berikut&lt;br /&gt;ini :&lt;br /&gt;a) Penderita diabetes melitus tipe I sebaiknya lperiksa oleh&lt;br /&gt;ahli mata setiap tahun dimulai dalam waktu a tahun setelah&lt;br /&gt;diagnosis diabetes melitus ditegakkan, karena retinopati tidak&lt;br /&gt;timbul hingga lima tahun setelah dia:nosis.&lt;br /&gt;b) Penderita diabetes melitus tipe II perlu mendapatkan pemeriksaan&lt;br /&gt;ahli mata setiap tahun dalam waktu beberapa bulan&lt;br /&gt;setelah diagnosis, sebab retinopati yang dapat diobati mungkin&lt;br /&gt;terjadi pada saat diagnosis.&lt;br /&gt;c) Penderita yang tidak mendapatkan kontrol diabetes,&lt;br /&gt;tekanan darah tinggi atau proteinuri secara memadai sebaiknya&lt;br /&gt;menjalani pemeriksaan yang lebih sering, karena penderita&lt;br /&gt;tersebut mempunyai risiko yang sangat tinggi untuk mengalami&lt;br /&gt;retinopati yang timbul cepat.&lt;br /&gt;d) Penderita dengan retinopati pra-proliferatif perlu diperiksa&lt;br /&gt;oleh ahli mata setiap tiga sampai empat bulan, karena terdapat&lt;br /&gt;risiko menderita retinopati proliferatif.&lt;br /&gt;e) Penderita yang telah menjalani perawatan bedah laser atau&lt;br /&gt;vitrektomi sebaiknya menepati jadtial perawatan lanjutan yang&lt;br /&gt;ditetapkan oleh ahli mata yang merawatnya.&lt;br /&gt;f) Wanita hamil dengan diabetes tipe I sebaiknya menjalani&lt;br /&gt;pemeriksaan ahlimataselama trimester pertamadanselanjutnya&lt;br /&gt;setiap tiga bulan hingga melahirkan(3).&lt;br /&gt;RINGKASAN&lt;br /&gt;a) Penderita diabetes mempunyai risiko 25 kali lebih besar&lt;br /&gt;untuk mengalami kebutaan(1,3).&lt;br /&gt;b) Lebih dari 50% kasus kebutaan sebagai akibat retinopati&lt;br /&gt;diabeti dapat diobati dan dicegah dengan sinar laser dan operasi&lt;br /&gt;korpus viterum.&lt;br /&gt;c) Agar mendapatkan hasil yang efektif, penatalaksanaan&lt;br /&gt;hams dilakukan pad stadium dini retinopati; dengan demikian&lt;br /&gt;deteksi dini oleh do er puskesmas memegang peranan yang&lt;br /&gt;sangat panting.&lt;br /&gt;d) Retinopati diabetik dapat asimptomatik pada stadium awal,&lt;br /&gt;dan jugapada stadium lanjut meskipun terdapat risiko tinggi&lt;br /&gt;retinopati proliferatif.&lt;br /&gt;e) Deteksi dini dan sistem rujukan memegang peranan penting(3).&lt;br /&gt;&lt;br /&gt;&lt;span style=&quot;font-style: italic;&quot;&gt;KEPUSTAKAAN&lt;/span&gt;&lt;br /&gt;1. Askandar Tj. Makro dan Mikroangiopati Diabetik. Ilmu Penyakit Dalam.&lt;br /&gt;Balai Penerbit FKUI, 1987; 2:394.&lt;br /&gt;2. Patel V. et al. Retinal blood flow in diabetic retinopaday. BMJ 1992; 305:&lt;br /&gt;678-83.&lt;br /&gt;3. Patrick CP Hp. Preventing blindness from diabetes. Asian Medical News&lt;br /&gt;1993;15(10):17.</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/2893640511381459002/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/08/deteksi-dini-kebutaan-akibat-diabetes.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/2893640511381459002'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/2893640511381459002'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/08/deteksi-dini-kebutaan-akibat-diabetes.html' title='Deteksi Dini Kebutaan akibat Diabetes Melitus di Puskesmas'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-440223285707902670.post-967006730917989599</id><published>2011-08-24T19:55:00.000-07:00</published><updated>2011-08-24T20:04:25.756-07:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="diabetes mellitus"/><category scheme="http://www.blogger.com/atom/ns#" term="vitamin d"/><title type='text'>Vitamin D yang Rendah Meningkatkan Risiko Kejadian Diabetes Mellitus</title><content type='html'>                                                                                           			    &lt;div&gt;&lt;div align=&quot;justify&quot;&gt;Kalbe.co.id  - Menurut Badan kesehatan dunia,  World Health Organisation (WHO),  secara global, penyakit diabetes mellitus menjangkiti sekitar 220 juta  orang dan mempunyai angka mortalitas sebesar 3,4 juta orang setiap  tahun. Berdasarakan data statistik, badan dunia WHO memprediksi tingkat  kematian yang disebabkan oleh penyakit diabetes melitus ini dapat  meningkat menjadi 2 kalinya pada tahun 2005 sampai 2030.  Para peneliti  dari Tufts Medical Center &amp;amp; Carney Hospital di Massachusetts,  Amerika Serikat, dipimpin oleh Dr. Mitri, menyampaikan informasi bahwa  orang-orang dengan kadar vitamin D dalam darah yang tinggi (&amp;gt; 25  ng/mL), mempunyai risiko sebesar 43 % lebih rendah terhadap perkembangan  penyakit Diabetes tipe 2 dibandingkan orang dengan kadar yang sangat  rendah  (&amp;lt; 14 ng/mL). Hasil studi metaanalisa ini dipublikasikan  dalam &lt;strong&gt;European Journal of Clinical Nutrition&lt;/strong&gt; edisi Juli 2011.&lt;p&gt;Vitamin  D dapat memodifikasi faktor risiko diabetes melitus tipe 2. Tujuan  review penelitian ini untuk menilai hubungan antara  status vitamin D  dengan insidensi diabetes tipe  2, dan melihat efek suplementasi vitamin  D terhadap hasil glikemik. Dalam studi ini, para peneliti melakukan  review sistemik terhadap beberapa studi yang dicari menggunakan MEDLINE  selama Februari 2011. Studi kohor longitudinal melaporkan adanya  hubungan antara status vitamin D dan insidensi diabetes tipe 2 termasuk  didalamnya studi klinis secara teracak suplementasi vitamin D. &lt;/p&gt;&lt;p&gt;Hasil  studi diekstrak dan kualitas studi juga turut dilakukan assessment.  Hasil total 8 studi kohort observasional serta 11 studi secara  randomisasi. Metaanalisa studi observasional, asupan vitamin D &amp;gt;500  international units (IU)/ hari menurunkan risiko  diabetes type 2  sebanyak 13% dibandingkan dengan asupan vitamin D &amp;lt;200 IU/hari.  Individu dengan status vitamin D yang lebih tinggi ( &amp;gt; 25 ng/ml)  mempunyai risiko 43% lebih rendah untuk mendapatkan diabetes tipe 2 (95%  CI : 24,57%) dibandingkan dengan kelompok yang sangat rendah ( &amp;lt; 14  ng/ml). Pada analisa dari 8 penelitian diantara  peserta dengan  toleransi glukosa  normal pada awal dan 3 penelitian kecil yang kurang  bermakna  (dengaan n = 32-62) pasien dengan diabetes tipe 2 diabetes,  tidak terdapat efek suplementasi vitamin D pada hasil glikemik.   Sedangkan pada 2 penelitian diantara  pasien dengan baselineintoleransi  glukosa, Suplementasi vitamin D memperbaiki resistensi insulin.&lt;/p&gt;&lt;p&gt;Kesimpulan  dari metaanalisa, Vitamin D mungkin berpengaruh dalam tipe 2 diabetes;  meskipun, untuk mendapatkan peran yang lebih baik untuk  vitamin D dalam  perkembangan dan progresi diabetes tipe 2, studi observasional kualitas  tinggi dan studi randomisasi untuk mengukur kadar  25-hidroksivitamin D  dan klinis yang berkaitan dengan hasil akhir glikemik tetap diperlukan.&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</content><link rel='replies' type='application/atom+xml' href='http://penyakitdiabetesmellitus.blogspot.com/feeds/967006730917989599/comments/default' title='Post Comments'/><link rel='replies' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/08/vitamin-d-yang-rendah-meningkatkan.html#comment-form' title='0 Comments'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/967006730917989599'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/440223285707902670/posts/default/967006730917989599'/><link rel='alternate' type='text/html' href='http://penyakitdiabetesmellitus.blogspot.com/2011/08/vitamin-d-yang-rendah-meningkatkan.html' title='Vitamin D yang Rendah Meningkatkan Risiko Kejadian Diabetes Mellitus'/><author><name>Unknown</name><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry></feed>